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Abstract 
22q11.2 Deletion Syndrome (22q11.2DS) is a genetic disorder that results from a 
hemizygous deletion at chromosome 22q11.2, occurring at an incidence of 1 in 4000 live 
births. It is associated with a wide range of clinical features, such as congenital heart 
disorders and abnormal facial features. 22q11.2DS patients also have an increased risk of 
neuropsychiatric disorders, with deletions at 22q11.2 being the highest known risk factor 
for schizophrenia. However, the mechanisms underlying 22q11.2DS symptomatic 
variability are still unclear. This thesis addresses this issue by investigating genetic, 
epigenetic and transcriptomic changes related to 22q11.2DS. 
Firstly, by using a polygenic risk score profiling approach it shows that the increased 
risk of schizophrenia in 22q11.2DS patients is partly due to an increased burden of 
common genetic variants associated with this neuropsychiatric disorder. 
This thesis also presents evidence that DNA methylation, an epigenetic mark, is altered 
in 22q11.2DS patients compared to a control population that do not carry a deletion at 
22q11.2. Microarray-based whole epigenome analysis showed that these patients have an 
altered DNA methylation profile that affects genes and biological pathway relevant to 
schizophrenia. 
Finally, the CRISPR/Cas9 genome editing technology has been employed in human 
embryonic stem cells to delete one of the genes spanned by the 22q11.2 deletion. This 
gene, DGCR8, is a major component of the microRNA biogenesis pathway that is 
involved in the regulation of gene expression. The knock-out cell lines generated in this 
study were differentiated into neural progenitor cells to investigate transcriptome changes 
due the deletion of this gene during neurodevelopment.  
In conclusion, this thesis shows that the increased risk for schizophrenia in 22q11.2DS 
patients depends in parts on common genetic variants located outside of the deletion. 
Moreover, different mechanisms involved in genetic regulation (DNA methylation, 
microRNAs) can possibly modulate the schizophrenia phenotype by affecting relevant 
genes and pathways.  
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 General Introduction 
1. General Introduction 
1.1. Overview and nomenclature 
22q11.2 deletion syndrome (22q11.2DS) is a genetic disorder caused by a hemizygous 
deletion of chromosome 22q11.2. In the past it has been also designated by other names, 
such as DiGeorge syndrome, Velo-Cardio-Facial syndrome (VCFS), CATCH 22 
syndrome or conotruncal anomaly face syndrome 1. The different syndromes associated 
with 22q11.2 deletion and their date of discovery are described Table 1-1. 22q11.2DS 
syndrome patients can present with a wide range of diverse symptoms, for instance 
congenital heart disorders, facial dysmorphism, immune disorders as well as cognitive 
and neuropsychiatric disorders. Robin and Schprintzen reported in 2005 more than 180 
clinical features associated with this syndrome 2. The presence of these diverse symptoms 
is variable and lead to the use of different syndrome names depending on the diagnosis 
established from these features. The advances in genetic testing allowed the unification 
of these syndromes and facilitated the identification of patients who have the symptoms 
associated with the syndrome but do not carry the 22q11.2 deletion. For instance, a study 
by Driscoll et al. in 1993 identified that the deletion was detected in only 83% of patients 
diagnosed with DiGeorge syndrome and 68% of those diagnosed with VCFS in a cohort 
of 76 patients 3. Consequently, 22q11.2 deletion syndrome is now only designated to 
patients that have this copy number variant (CNV) mutation, regardless of exhibited 
symptoms. For this reason, throughout this thesis only the denomination 22q11.2 deletion 
syndrome (22q11.2DS) is used.  
 
Event Date
Congenital thymic hypoplasia associated with hypocalcemia 1959
DiGeorge syndrome described 1972
Takao syndrome described (conotruncal anomaly face syndrome) 1976
Velocardiofacial syndrome described (Shprintzen syndrome) 1978
DiGeorge syndrome speculatively linked to chromosome 22 1981
Partial monosomy of chromosome 22 described 1982
"CATCH-22 syndrome" described 1989
Cayler syndrome associated with del22q11.2 1994
Table 1-1. Historical overview of the syndromes associated with the 22q11.2 deletion. Table 
adapted by permission from Springer Nature:  Genetics in Medicine, De Decker 2001 489, 
copyright (2001). 
 2 
 
 General Introduction 
1.2. Epidemiology 
Due to the variability of symptoms observed in 22q11.2DS patients and the absence 
of systematic genetic testing, the prevalence rates reported in the past were variable and 
affected by ascertainment bias. Birth defects are the most common symptom leading to a 
diagnosis of 22q11.2DS. Children born in the United Kingdom in 1993 with congenital 
disorders (mainly significant heart diseases) have been screened for the presence of the 
deletion by Goodship et al. in 1998 4. It established a prevalence of a deletion at 22q11  
of 25.7 per 100,000 live births (around 1:3891). An ascertainment bias has been 
demonstrated in a Swedish population study 5. They determined an incidence of 
18.1:100,000 (1:5524) live births for the Western Götaland region and an incidence of 
23.4:100,000 (1:4273) in the city of Gothenburg where a team of specialists of 22q11.2DS 
was posted. A 2016 systematic review of birth prevalence in Belgium, France, Singapore, 
Sweden, the United Kingdom and the United States of America reported 156 cases for 
1,111,336 live births, with per-study rates ranging from 1:4525 to 1:9805 6. When 
restricting to cohorts of patients with heart diseases, the range was between 1:4000 and 
1:7092 live births. No significant difference was observed when comparing prevalence 
rates between different racial groups within populations 6. The commonly discussed 
prevalence rate in 22q11.2DS is 1 in 4000 live births. The incidence of 22q11.2DS cases 
in miscarriages has been estimated to be 1:1497, which is about three time higher than 
reported rates in the general population 7. 
The 22q11.2 deletion is typically a de novo mutation, but parental transmission has 
been estimated to occur in between around 6 to 17% 8,9. There is a significant difference 
in the parental origin of the deletion, with around 56-58% of maternal transmission 10,11.  
  
1.3. The 22q11.2 deletions 
Multiple hemizygous deletions have been characterised at the cytoband 22q11.2. The 
most frequent deletions in 22q11.2DS is around 3 Mb long and is shared by around 85 to 
90% of the patients. The second most frequent deletion (5-10% of patients) is a smaller 
deletion of around 1.5 Mb which is nested within the 3 Mb deletion. Thus, the majority 
of 22q11.2DS patients share a common 1.5 Mb deletion. Some patients (2-4%) present 
more atypical deletions, such as central deletions. 12–17 (Figure 1-1.B).  
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The deletions have been shown to be delimited by breakpoints occurring in regions 
that contains low-copy repetitive (LCR) sequences. These regions are also flanked by 
inverted repeats 18. The 22q11.2 region contains eight LCR regions (LCR A-H, as shown 
Figure 1-1. Genomic rearrangements in 22q11.2DS. (A) Non-allelic homologous 
recombination (NAHR) events between paired low-copy repeats (LCRs)/segmental 
duplications (SDs). Paired LCRs/SDs are depicted as bold arrows (red and blue) with the 
orientation indicated by arrowheads. (A.1) The inter-chromatid NAHR events between directly 
oriented LCRs/SDs result in deletions and duplications. (A.2) The intra-chromatid NAHR events 
between directly oriented LCRs/SDs can generate deletions and ring-shaped DNA segments that 
will be lost in subsequent cell divisions. Figure and legend adapted from Chen 2015 490, used 
under CC BY-NY 3.0 license. (B) 22q11.2 region breakpoints and recombination events. The 
22q11.2DS LCR A to LCR B and LCR A to LCR D deletions are also referred as proximal 
deletions. Not all types of atypical deletions are represented. The region delimited by the LCR A 
to LCR B deletion is highlighted in light blue. Source: UCSC Genome Browser 491. Deletions and 
duplication events as described in Torres-Juan 2007 24 and Burnside 2015 17. LCR regions 
coordinates are as defined in Mikhail 2014 22 (GRCh37/hg19). 
A.1 
B 
A.2 
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Figure 1-1.B). Low-copy repeats are regions of the genome whose sequence share high 
degree of similarity and act as hotspots for non-allelic homologous recombination 
(NAHR) (as reviewed in Gu 2008 19). During meiosis and mitosis, alignment of these 
highly similar sequences can occur and cause recombination events that will lead to 
deletion or duplication of the regions surrounded by LCRs (Figure 1-1.A). The 22q11.2 
region is affected by many NAHR events due to the presence of 8 LCRs. The common 
~1.5Mb deletion occurs between LCR A and LCR B, while the larger ~3Mb deletion 
occurs between LCR A and LCR D (Figure 1-1.B). A small percentage of 22q11.2DS 
patients (around 2%) have a deletion of around 2Mb that spans the region from LCR A 
to LCR C 20. These 3 deleted regions are also called proximal deletions. Central deletions 
have also been reported to span LCR B/C and LCR D 17. There are also deletions that 
occurs outside of these regions and that are not part of 22q11.2DS. 22q11.2 distal deletion 
syndrome is characterised by the presence of deletions of different lengths nested within 
LCR C and LCR G 21,22. Finally, 22q11.2 duplication syndrome is defined by a 
duplication of regions including LCR A to LCR D and that stop at either LCR D, LCR E 
or LCR G 23,24. 
Interestingly, it has been observed in a small sample study that familial (inherited) 
22q11.2 deletions are significantly enriched for the smaller A-B deletion rather than the 
usually more frequent A-D deletion 25.  
 
1.3.1. 22q11.2DS molecular diagnosis 
Early detection of 22q11.2 deletions implicated in 22q11.2DS was performed by 
fluorescence in situ hybridisation (FISH) 4,26. Cytogenetic testing provides accurate 
results but is time consuming, and the extent of the deletion needs to be investigated by 
the use of multiple probes. Moreover, the probes might miss more atypical deletions. This 
method is still used but does not allow more high-throughput approaches. Multiplex 
ligation-dependent probe amplification (MLPA) has also been successfully used to detect 
the presence and the size of the deletion 27,28. Using this method, a high-definition MLPA 
22q11 kit has been developed to detect CNVs at 37 loci included within the region deleted 
in 22q11.2DS and more distal regions 28. MLPA has been used to detect deletions with 
perfect sensitivity and specificity in dried blood spot samples from neonatal screening, 
which shows its potential for early diagnosis 29. Other fast and cost-effective methods that 
have been used include real-time quantitative polymerase chain reaction (qPCR) and 
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multiplexed qPCR 30,31. More advanced methods that have been employed for accurate 
detection of 22q11.2 deletions are array comparative genomic hybridization (aCGH) 32 
and next-generation sequencing. The latter has been used to detect the deletion from 
maternal plasma 33. Furthermore, these methods allow to screen the entire genome and 
assess the presence of other genomic aberrations than the deletion at 22q11.2. 
 
1.4. 22q11.2DS symptoms 
22q11.2DS patients can present a large range of different symptoms affecting many 
organs (Figure 1-2). The characteristic features of 22q11.2DS patients used to be referred 
as CATCH-22, as defined by Wilson et al. (1993): “Cardiac defects, Abnormal facies, 
Thymic hypoplasia, Cleft palate, and Hypocalcaemia resulting from 22q11 deletions” 34. 
However, it does not describe well the important heterogeneity of clinical features present 
in 22q11.2DS patients, and ignore the high incidence of neuropsychiatric symptoms 
observed. The main symptoms observed in 22q11.2DS below are reported below; a more 
extensive list of clinical feature features can be found in Robin and Schprintzen (2005) 2. 
 
1.4.1. Non-neuropsychiatric/neurological symptoms 
1.4.1.1. Congenital heart disorders 
One of the most common and well-characterised symptom in 22q11.2DS is the 
presence of congenital heart disorders. Around 80% of children born with 22q11.2 
deletion have cardiovascular anomalies (ranging from 64 to 87% depending on studies) 
35,36. The most frequent (23%, range: 13-39%) of these anomalies is the Tetralogy of 
Fallot (TF), followed by Ventricular Septal Defects (VSD) (14%, range: 13-18%), 
Interrupted Aortic Arch (IAA) (10%, range: 4-16%) and Truncus Arteriosus (TA) (6%, 
range: 0.5-10%) 35. Prenatal diagnose of congenital heart disorders in foetuses positively 
screened for 22q11.2 deletion found that only 4% of individuals presented a normal 
cardiac anatomy 37. However, 65% of all pregnancies of 22q11.2DS foetuses resulted in 
a termination of pregnancy, which would explain the difference in observed rates of 
cardiovascular anomalies.  
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1.4.1.2. Craniofacial features  
Facial dysmorphism is present in nearly all children with 22q11.2DS. The most 
commonly observed features are malar flatness, hooded eyelids, broad nasal bridge and/or 
tip, round/broad ears with thick/overfolded helix 38. Attempts at using these facial 
characteristics as a diagnosis tool by specialists resulted however in relatively low 
specificity of 22q11.2DS diagnosis (51%, and 70% sensitivity) 39. An important 
proportion of 22q11.2DS patients also present palatal anomalies. The most frequent are 
velopharyngeal insufficiencies (27-32%) and/or a cleft palate (9-11%) 40,41. Finally, 14% 
of 22q11.2DS patients have an asymmetric crying facies (due to the a unilateral 
hypoplasia of one facial muscle, the depressor anguli oris) 42. 
 
Figure 1-2. Organ and system involvement in 22q11.2 deletion syndrome. Figure reprinted by 
permission from Springer Nature: Nature Reviews Disease Primers, McDonald-McGinn 2015 492, 
copyright (2015). 
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1.4.1.3. Immune and endocrine disorders 
The abnormal development (hypoplasia) or complete absence (aplasia) of the thymus 
is relatively common in 22q11.2DS. Thymus hypoplasia is seen in around 80% of 
22q11.2DS and leads to T-cell deficits (lymphopenia) 43,44. Thymus aplasia and its 
resulting severe lymphopenia are however rare (0.5%) 45. Recurrent infections as well as 
autoimmune diseases (e.g. juvenile rheumatoid arthritis or idiopathic thrombocytopenia 
purpura) have been observed in 22q11.2DS patients but do not seem to be correlated with 
the lymphocyte counts 43. 
Around 25-30% of 22q11.2DS patients have hypoparathyroidism 46,47. It leads to low 
calcium levels (hypocalcaemia) in the majority of these patients (90%) 47 and is possibly 
associated with autoimmune diseases 46. Moreover, growth hormone deficiency has been 
observed in 22q11.2DS individuals 48,49 for which growth is known to be altered 50. 
 
1.4.2. Neuropsychiatric/Neurological symptoms 
Neuropsychiatric and cognitive impairments have a high incidence in 22q11.2DS 
patients. Learning disabilities were among the symptoms first described in the 22q11.2 
deletion-associated VCFS syndrome 51. It has since then been shown that around 55-60% 
of 22q11.2DS patients have a neuropsychiatric disorder 52–54. A study of 32 patients with 
a confirmed 22q11.2 deletion (with ages ranging from 5 to 33 years) indicated that only 
6% of them had a normal IQ and no psychiatric disorders. These disorders have varying 
incidence during the patients’ lifetime and include notably psychotic disorders 
(schizophrenia in particular), mood and anxiety disorders, autism spectrum disorders 
(ASD), attention-deficit/hyperactivity disorders (ADHD) 55. Many studies have 
investigated the cognitive and psychiatric changes in 22q11.2DS patients, as reviewed by 
Philip and Bassett (2011) 56, however most were of relatively small sample cohorts. The 
International 22q11.2 Brain Behaviour Consortium (22q11 IBBC) is an international 
effort to study 22q11.2DS genotypes, phenotypes and their relations at a large scale. The 
results from their published studies, including hundreds of 22q11.2DS patients, are 
discussed below. 
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1.4.2.1. Neuropsychiatric symptoms 
The 22q11 IBBC published in 2014 a study that investigated psychiatric morbidity in 
1402 patients with 22q11.2DS 57. Participants (6-68 years, mean = 18.78, SD=10.66) were 
divided into 5 age groups: children (6–12 years), adolescents (13–17 years); emerging 
adults (18–25 years), young adults (26–35 years), and mature adults (≥36 years) (N = 
456/346/323/150/127 respectively). The prevalence of each psychiatric disorder obtained 
in this study is described in Table 1-2. In children, the prevailing disorders observed were 
ADHD (37%), anxiety disorders (36%), disruptive disorders (14%) and ASD (13%). On 
the other hand, in adult there was a large incidence of schizophrenia spectrum disorders 
(23% to 42% depending on age group) which was mostly due the presence of 
schizophrenia (13% to 30%). These results were concordant with early studies showing 
a prevalence rate of psychotic disorder in 22q11.2DS adult patients of 30% and around 
23-24% for schizophrenia 58,59. The other most prevalent disorders in adults are anxiety 
disorders (24-28%), mood disorders (15-20%), ASD (16%) and ADHD (16%). 
During the lifespan of these 22q11.2DS patients, there was a significant increase in the 
prevalence rate of schizophrenia spectrum disorder, panic disorders and major depressive 
disorder. Conversely, there was a decrease in the rates of most anxiety disorders 57. There 
were significant comorbidity associations between anxiety disorders, mood disorders and 
schizophrenia. Gender was not shown to affect the prevalence of psychotic disorders but 
there was a higher frequency of disruptive disorders and ADHD in males and a higher 
frequency of mood and anxiety disorders in females (for adults). 
 
1.4.2.2. Cognitive impairment and links to schizophrenia 
It has been shown in the past that 22q11.2DS patients have on average a lower full-
scale IQ, typically within the borderline intellectual functioning range (70-85) 52,60,61. In 
the 22q11.2 IBBC cohort the average full-scale IQ was 71 points, with 46% of patients 
presenting intellectual disability scores (< 70) 57. Moreover, cognitive impairments were 
associated with schizophrenic spectrum disorders. A longitudinal study by the same 
consortium (N = 829 patients) has reported that 22q11.2DS patients with an IQ lower at 
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first cognitive assessment had an increased rate of psychotic disorder in subsequent IQ 
with age, and this decline was significantly increased in the patients that developed a 
psychotic disorder compared to the ones that did not. However, this decrease in IQ in 
22Q11.2DS patients was not observed in another recent study 62. 
 
Table 1-2. Prevalence of psychiatric disorders (DSM-IV-TR) in five age groups of subjects 
with 22q11.2 DS. Figure from Schneider 2014 57. Reprinted with permission from The American 
Journal of Psychiatry, (Copyright©2014). American Psychiatric Association. All Rights 
Reserved. 
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1.4.2.3. Early-onset Parkinson disease  
Multiple clinical cases of 22q11.2 patients with early onset (< 45 years old) 
Parkinson’s disease (PD) have been reported 63–66. Butcher et al. reported in 2013 that the 
occurrence of early-onset PD was significantly increased in 22q11.2DS patients 
compared to the general population 67. Similar results were shown in 2016 by Mok et al. 
who also demonstrated that in a large cohort of PD patients, the rate of previously 
undetected deletions at 22q11.2 was significantly greater than that seen in population 
controls, and that this was further enriched in patients with early onset PD 68. 
 
1.4.3. Reduced lifespan in 22q11.2DS patients 
A retrospective study done by Repetto et al. in 2014 investigated fatality rates in 
22q11.2DS from 0 to 52 years (median age of patients: 12 years old) 69. They observed a 
median age of death of 3.4 months (ranging from 3 days to 32.4 years, with only two 
patients dying later than 2 years old). The study showed a significant association of 
mortality with the presence of congenital heart disorders, hypocalcaemia and airway 
malacia. A study including only adult 22q11.2DS patients showed that only 95%, 90% 
and 74% survived to age 30, 40 and 50 respectively, with a median age of death of 41.5 
years (ranging from 18 to 69 in a study including only adults) 70. Death rates in adults 
were not apparently associated with congenital heart disorders nor schizophrenia. 
 
1.4.4. Deletion size and phenotypes 
No study has identified a significant correlation between clinical and neuropsychiatric 
phenotypes and the size of the deletion (smaller A-B or larger A-D) 16,71,72. However, due 
to the small percentage of 22q11.2DS patients with the A-B deletion (5-10%), statistical 
analysis is challenging. For instance, Michaelovsky et al. compared symptoms of 97 
patients with the larger A-D deletion versus 8 patients with a smaller A-B deletion 71. No 
patient with an A-B deletion presented hypocalcaemia, while around 30% of patients with 
the large A-D deletion had this symptom. Despite this, it was not possible to draw a 
definitive conclusion based on the relatively low number of patients. On the other hand, 
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there is evidence indicating that patients with an atypical distal deletion that does not 
overlap with the A-B region might show different phenotypes. This type of deletion has 
not been detected in patients with typical VCFS phenotypes and/or conotruncal heart 
defects, but it has been reported in patients with milder and more atypical VCFS 
phenotypes 73.  
A B 
Figure 1-3. Genes located within the 22q11.2 region. (A) Transcripts included within the 
large and small 22q11.2 DS deletion. The genes included within the small regions are 
highlighted in light blue. Source: UCSC Genome Browser 491. (B) List of all genes included 
within the LCR A to LCR B deletion. Protein coding genes are indicated in bold. Brain 
expressed genes are noted with an asterisk * 74. The genes are sorted by chromosomal location. 
Source: UCSC Genome Browser 491 - RefSeq genes data.  
Gene name
USP18
LOC100996415
LOC105379550
LINC01662
GGT3P
LOC102725072
LINC01663
DGCR6 *
PRODH *
DGCR5
DGCR9
DGCR10
DGCR2 *
DGCR11
DGCR14 *
TSSK2
GSC2
LINC01311
SLC25A1 *
CLTCL1 *
HIRA *
MRPL40 *
C22orf39 *
UFD1 *
CDC45 *
CLDN5 *
LINC00895
SEPT5 *
SEPT5-GP1BB
GP1BB *
TBX1 *
GNB1L *
RTL10 *
TXNRD2 *
COMT *
MIR4761
ARVCF *
TANGO2 *
MIR185 *
DGCR8 *
MIR3618
MIR1306 *
TRMT2A *
MIR6816
RANBP1 *
SNORA77B
ZDHHC8 *
CCDC188
LOC284865
LINC00896
RTN4R *
MIR1286 *
DGCR6L *
LOC101927859
FAM230A
TMEM191B
PI4KAP1
RIMBP3
LINC01660
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1.5. 22q11.2 deletion: genes, synteny and animal models 
1.5.1. Genes within the deletion 
There are 92 genes spanned by the larger A-D 22q11.2 deletion, of which 53 are 
protein coding (UCSC RefSeq gene data) (Figure 1-3.A). 59 genes are included in the 
smaller ~1.5 Mb region that is flanked by LCR A and LCR B. This includes 32 protein 
coding genes (Figure 1-3.B), 27 of which (84%) have been shown to be expressed in the 
brain 74. The other genes are microRNA genes (miR-4761, miR-185, miR-3618, miR-
1306, miR-6816, miR-1286), non-coding RNA genes and pseudogenes.  
 
1.5.2. Inter-species synteny 
Genes within the 22q11.2 region appear to be well conserved between species. 
Comparative mapping of 46 protein coding genes contained within the human 22q11.2 
A-D deletion has found 40 conserved homologues genes in M.musculus, 37 in D.rerio, 
22 in D.melanogaster and 17 in C.elegans 74. The mouse syntenic region is shown in 
Figure 1-4. This homology between species has allowed animal models to be created and 
these have facilitated studies of the impact of the heterozygous or homozygous deletions 
of 22q11.2 genes. Guna et al. have reviewed in 2015 all the available single-gene knock-
out and knock-down models for 22q11.2 genes in these 4 animal species, as well as 
phenotypic observations 74. In particular, 31 of the 40 mouse homologues of 22q11.2 
deletion genes have available knock-out strains. Moreover, multigene deletions have also 
been generated, some of which include all 27 conserved protein coding genes homologous 
to the human LCRA to LCR D deletion genes (Figure 1-4). 
 
1.5.3. 22q11.2DS mice model principal phenotypes 
The deletion in mice of the region syntenic to the smaller A-B deletion (such as Df1, 
LgDel or Df(16)A models, Figure 1-4) has been shown to result in phenotypes that 
reproduce some of the clinical features observed in 22q11.2DS patients. In 1999 Lindsay 
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et al. reported the first 22q11.2DS mouse model, Df1/+ 75. Mice from this strain exhibited 
cardiovascular defects similar to what is observed in 22q11.2Ds patients 35, such as 
Figure 1-4. Human chromosome 22q11.2 region, syntenic mouse region and mouse models 
of 22q11.2 deletion. Each circle represents one gene. The lower part of the figure represents 
various multigene deletion models that have been characterized for neuronal and behavioural 
abnormalities labelled using their Mouse Genome Database (MGD) allele symbols and commonly 
used synonyms. Upper part: figure adapted from Arguello 2013 493, used under CC-BY 3.0 
licence; lower part: figure reprinted by permission from Springer Nature: Nature Reviews 
Neuroscience,  Karayiorgou 2010 494, copyright (2010). 
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interrupted aortic archs or ventricular septal defects. Mersher et al. found similar 
cardiovascular defects in another model that included 5 more genes (LgDel/+, cf. Figure 
1-4) 76. Other observations in these mice included increased perinatal lethality and 
parathyroid hypoplasia, which are 22q11.2DS human phenotypes 46,47,69. 
22q11.2DS mouse models also exhibited behavioural deficits. Paylor et al. reported 
that the Df1/+ mice have an abnormal sensorimotor gating 77. This has also been reported 
in the Df(16)A+/- 22q11.2DS mouse model 78. The observed reduced pre-pulse inhibition 
has been considered to be an endophenotype of schizophrenia 79, and this reduction in 
pre-pulse inhibition has also been reported in children with 22q11.2DS 80. Other reported 
behavioural changes for these 22q11.2DS mice includes hyperactivity, reduced freezing 
during contextual fear-conditioning tests and impaired spatial working memory-based 
learning (Df(16A+/-) 78. The deficits in spatial memory in adult 22q11.2DS mice have been 
linked to enhanced hippocampal long-term potentiation (LTP) 81–83. 
 
1.6. 22q11.2 deletion: potential schizophrenia candidate genes 
The observed rate of schizophrenia in 22q11.2DS adult patients (around 25-30%) 57–
59 is more than 30 time higher than the lifetime morbid risk of schizophrenia in the general 
population of 0.72% (median lifetime morbid risk from a 2008 systematic review of 
schizophrenia prevalence rates, mean = 1.19%, sd. = 1.08% 84). The 22q11.2 deletion is 
the highest known risk factor associated with schizophrenia and is present in around 0.3% 
of all schizophrenia patients 85–87. For these reasons, this thesis is mainly focused on the 
study of schizophrenia in the context of 22q11.2DS. The similarity of neuropsychiatric 
symptoms in 22q11.2DS patients with both A-B and A-D deletions suggest that the genes 
relevant to these psychiatric features are included within the 1.5 Mb deletion spanning 
from LCR A to LCR B. The following sections briefly discuss the most relevant genes 
mapped to the A-B 22q11.2 deletion and their potential links to schizophrenia.  
 
1.6.1. COMT 
The COMT gene codes for the catechol-O-methyltransferase protein, an enzyme 
involved in the metabolic degradation of catecholamines such as the neurotransmitters 
dopamine and norepinephrine. The gene codes for two variants, one soluble (S-COMT) 
and one membrane bound (MB-COMT) 88. A polymorphism located at position 108 and 
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158 of these two variants respectively (Val/Met, known as Val158Met) have been shown 
in 1996 by Lachman et al. to be associated with the COMT enzyme activity 89. It was 
later demonstrated that it was altering both the activity and quantity of the enzyme in 
post-mortem human brain 90. Despite early studies showing an association of this 
Figure 1-5. Schizophrenia GWAS results for the region 22q11.2 (LCR A to LCR B) (non-
22q11.2DS specific analysis). Data from the summary statistic of the most powerful genome-
wide association study (GWAS) to date (Ripke et al. 2014 92). Plot generated with LocusZoom.js 
(LocusZoom.org 495) and UCSC genome browser 491. No common polymorphism has p-value 
lower than the genome-wide significance threshold (p = 5*10-8); thus no polymorphism within 
the small 22q11.2 deletion is significantly associated with schizophrenia in this study. The lowest 
P-value is associated with the ZDHHC8 gene (purple diamond, p = 3.98*10-6). 
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polymorphism with schizophrenia risk there is no consensus in more recent studies and 
its implication in schizophrenia is debated (as reviewed by Williams 2007 91). While no 
association between common polymorphisms at the COMT locus and schizophrenia has 
been detected in the largest schizophrenia genome-wide association study (2014, cf. 
Figure 1-5) 92, a meta-analysis performed by Gonzalez-Castro et al. in 2016 (including 
more than 15000 schizophrenia patients and 17000 controls) has shown an association 
between the Val158Met allele and this psychiatric disorder 
93. Moreover, it has been shown 
that the DNA methylation levels (an epigenetic mark) of COMT isoforms promoters are 
altered in schizophrenia patients 94–96. 
 
1.6.2. PRODH 
The PRODH gene codes for the proline dehydrogenase 1, also named proline oxidase. 
Its homozygous deletion in mouse results in altered pre-pulse inhibition 97. These animals 
have highly increased proline levels, which is consistent with the hyperprolinemia that 
have been observed in schizophrenia patients with PRODH mutations 98 but also in some 
22q11.2DS patients 99. In these 22q11.2DS patients with hyperprolinemia, high proline 
levels was associated with lower IQ 99. Association studies investigating links between 
PRODH polymorphisms and schizophrenia have had mixed results, as reviewed in Willis 
2008 100.  
 
1.6.3. TBX1 
The TBX1 gene (T-box 1) is a member of the transcription factors T-box gene family 
which are involved in development 101. Multiple studies in 2001 have demonstrated that 
deletion of Tbx1 in mice lead to cardiovascular defects in heterozygous mutants 76,102 as 
well as thymus and parathyroid hypoplasia and craniofacial defects in homozygous 
mutants 103. TBX1 has therefore been proposed to be one of main genetic drivers related 
to the abnormal development and congenital disorders observed in 22q11.1DS patients. 
It has been suggested that these observed phenotypes are due to an abnormal migration 
and distribution of the neural crest cells 104 which are involved in the development of 
these tissues 105–107. The heterozygous deletion of Tbx1 has been shown to affect 
sensorimotor gating in mice (reduced pre-pulse inhibition) 77. Moreover Tbx1+/- also 
present behavioural deficits related to autism spectrum disorders such impaired working 
memory, ultrasonic vocalisation and social interaction 108. Finally, mesoderm-specific 
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heterozygous expression of Tbx1 also results in abnormal cortical development 109. 
Clinical case studies have reported patients with specific mutations of TBX1 but without 
the 22q11.2 deletion that presented similar clinical features than 22q11.2DS patients, such 
as the characteristic facial features, congenital heart disorders and neuropsychiatric 
disorders (ASD, mental retardation or behavioural issues) 77,110,111.  
 
1.6.4. GNB1L 
The heterozygous knock-out of the Gnb1l gene (guanine nucleotide-binding protein, 
beta-1-like) in mouse has shown reduced pre-pulse inhibition 77. Moreover, while single 
nucleotide polymorphisms (SNPs) within this gene have been associated with increased 
schizophrenia risk in association studies 112,113, the results have not been replicated in the 
most powerful genome-wide association study to date 92 (Figure 1-5). Nevertheless, it has 
been shown that some GNB1L SNPs alleles are expression quantitative trait loci 
(eQTLs)113,114, which means that they are correlated with, and could possibly have an 
effect on gene expression. This is of particular interest as GNB1L mRNA and protein have 
been shown to be reduced in brain tissue of schizophrenia patients, and that treatment 
with haloperidol, an antipsychotic drug, in mouse lead to increase Gnb1l expression 115. 
 
1.6.5. ZDHHC8 
Early studies have associated SNPs within the ZDHHC8 gene (zinc finger DHHC 
domain-containing protein 8) with schizophrenia risk 116–118. However, more recent 
association studies (trio studies and genome-wide association studies) in larger samples 
have failed to replicate this result 92,119 (Figure 1-5). Nonetheless, ZDHHC8 is an 
interesting candidate to study 22q11.2DS neuropsychiatric disorders. This gene codes for 
a brain-expressed palmitoyltransferase 118. Palmitoylation is a type of lipid modification 
that has been shown to be important for neuronal development and synaptic plasticity, 
targeting proteins such as the post-synaptic protein PSD95 and paralemmin 1 protein 
which are essential for dendritic spine formation (as reviewed in Fukata 2010 120). Mice 
knocked-out of this gene have been shown to have behavioural effects such as decreased 
pre-pulse inhibition 118 and impaired spatial working memory 121. Primary neuronal 
culture from Zdhhc8+/- mice has shown a reduced dendritic complexity and spine density 
that was also observed for a mouse model of 22q11.2DS 122. Interestingly, transfecting 
ZDHHC8 back into neurons of this mouse model resulted in the abnormal spine density 
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phenotype being rescued. Studies suggest that the observed dendritic and as well as 
axonal deficits in Zdhhc8+/- mice are due to abnormal palmitoylation of PSD95 and 
particularly CDC42, a protein involved in the Akt/Gsk3 pathway 121–123. 
 
1.6.6. DGCR2 
Polymorphisms within the DGCR2 gene (DiGeorge syndrome critical region Gene 2) 
have been associated with schizophrenia and a reduction of DGCR2 mRNA levels 124. 
While this association has not been replicated in the most powerful schizophrenia GWAS 
92 (Figure 1-5), other lines of evidence support potential links between DGCR2 and 
schizophrenia. Firstly, exome sequencing identified a potentially disruptive de novo 
mutation in this gene in a schizophrenia patient 125, while secondly, its expression has 
been found to be greater in the dorsolateral prefrontal cortex of schizophrenic patients 
compared to individuals without neuropsychiatric disorders 124. Moreover, treatment with 
antipsychotics such as clozapine lead to higher levels of DGCR2 mRNA in rat prefrontal 
cortex 124. 
 
1.6.7. DGCR8 
DGCR8 (coded by DiGeorge syndrome critical region Gene 8) is a protein part of the 
microprocessor complex involved in the canonical microRNA biogenesis pathway 126. 
MicroRNAs are small RNAs molecules (~22 bp) that have been shown to have a key role 
in the posttranscriptional regulation of gene expression 127. Dgcr8 deletion leads to 
reduced microRNA levels in mouse embryonic stem cells 128. A reduction of microRNA 
levels was similarly found in the brain of Dgcr8+/- mice and the Df(16)A+/- 22q11.2 mice 
78. This dysregulation of microRNA levels was also found in the blood of 22q11.2DS 
patients 129. Analysis of post-mortem brain from schizophrenia patients has shown that a 
subset of microRNAs had significantly altered levels, which were reduced in most cases 
130–133. Many microRNAs have been linked to schizophrenia, as reviewed in Beveridge 
and Cairns (2012) 134. The potential role of DGCR8 in the aetiology of schizophrenia in 
the context of 22q11.2DS is further discussed later in this introduction (section 1.7.3.4 
p.24) as well as in Chapter 4 (p.81) and Chapter 5 (p.106). 
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1.7. Phenotypic variability and neuropsychiatric disorders in 
22q11.2DS. 
22q11.2DS diagnosis is defined by the presence of the hemizygous deletion at 
chromosome 22q11.2. However, despite the primary mutation being common between 
all patients there is an important heterogeneity of symptoms between these individuals 
with the deletion. Some 22q11.2DS patients are relatively asymptomatic and the presence 
of the deletion is only discovered due to its transmission to a child in familial cases 9. 
While the incidence of congenital disorders such as cardiovascular and craniofacial 
defects tend to be high 35,36,38, the incidence of neuropsychiatric disorders is more variable 
(Table 1-2). The following sections will review possible molecular mechanisms that 
could explain the phenotypic variability observed in 22q11.2DS patients. 
 
1.7.1. Deletion size and breakpoint heterogeneity 
The different size and breakpoints (proximal, central, distal) of the 22q11.2DS deletion 
could lead to a phenotypic variability between patients by encompassing different set of 
genes. Lopez-Rivera et al. (2017) have screened 2080 patients with kidney and urinary 
tract congenital defects for the 22q11.2 deletion and have detected 14 patients with a 
deletion at chromosome 22q11.2 135. Three types of deletions were detected in these 
patients: large proximal deletion (LCR A to LCR D), and two types of central deletions 
(LCR B to LCR D and LCR C to LCR D, cf. Figure 1-1.B). They all had in common the 
region going from LCR C to LCR D; and further work associated these congenital defects 
to the deletion of the CRKL gene included in this region 135. In consequence, patients with 
either the typical small (LCR A to B) or large (LCR A to D) proximal 22q11.2 deletion 
are likely to show different renal phenotypes due to the deletion (or not) of this gene.  
No differences in neuropsychiatric symptoms have been observed between patients 
with either A-B or A-D deletions 16,71,72. This indicates that the main genetic driver of 
these features is included within the A-B deletion, which is nested within the larger A-D 
deletion. 
However, while all patients with these deletions will share a common set of deleted 
genes, the exact size of the deletion may vary. Non-allelic homologous recombination 
(NAHR) events leading to the deletion occurs at the LCR regions (Figure 1-1.A), but the 
exact breakpoint within these LCRs has been shown to vary, resulting in different deletion 
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sizes. Weksberg et al. used qPCR analysis to identify that some patients reported to have 
an A-D 22q11.2 deletion still had both chromosomal copies of the region between 
PRODH and DGCR2, while this region was included within the deletion of the majority 
of patients 136. The variability in deletion breakpoints between 22q11.2DS patients was 
also confirmed using a more precise method (microarray comparative genomic 
hybridisation) 32,137. In a set of 20 patients, the size of the deletion ranged from 2.49 Mb 
to 3.09 Mb due to different breakpoints; for instance, 6 different breakpoints were 
detected within LCR-A 32. As a consequence, genes such as DGCR6 or PRODH are not 
necessarily included within the deletion for all patients and it might lead to inter-patient 
symptomatic variability. In particular, PRODH has been shown to be potentially 
associated with hyperprolinemia, IQ and schizophrenia 97–100.  
 
1.7.2. Variability of expression of dosage-sensitive genes  
The deletion of 22q11.2 genes will, theoretically, lead to a reduction in gene expression 
by half. This expression could however differ from this expected result due to different 
mechanisms of post-transcriptional regulation and homeostasis. Some genes, called 
dosage-sensitive genes, are particularly affected by such changes in expression and are 
more likely than others to lead to phenotypic changes 138. These phenotypes can occur if 
the amount of protein coded by a dosage-sensitive gene is below or above a certain 
threshold. The heterozygous knock-out of single genes within 22q11.2 syntenic region in 
mouse models suggest that certain genes within the deletion are dosage-sensitive (cf. 
section 1.6 page 14). Moreover, chromosomal duplication of the 22q11.2 region (cf. 
Figure 1-1.B) has been reported to be associated with a decreased risk for schizophrenia 
139. This evidence reinforces the hypothesis that genes within the 22q11.2 region that are 
potentially involved in neuropsychiatric disease are dosage sensitive. 
Gene expression is variable between individuals, and will depends on other factors, 
such as inherited variation 140 as well as environmental signals 141. These different effects 
on gene expression will be added to the changes due to the hemizygous deletion of 
22q11.2 genes. This will lead to a heterogeneity on the expression of these genes between 
individuals, and for dosage-sensitive genes some 22q11.2DS patients might have enough 
of the protein to not develop a phenotype while others will have the opposite effect. This 
may result in an apparent symptomatic heterogeneity. 
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1.7.3. The multiple-hit model 
The two-hit -or multiple hit- hypothesis was first proposed and later formulated by 
Nordling (1953) and Knudson (1971) respectively in the context of cancer 142,143. It 
proposes that cancer aetiology can be due to the presence of an accumulation of two or 
more mutations/genetic variants. It has since been applied to other disorders such as 
schizophrenia 144. It commonly refers to the accumulation of multiple risk factors for a 
disorder, that can be either genetic or environmental. For instance, Girirajan et al. have 
reported in 2010 evidences for such model for the developmental delay-associated 
deletion 16p12.1 145. Patients with this deletion were more likely to have a second large 
CNV (> 500kb) or chromosomal abnormality than controls. Moreover, patients with the 
16p12.1 deletion and a second “hit” had different or more severe phenotypes than the 
patients with only the 16p12.1 deletion. 
The following sections review different mechanisms that could apply to explain the 
development of psychotic disorders in 22q11.2DS symptoms, in the hypothesis of a 
multiple-hit model.  
 
1.7.3.1. Allelic variation within the intact 22q11.2 chromosome 
The deletion at chromosome 22q11.2 is hemizygous; one copy of all deleted genes is 
still present in 22q11.2DS patients. Mutations within this region that are present on the 
non-deleted allele could potentially affect the expression of these genes and/or the 
structure or function of the proteins coded by some of these genes. For instance, 
Hoogendoorm et al. have shown in 2004 in vitro (with reporter gene vectors) that different 
promoter haplotypes could lead to changes in expression of more than 1.5 fold in genes 
such as PRODH or DGCR14 146. Association studies in non-deleted individuals have been 
performed to try and determine if variants such as SNPs in genes of the 22q11.2 region 
could be linked with an increased risk of schizophrenia (for instance in Liu 2002 116). 
Some positive association with schizophrenia have been reported (cf. section 1.6 page 14) 
but no common variants within the 22q11.2 deletion have been reported in the most 
powerful to date genome-wide association study 92 (Figure 1-5). However, variants within 
this region could have a different effect in 22q11.2DS patients than in the general 
population due to the loss of one copy of the genes.  
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To investigate this issue Hestand et al. (2016) curated around 12,000 hemizygous 
variant positions after performing targeted resequencing of the deletion region in 127 
22q11.2DS patients 147. They identified in the coding regions of 22q11.2 genes 95 non-
synonymous variants, as well as three stop codon gains and two frameshift insertions. No 
significant association with schizophrenia has been found in a genetic association study 
testing single nucleotide variants, small insertions/deletions mutations and copy number 
variants within the non-deleted 22q11.2 chromosome 148. However, in comparing 40 
22q11.2DS patients with psychotic disorders and 48 22q11.2DS patients without, this 
study was probably underpowered to detect such effects and the analysis will need to be 
repeated with larger sample size cohorts. 
Variation within the intact alleles could however be associated with other 
neuropsychiatric disorders and/or affects schizophrenia endophenotypes. For instance, 
the COMT Val158Met polymorphism has been associated with multiple neuropsychiatric 
features. The COMT Met158 allele has been found to be associated with both ADHD and 
OCD in 22q11.2DS patients 149. Studies have also studied the impact of this Met158 allele 
in cognition in 22q11.2DS patients, with however mixed results 150–153. 
 
1.7.3.2. Importance of the genetic background 
Genetic association studies have identified that the genetic risk for schizophrenia 
involves multiple classes of mutations, as reviewed by Rees et al. (2015) 154. Currently, 
the analyses have focussed on two main classes of mutations, copy number variants 
(CNVs) and single-nucleotides variants (SNV), both of which can be either inherited or 
de novo mutations. The allelic frequency of these risk variants can vary from being 
common (frequency greater than 1% in the general population) to rare (<1%). In 
schizophrenia there is evidence for risk variants covering the full frequency spectrum 154. 
This includes predominantly rare CNVs such as 22q11.2DS, rare SNVs and 
insertion/deletion (indel) mutations as well as common SNVs (also named common 
single-nucleotide polymorphisms, or SNPs). In 22q11.2DS patients, such genetic variants 
that are located outside the deleted region at 22q11.2 could contribute additively to the 
total risk for schizophrenia (or other clinical features).  
This could be for instance one or more other CNVs. It has been estimated that around 
5 to 10% of the genome contributes to these mutations; however some CNVs affect 
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possible non-essential genes and do not seem to have a phenotypic effect 155. In a cohort 
of 20 22q11.2DS patients, Bittel et al. detected the presence of 254 CNVs ranging from 
400 bp to 2.4 Mb (94 duplications, 160 deletions) 32. The frequency and size of these 
CNVs appeared to be similar than in the general paediatric population. At least 11 CNVs 
have been previously implicated with an increased risk for schizophrenia (as reviewed in 
Kirov 2015) 156. Presence of one of these CNVs could thus lead to further risk in 
22q11.2DS patients, and potentially other CNVs could increase this risk interactively too 
due to the presence of the 22q11.2 deletion.  
In 2013 Williams et al. tested the two-hit hypothesis of schizophrenia in the context of 
22q11.2DS by specifically investigating CNVs presence in 48 22q11.2DS patients with 
(N=23) or without (N=25) schizophrenia 157. This study revealed that 22q11.2DS patients 
with psychosis had on average significantly larger CNVs than those without. A similar 
study was performed in 2017 by the International 22q11.2 Brain Behaviour Consortium 
(22q11 IBBC) with increased sample size (N=329 adults (>25 years old) with 22q11.2DS, 
158 with any schizophrenia spectrum disorder and 171 non-psychotic patients) 158. It did 
not report significant between-group differences in the number or size of CNVs, but the 
number of genes included within the rare exonic deletions was significantly greater in the 
22q11.2DS patients with schizophrenia. Gene-set enrichment analysis for genes within 
the CNVs (duplication or deletions) notably showed an enrichment in “Nervous system 
phenotype” genes among the duplicated genes. 
Interestingly, another study comparing 22q11.2DS patients with or without congenital 
heart disorders (CHD) revealed a significant enrichment of a specific CNV (a duplication 
at 12p13.31) in the CHD group 159. This further supported the two-hit model hypothesis 
in the development of specific symptoms for 22q11.2DS patients. 
Merico et al. (2015) assessed the presence of multiple classes of variants (common 
polymorphisms, structural variants and CNVs) in whole-genome sequencing data from 
22q11.2DS patients with or without schizophrenia 160. They identified an increased 
number of rare deleterious variants that were enriched in neurofunctional protein-coding 
genes in 22q11.2DS patients with schizophrenia. However, this nominally significant 
difference did not survive multiple-testing correction and the study was underpowered 
(N=6 for 22q11.2DS patients with schizophrenia, N=3 without). A 2016 study by Tansey 
et al. reported that schizophrenia patients with a known pathogenic CNV (such as 22q11.2 
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deletion) had an increased burden of common risk alleles compared to the general 
population 161. While this study was underpowered to detect differences between 
schizophrenic and non-schizophrenic patients for specific CNVs, it supports a multiple-
hit model in which schizophrenia risk in pathogenic CNV carriers is also due to the 
presence of other risk variants. The multiple-hit CNV/common variants hypothesis in the 
context of 22q11.2DS is discussed further and explored in Chapter 2 (p.31). 
 
1.7.3.3. Gene-environment interaction 
Multiple clinical case studies have reported monozygotic twins with a 22q11.2 deletion 
but with discordant phenotypes 162–165.While it is unclear if the size of the deletion was 
identical in these twins due to the limited resolution of the method of detection (FISH) 
used in most of these studies, one study used a microarray-based detection and did report 
that the deletion breakpoints between two monozygotic twins were discordant 165. Only 
one gene (GGT3P), included within the LCR-A region, differed between the deletions in 
the two twins, with the patient having the GGT3P+/- genotype presenting with more severe 
features of 22q11.2DS and dying prenatally (6 weeks). The inclusion or not of GGT3P in 
the deletion has not been associated to date with a different phenotype in other 22q11.2DS 
patients. The phenotypes assessed in these clinical case studies were non-psychiatric. The 
presence of different phenotypes between monozygotic twins could be due to the presence 
of postzygotic de novo mutations (such as other CNVs) but also due to environmental 
factors. 
It has been suggested that genetic and environmental interactions could increase 
schizophrenia risk, as reviewed by Brown (2011) 166. Possible environmental risk factors 
include for instance maternal infection during pregnancy, prenatal nutrients deficiencies, 
cannabis use and childhood trauma 166. Environmental factors have been shown to alter 
epigenetic mechanisms such as DNA methylation and result in changes in gene 
expression 167. Such events could occur in 22q11.2DS patients and partly explain the 
observed heterogeneity of symptoms.  
 
1.7.3.4. Epistatic interactions 
Epistasis is a term related to the interactions between genes. It has been used to define 
different ideas, as reviewed by Phillips (2008) 168. In the context of complex traits, 
 25 
 
 General Introduction 
epistatic interactions are commonly defined as “Statistical interactions between loci in 
their effect on a trait such that the impact of a particular single-locus genotype depends 
on the genotype at other loci” 169. This can be interpreted as a deviation from the expected 
outcome from the cumulative effect of two (or more) alleles or mutations (i.e. the 
cumulative effect of allele A and allele B is different from the sum of the effect of allele 
A and the effect of allele B). Epistatic interactions can for instance occur between genes 
with a redundant function or even between genes involved in the same regulatory 
pathways. The mechanisms of epistatic interactions are reviewed in Lehner 2011 170. 
Epistatic interactions affecting phenotypes in 22q11.2DS patients could occur between 
genes located within the deletion. Paternili et al. described in 2005 a murine model of 
PRODH deficiency with increased expression of COMT mRNA and protein levels 171. 
Moreover, COMT inhibition led to behavioural changes in PRODH mutants (compared 
to wild-type mice with COMT inhibition), suggesting the presence of an epistatic 
interaction between these two 22q11.2 genes. It has been shown that 22q11.2DS patients 
that have both the COMT Met158 allele and hyperprolinemia have an increased risk for 
psychosis (but not patients with only one of the two) 99. Interaction between the Met158 
allele and high proline levels have also been associated with ASD symptom severity in 
22q11.2DS patients 172. 
Epistatic interactions could also occur between genes within the deletion and genes 
located elsewhere in the genome. However, analysis of epistasis in complex traits such as 
schizophrenia is statistically and computationally challenging and will likely require large 
sample size to get significant results 169. 
 DGCR8 is one particularly interesting candidate for epistatic interactions due to the 
function of its protein in the microRNA biogenesis pathway 173. MicroRNAs are 
regulators of gene expression and can be regarded as a “buffering” system that reduce 
noise in gene expression 174. By being involved in homeostatic mechanisms, it can 
potentially reduce fluctuations in mRNA levels due to a particular stress or mutations. 
This also potentially allows the accumulation of cryptic mutations that are not expressed. 
However, in 22q11.2DS where DGCR8 is deleted, the effects of these previously silenced 
mutations could be expressed (Figure 1-6). 
Grice et al. (2015) have investigated the effect of deleting one copy 22q11.2 genes in 
Drosophila (genes orthologues of DGCR8, HIRA, SLC25A1, SEPT5, TBX1, GLBN1, 
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ZDHHC8) 175. They examined the number of neuromuscular junctions (NMJ) bouton 
number and circadian rhythms of these mutant flies, and did not observed any significant 
difference. However, they did observed differences when they examined double-
knockouts of DGCR8 (pasha in drosophila) as well as TBX1 (org-1) or DGCR8 and 
SEPT5 (sep4), which resulted in reduced NMJ bouton number and altered circadian 
rhythms. This result supports the hypothesis of DGCR8-mediated epistatic interactions 
within the 22q11.2 deletion, and could potentially be extrapolated to interactions with 
genes located outside this region. 
The hemizygous deletion of DGCR8 could also interact with other mutations affecting 
microRNAs, further affecting their expression levels. For instance, microRNA-185 (miR-
185) is among the genes deleted in 22q11.2DS (cf. Figure 1-3) but is also regulated by 
DGCR8, thus resulting in more than 50% reduction of the levels of this microRNA in the 
brain of 22q11.2DS mice (Df(16)A+/- strain) 176. Moreover, reduction of miR-185 has 
been shown to cause neuromorphological changes (such as reduced dendritic complexity) 
176. MiR-185 has also been shown to target the DNA methyltransferase protein DNMT1 
177,178. DNA methylation is an epigenetic mark known to affect gene expression and to be 
impacted by gene variation 179, potentially adding another layer of complexity in the 
possible epistatic interactions between the 22q11.2 deletion and the rest of the genome. 
A detailed description of the relationship between DNA methylation and 22q11.2DS are 
further discussed in Chapter 3 (p.49). 
Figure 1-6. DGCR8-mediated epistatic interactions in 22q11.2DS. Figure from Brzustowicz 
2012 480, used under CC BY 3.0 license. 
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Other mutations affecting microRNAs could act synergistically with the dysregulation 
of microRNA regulation due to DGCR8 haploinsufficiency. Analysis of the gene content 
of CNVs outside of 22q11.2 in 22q11.2DS patients has shown that some of them are 
overlapping a microRNA gene 137,158. While there was not an enrichment of “miRNA-
CNVs” in 22q11.2DS patients with schizophrenia (compared to 22q11.2DS patients 
without) 158, it has been shown that miRNA-CNVs are involved in biological pathways 
relevant to 22q11.2DS symptoms 137. 
 
1.8. Modelling schizophrenia with pluripotent stem cells 
Murray and Lewis (1987) formulated the hypothesis that schizophrenia is a 
neurodevelopmental disorder 180. Nowadays, this hypothesis is the most commonly 
accepted for schizophrenia aetiology, and states that neurodevelopmental deficits leading 
to schizophrenia start developing in utero and continue to develop until adolescence / 
Figure 1-7. Stem-cell derived models of schizophrenia. (A) Generation of human induced 
pluripotent stem cells (hiPSCs): fibroblasts are derived from a biopsy (e.g. skin, hair) from a 
schizophrenia patient and then reprogrammed into hiPSCs. These hiPSCs will have the same 
genetic background as the patients, including schizophrenia-associated variants (such as 22q11.2 
deletion). (B) Generation of human embryonic stem cells (hESCs) mutants. hESCs are derived 
from the inner cell mass of a human blastocyst; then a potential schizophrenia gene candidate can 
be modified with genome editing (e.g. CRISPR/Cas9, TALEN) to obtain a mutant line to test 
(such as a 22q11.2 gene knock-out). Pluripotent stem cells (hiPSCs/hESCs) can then be 
differentiated into neural progenitor cells and neurons to test a phenotype of interest.  
A 
B 
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early adulthood. This is supported by multiple lines of evidences, from longitudinal 
studies of neuropsychiatric disorders to neuroimaging studies, as reviewed in Rapoport et 
al. (2012) 181. Due to the limited availability of human brain tissue during development 
for research studies, in vitro neural differentiation of human pluripotent stem cells to 
model schizophrenia is a valid alternative. For this, two types of pluripotent stem cells 
are particularly interesting. The first ones are human induced pluripotent stem cells 
(hiPSCs). Tahakashi et al. demonstrated in 2007 that it is possible to reprogram 
differentiated cells (adult human fibroblasts) into hiPSCs by expressing only 4 factors: 
Oct3/4, Sox2, Klf4 and c-Myc (commonly called Yamanaka factors) 182. These cells will 
have the same genetic background than the original patients, including disease-associated 
mutations (Figure 1-7.A). Another type of pluripotent stem cells that can be used to study 
schizophrenia is human embryonic stem cells (hESCs). Thomson et al. (1998) 
demonstrated that it is possible to isolated these cells from the inner cell mass of human 
blastocysts 183. It is then possible to edit the genome of these cells using technologies such 
as TALEN or CRISPR/Cas9 to introduce specific disease-associated mutations (as 
reviewed by Musunuru 2013 184) (Figure 1-7.B). These two type of stem cells 
(hiPSCs/hESCs) can then be differentiated into cells from the neural lineage such as 
neural progenitor cells and cortical neurons 185,186. This allows the study of potential 
defects occurring during the formation and maturation of neurons due to schizophrenia-
specific mutations, such as the 22q11.2 deletion. For instance, by generating hiPSCs from 
patients with Rett syndrome, Marchetto et al. generated an autism spectrum disorder cell 
model. This allowed them to demonstrate that neurons derived in vitro from these cells 
had both morphological and physiological deficits compared to neurons derived from 
control hiPSCs 187. 
Multiple stem cell models of schizophrenia have already been studied. Wen et al. have 
generated hiPSCs from patients with mutations in the schizophrenia-associated gene 
DISC1 188, allowing them to observe that after neural differentiation these cells exhibited 
synaptic deficits and had an altered transcriptome 189. DISC1 disruption by genome-
editing in control hiPSCs has also been shown to affect cell fate during neuronal 
differentiation 190. Neural progenitor cells (NPC) are neurons’ precursor cells and as early 
defects observed at this stage are likely to have repercussions later during development 
in vivo, they are generally considered to be a good model to study neurodevelopmental 
defects. It has been shown that NPCs generated from hiPSCs of schizophrenia patients 
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exhibit multiple deficits such as reduced cell migration as well as transcriptomic and 
proteomic changes 191,192. The use of neurons and NPCs derived CRISPR/Cas9-edited 
hESCs and patient-specific hiPSCs in the context of 22q11.2DS and schizophrenia is 
further discussed in Chapter 4 (p.81) and Chapter 5 (p.106). 
 
1.9. Aims of the thesis 
The main aims of the thesis are: 
- To investigate the genetic and epigenetic background of 22q11.2DS patients and their 
possible links to schizophrenia. 
- To explore the role of DGCR8 during cortical neuron differentiation in human cell lines 
and its effect on gene expression. 
 
This thesis is divided into 4 results chapters with the following objectives: 
- In the Chapter 2 (p.31), I investigated the burden of common polymorphisms (SNPs) 
associated with schizophrenia in 22q11.2DS patients. For this I used a polygenic risk 
score analysis approach 193,194 that allowed me to determine if the 22q11.2DS patients 
with schizophrenia had more schizophrenia-associated SNPs than 22q11.2DS patients 
with no psychotic disorders or individuals with no pathogenic CNV and no psychotic 
disorders. It permitted to assess if these variants are playing a role in the aetiology of this 
neuropsychiatric disorder in 22q11.2DS patients. 
- In the Chapter 3 (p.49), I tried to determine changes in DNA methylation due to the 
22q11.2 deletion. I used a microarray-based method to compare the methylome of 
individuals with or without the deletion to see if there was significant changes due to these 
CNVs, and if these changes were affecting known schizophrenia genes or pathways. 
- In the Chapter 4 (p.81), I used a recent genome editing technology (CRISPR/Cas9) to 
generate DGCR8 knock-out human embryonic stem cells (hESCs). The goal of this 
chapter was to obtain haploinsufficient DGCR8+/- hESCs line that can be differentiated 
into neuronal precursor cells to study the impact of DGCR8 depletion during 
neurodifferentiation of human cell in vitro. This chapter focussed on the generation of 
these cell lines and on providing evidence of haploinsufficiency. 
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- In the Chapter 5 (p.106), I investigated the mRNA transcriptome of DGCR8+/- neural 
progenitor cells to determine the impact of the haploinsufficiency on gene expression 
during neurodifferentiation. I then compared these results to the transcriptome changes 
due to the A-D deletion at chromosome 22q11.2 in human induced pluripotent stem cell-
derived neural progenitor cells to try and determine common affected genes and 
pathways. 
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2. Schizophrenia polygenic risk score analysis in 22q11.2 
deletion syndrome patients 
2.1. Introduction  
2.1.1. Common polygenic variation and schizophrenia 
Schizophrenia has a strong genetic component leading to a high heritability in liability, 
as it has been shown by the high concordance rates in monozygotic twins (41-65%) 195. 
Sullivan et al. (2003) estimated that heritability to be around 80% 196. Schizophrenia 
heritability has been shown to follow a polygenic model rather than a single-locus model 
197,198. The genetic risk is a combination of alleles present in the population with high to 
low frequency, called common and rare variants/alleles respectively, the large majority 
of which have only a small effect on schizophrenia risk 154. Genome wide-association 
studies (GWAS) have been able to identify common variants that are associated with 
schizophrenia 199. The largest study to date was conducted by the Schizophrenia Working 
Group of the Psychiatric Genomics Consortium (PGC) and consisted of around 150,000 
samples (~1:3 cases/controls ratio) 92. It reported 108 independent genetic loci to be 
associated with schizophrenia at a level that exceeded the threshold for genome wide 
significance (p ≤ 5*10-8, as represented by the red line in Figure 2-1.A) 92. Larger sample 
sizes and advancement of analysis methods will likely lead to the discovery of more 
common variants associated with this disorder.  
 
2.1.2. Polygenic risk score 
Based on the multifactorial threshold model 200, an individual can be considered to 
develop schizophrenia when their total liability, which is composed of the cumulative 
effects of all genetic risk alleles carried (total genetic risk) as well as their exposure to 
environmental risk factors, is greater than a liability threshold (Figure 2-1.D). It is 
estimated that single-nucleotide polymorphisms (SNPs) cumulatively contribute around 
23% of the variance in liability in schizophrenia, mostly due to common variants 201. The 
aggregate risk to a disorder contributed by such common genetic variants can be 
calculated with a polygenic risk score (PRS) 193. It can be calculated with GWAS 
summary association statistics, that contains information about each SNP tested in 
GWAS, such as per-allele effect size and association p-value. The effect size, in the case 
of a binary phenotype such as schizophrenia is defined as a log odd-ratio and represents 
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the genetic risk associated with a particular SNP allele. The risk for all variants with an 
A 
B 
C D 
Figure 2-1. Polygenic risk score: theory overview. (A) Genome-Wide Association Study 
(GWAS) results: Manhattan plot showing schizophrenia association. The x axis is 
chromosomal position and the y axis is the significance (–log10 P; 2-tailed) of association 
derived by logistic regression. The red line shows the genome-wide significance level (5*10-
8). SNPs in green are in linkage disequilibrium with the index SNPs (diamonds) which 
represent independent genome-wide significant associations. Figure reprinted (adapted 
legend) by permission from Springer Nature: Nature, Ripke et al.2014 92, copyright (2014)(cf. 
ref for study details). (B) Polygenic risk score calculation. The polygenic risk score is the 
weighted sums of independent risk alleles that have been detected in GWAS such as presented 
in (A), for a p-value threshold pT. (C) Case/control PRS distribution. The distribution of PRS 
in a population follow a normal distribution. Cases/patients tested for the disease/disorder-
specific PRS will have, on average, a higher PRS even though case and control distributions 
will overlap. High or low PRS imply high or low probability of developing the disorder. (D) 
Genetic liability. The PRS is part of the total genetic liability that also include other type of 
variants. The minimum genetic liability sufficient to cause the disorder (liability threshold) is 
represented by a red dotted bar. 
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association p-value below a pre-defined significance level is considered in aggregate to 
constitute the PRS, as shown Figure 2-1.B. This allows a PRS for a given disease to be 
calculated for each individual. For a polygenic disorder, the average PRS will be expected 
to be higher for the case population (with the disorder) than for the controls (Figure 
2-1.C). PRS is typically calculated using SNPs selected at a range of p-value thresholds, 
and while lower thresholds will include less false-positive SNPs, their smaller numbers 
will limit the power of detecting differences in the PRS between cases and controls. 
 
2.1.3. Polygenic risk score and schizophrenia 
Polygenic risk score has been successfully applied to schizophrenia GWAS data 202 
when it was demonstrated that, despite failing to meet the stringent genome-wide 
association criteria, a large proportion of genetic loci accounted for a consequential 
proportion of variation in risk between individuals. A more recent analysis of common 
variants in a larger, more powerful GWAS determined that around 7% of variance in 
liability can be explained by PRS, with around half of it due to genome-wide significant 
loci 92.  
 
2.1.3.1. Schizophrenia PRS and schizophrenia aetiology 
The schizophrenia PRS has been used to get a better understanding of the aetiology 
of this disorder. In children (7-9 years), this risk score is significantly associated with a 
range of cognitive, social, behavioural and emotional deficits that are linked with 
schizophrenia 203,204. Schizophrenia PRS has also shown association with negative 
syndromes and anxiety disorders during adolescence (12-18 years), but not positive 
symptoms such as psychotic experiences 205. Moreover, children with child-onset 
schizophrenia, a severe form of the disorder with an age of onset before 13 years of age, 
have a higher polygenic risk score than their healthy siblings 206. This suggests the 
importance of the schizophrenia PRS to understand the disorder and possibly try and 
predict its onset. In individuals with first-episode psychosis, PRS has been shown to 
significantly discriminate individuals that were later on diagnosed with either 
schizophrenia or other psychotic disorders 207. The accuracy of this method is however 
still limited. The PRS of individuals with schizophrenia that reported a family history of 
psychotic illness have been reported to be higher than the ones without such history 208. 
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This could indicate a more familial subtype of schizophrenia, in which case in the future 
PRS screening could potentially help early diagnosis of schizophrenia. 
 
2.1.3.2. Schizophrenia PRS and brain imaging studies 
The joint analysis of brain imaging techniques and polygenic risk score is also helping 
to understand schizophrenia and its endophenotypes. Higher PRS for schizophrenia have 
been significantly associated with reduced total brain 209 and white matter volumes 209,210, 
as well as greater globus pallidus volumes 211. However the association with white matter 
volume was not replicated in another study 212. Moreover, larger studies testing 
association between PRS and brain volumes in healthy individuals did not show 
significant results 213,214. In patients with first-episode psychosis or at-risk mental state 
individuals, higher PRS is associated with reduced hippocampal volume, a known marker 
of these disorders 215. Functional imaging also revealed that increased PRS was associated 
with multiple deficits such as altered brain activation in the ventral striatum and the 
frontal pole during probabilistic decision-making (choice behaviour) in healthy 
individuals 216 and neural inefficiency in the left dorsolateral prefrontal cortex in 
schizophrenia patients 217. 
 
2.1.3.3. Schizophrenia PRS and cross-disorder associations 
Some of the common variants that have been associated with schizophrenia have also 
been shown to be associated with other disorders. For instance, schizophrenia PRS is able 
to significantly discriminate individuals with bipolar disorder from controls, indicating 
that both psychiatric disorders share a genetic component 202. These results have since 
been replicated 218. Further studies showed that some genetic loci can be associated with 
multiple psychiatric disorders. A cross-study of five major psychiatric disorder (Attention 
Deficit-Hyperactivity Fisorder (ADHD); Autism Spectrum Disorders (ASD); Bipolar 
Disorder (BPD); Major Depressive Disorder (MDD); Schizophrenia) showed that the 
schizophrenia PRS discriminate controls from patients with either BPD, MDD or ASD 
(but not ADHD) 219. Conversely, PRS analyses based on either BPD, MDD or ASD 
GWAS summary statistics were able to discriminate between controls and schizophrenia 
patients. Moreover, the BPD PRS is associated with clinical symptoms in schizophrenia 
cases (namelymanic symptoms) 220. It suggests that the severity of the disorder could be 
influenced by common risk variants. Another study also presented a significant 
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association of schizophrenia PRS with obsessive-compulsive disorder (OCD) status 221. 
These cross-disorder associations with polygenic risk scores suggest that common 
biological pathways are altered within these different disorders, such as voltage-gated 
calcium-channel signalling 219.  
 
2.1.3.4. Schizophrenia PRS and 22q11.2 deletion syndrome 
A study by Merico et al. in 2015 looked at a possible association of schizophrenia PRS 
and schizophrenia status in 22q11.2 deletion syndrome patients 160. No significant 
association were found (despite a trend toward significance) but the number of samples 
tested were quite limited (6 individuals with schizophrenia versus 3 without). Tansey et 
al. have tested if the schizophrenia PRS was associated with schizophrenia status in 
individuals with a schizophrenia-associated copy-number variant (CNV) and found a 
significantly higher PRS compared to controls 161. Similarly, this study was 
underpowered to test association for individual CNVs. The results were however 
consistent with a liability threshold model (Figure 2-1.D) in which the CNVs add to the 
cumulative risk alongside other alleles such as common variants. Indeed, they reported 
that schizophrenia cases carrying a high schizophrenia odd-ratio CNV (such as 22q11.2) 
have a lower PRS than schizophrenia cases carrying a low odd-ratio CNV or no 
schizophrenia-associated CNV. In this model, the increased risk due to the presence of 
the CNV means that a lower PRS is needed to pass the liability threshold. 
 
2.2. Aims of the chapter 
The work described in this chapter set out to determine if 22q11.2 deletion carriers 
with schizophrenia have a significantly greater schizophrenia PRS than deletion carriers 
with no psychotic symptoms. To achieve this, schizophrenia PRS was calculated in the 
largest to date (to our knowledge) sample of 22q11.2 deletion syndrome patients. This 
will determine if the aetiology of schizophrenia in 22q11.2 deletion syndrome is due, at 
least in part, to common risk variants associated with the disorder. To follow up this 
analysis, the odds ratio conferred by schizophrenia PRS in 22q11.2 deletion carriers was 
compared to that seen in idiopathic schizophrenics and population controls who did not 
carry a CNV at 22q11.2. The aim of this secondary analysis was to help investigate if 
schizophrenia in 22q11.2 deletion syndrome followed a liability threshold model. 
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2.3. Methods   
2.3.1. Cohorts 
2.3.1.1. CLOZUK cohort 
In the following study, the “CLOZUK” samples refer to the cohort of idiopathic 
schizophrenia cases and general population controls. The UK Multicentre Research 
Ethics Committee approved the study and all samples were from participants who 
provided written informed consent (unless specified otherwise). Access to the dataset was 
provided by Mark Einon (Cardiff University) with the authorisation of Dr. James Walters 
(Cardiff University). It is defined as the following cases and controls: 
- Schizophrenia cases (named idiopathic schizophrenia samples) include samples from 
the CLOZUK1, CLOZUK2, COGS1 and COGS2 schizophrenia studies and have been 
described before 92,222–224. CLOZUK1/2 cases were diagnosed with treatment-resistant 
schizophrenia (TRS) and were taking Clozapine, an antipsychotic drug used to treat TRS 
and owned by Novartis, who provided CLOZUK1 blood samples. CLOZUK2 cases blood 
samples were collected in collaboration with Leyden Delta (a company involved in the 
supply and monitoring of Clozapine in the UK) as part of the European Union Seventh 
Framework Programme (EU-FP7) study CRESTAR. CLOZUK1/2 samples were 
collected anonymously in the across the United Kingdom without express patient consent 
consistently with the UK Human Tissue Act. The COGS cohorts (Cardiff Cognition in 
Schizophrenia study) include schizophrenia patients recruited in Wales and England from 
voluntary, community and inpatient sector mental health services. CLOZUK1 cases were 
genotyped at the Broad Institute (Massachusetts, USA) on Illumina HumanOmniExpress-
12v1 and HumanOmniExpressExome 8v1 arrays; CLOZUK2 and COGS cases were 
genotyped by deCODE Genetics (Reykjavík, Iceland) on Illumina HumanOmniExpress-
12v1-1_B arrays. These samples have been used in other studies 92,139,161,222,223,225–227 and 
the validity of use of TRS cases as schizophrenia samples have been demonstrated 225,227.  
- Controls are from publicly available datasets (dbGaP) and from the Wellcome Trust 
Case Control Consortium 2 (www.wtccc.org.uk/info/access_to_data_samples.html). An 
additional 900 controls (unscreened for psychiatric illness) were recruited from the UK 
National Blood Transfusion Service by Cardiff University. All controls were genotyped 
on Illumina Omni arrays. 
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2.3.1.2. 22q11.2 IBBC cohort 
The 22q11.2 IBBC (International 22q11.2 Deletion Syndrome Brain Behaviour 
Consortium) cohort has been described in Gur et al. 2017 228 and Bassett et al. 2017 158. 
Subjects were recruited from 22 international sites from Canada, USA and Europe and 
have provided informed consent. The study was approved by the local institutional 
research ethics board of each site. DNA samples were genotyped with Affymetrix 
Genome-Wide Human SNP Array 6.0 at the Albert Einstein College of Medicine (New 
York, USA). The presence and extent of the 22q11.2 deletion in individuals has been 
assessed by the consortium prior to analysis. 
In the present study only individuals older than 25 years, with or without 
schizophrenia, were kept for analysis (excluding individuals with non-schizophrenic 
psychotic disorders). Details of case/control sample sizes (after quality control) and their 
origin (international sites participating in the 22q11.2 IBBC) are described in 
Supplementary table 2-1. 
 
2.3.2. Data processing / Quality control (QC) 
The details of the data processing and quality control (QC) are described in 
Supplementary table 2-2. QC was performed with PLINK 1.9 229,230 (https://cog-
genomics.org/plink2) and in R (Microsoft R Open 3.4.0 (Microsoft), based on R-3.4.0 (R 
Statistics)). Note: 22q11.2 IBBC samples not analysed in this study (non-schizophrenic 
psychotic disorders patients and individuals < 25 y.o.) were processed at the same time 
to use for other analyses not presented here. 
A first serie of steps was performed on 22q11.2 IBBC data to prepare for imputation. 
Genotypes were called from raw intensity data with the Birdseed v2 genotyping algorithm 
231 integrated within the Affymetrix Genotyping Console (http://affymetrix.com). After 
confirming that the genotyped gender was concordant with the gender information 
available, non-autosomal SNPs, SNPs with no name or with a null allele were removed. 
Then low-quality SNPs (present in less than 95% of samples) and low-quality samples 
(with less than 97% of SNPs correctly genotyped) were removed. Genome-wide Identity-
By-Descent (IBD) was estimated to remove duplicate samples and determine cryptic 
relatedness (3rd degree relative or closer removed, PI_HAT > 0.125); for each pair of 
related samples the exclusion was done based on phenotype (cases prioritised over 
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controls) and then sample missingness (sample with lowest missingness kept). Population 
stratification analysis was performed by principal component analysis (PCA) after 
merging the data with 1000 Genomes Project data Phase 3 
(www.internationalgenome.org/data/; named 1000 Genomes data below) that contains 
genotyped samples from different ethnicities (PCA plots in Supplementary figure 2-1.A, 
1000 Genomes data population details in Supplementary table 2-3; only the Finish, Han 
Chinese (Beinjing) and Yoruba population are used for this first PCA). All PCAs were 
done using the smartpca function of EIGENSTRAT (EIGENSOFT package) 232. Samples 
that were further than 2 standard deviations from the mean of any principal components 
were excluded. Sample heterozygosity was checked, then SNPs with a Hardy-Weinberg 
equilibrium value HWE < 10e-5 have been excluded (with “mid-p” adjustment). The 
resulting dataset have been then imputed on the Michigan Imputation Server by Dr. Leon 
Hubbard, Cardiff University (Eagle V2.3 233 was used for pre-phasing, with the HRCv1.1 
as the imputation reference panel 234). 
The CLOZUK dataset has been provided already imputed, as described in Pardinas et 
al. 225. The CLOZUK dataset was phased and imputed using the SHAPEIT/IMPUTE2 
235,236 algorithms with a combination of the 1000 Genomes phase 3 (1KGPp3) and 
UK10K datasets as reference panel, while the 22q11.2 dataset has been phased and 
imputed using the Eagle2/Minimac3 algorithms 237 with the larger HRCv1.1 reference 
panel as it has been shown to allow for greater imputation accuracy than the two other 
reference panels 234. However, for common variants, both imputation algorithms have 
been shown to have similar accuracy regardless of the reference panel used 234,237. While 
the use of different imputation methods might lead to spurious association in variant 
discovery, it is less likely to affect the results of polygenic risk scoring which takes into 
account SNPs with small effect sizes all across the genome as a sum. Moreover, stringent 
quality control has been performed on both datasets before merging to obtain good quality 
data 238. 
After imputation, only SNPs with high confidence (imputation information score > 
0.9) were kept, and then filtered by missingness (< 1%) and HWE (< 10e-5, with “mid-
p” adjustment) for both 22q11.2 and CLOZUK datasets. The two datasets were then 
merged based on overlapping SNPs. SNPs present in less than 99% of samples in the 
merged dataset were removed, and an IBD analysis was performed to remove 3rd degree 
relatives and potential individuals present in both 22q11.2 and CLOZUK dataset. A 
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second population stratification analysis was done and samples further than 6 standard 
deviations away from the mean were removed (PCA plots in Supplementary figure 2-1.B, 
1000 Genomes data population details in Supplementary table 2-3). Samples from the 
CLOZUK cohort with a known pathogenic copy number variant (associated with 
schizophrenia, as characterised by Dr. Elliott Rees, Cardiff University 223) were removed, 
as well as SNPs included within the genomic region 22q11.2. Finally, SNPs with a minor 
allele frequency < 10% were removed prior to polygenic profiling. This final dataset is 
called in the following section the target sample. The number of individuals retained after 
QC are detailed Figure 2-2. 
 
2.3.3. Polygenic risk score calculation  
The polygenic risk score (PRS) of each individual has been calculated with the PRSice 
software 239. The analysis pipeline is described in Figure 2-3. We used as a discovery 
sample (training dataset) the summary statistics of a version of the latest Psychiatric 
Genomics Consortium (PGC) schizophrenia meta-analysis 92 that does not include 
samples used in the target sample (CLOZUK idiopathic schizophrenia samples and 
controls). These results generated by the PGC excluding CLOZUK samples are part of a 
leave-one out GWAS provided to the members of the consortium (Professors MJ Owen 
and MC O’Donovan), enabling independent discovery and replication data-sets for 
downstream analysis. While the 22q11.2 IBBC samples have not been molecularly 
compared for overlapping samples yet, the IBBC groups have all declared that they have 
not contributed any of these samples to the PGC. The discovery sample SNPs were 
selected at different significance of association p-value thresholds (pT < 0.0001, 0.001, 
0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1) and then clumped to include SNPs in linkage 
disequilibrium of R2 > 0.1 within 250kb windows. The polygenic risk scores were created 
Figure 2-2. Sample size and gender ratios for all groups used in analysis. 22q SCZ: 
22q11.2 deletion syndrome patients with schizophrenia (≥ 25 y.o.); 22q NonAffect: 22q11.2 
deletion syndrome individuals without psychotic disorders (≥ 25 y.o.); Controls: healthy 
control population individuals; Idiopathic SCZ: individuals with schizophrenia. Unless 
specified otherwise all the samples shown here are included in the analyses. 
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at each of the p-value thresholds pT for each sample by summing the GWAS log odd 
ratios of the included SNPs. SNPs within the MHC region were excluded from analysis 
due to the long range linkage disequilibrium in this region 240. 
 
2.3.4. Statistical analysis 
All statistical analysis was performed in R (Microsoft R Open 3.4.0 (Microsoft), based 
on R-3.4.0 (R Statistics)). The custom scripts used will be made available on GitHub 
(github.com/MonfeugaT) after publication of the results. Logistic regressions were used 
to determine the association between the PRS and phenotype status. A principal 
component analysis was run on the target sample and the first 20 principal components, 
as well as gender, were used as covariates in all statistical models. The 20 principal 
components used as covariates are represented in Supplementary figure 2-2. 4 different 
groups were defined and compared in the different analyses: 22q NonAffect: 22q11.2 
deletion syndrome patients without schizophrenia; 22q SCZ: 22q11.2 deletion syndrome 
patients with schizophrenia; Controls: control population individuals without known 
psychosis; Idiopathic schizophrenia: individuals with schizophrenia but without 22q11.2 
deletion.  
Figure 2-3. Overview of the analysis pipeline. The SNP selection, SNP clumping and PRS 
calculation steps were performed with PRSice software (REF). OR: Odd ratio; PRS: Polygenic 
Risk Score; R2: Linkage Disequilibrium R2 value; SNP: Single Nucleotide Polymorphism. 
Adapted from: SlideShare: “Analysis of the Genetic Overlap of Borderline Personality 
Disorder and Bipolar Disorder” by: Prof. Stephanie Witt (Central Institute of Mental Health, 
Mannheim) (https://www.slideshare.net/ISBD/analysis-of-the-genetic-overlap-of-
borderline-personality-disorder-and-bipolar-disorder). 
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The proportion of variance in the model explained by polygenic risk score, defined by 
the Nagelkerke R2, was obtained by subtracting the R2 of a full model including PRS and 
covariates (Phenotype ~ PRS + covariates, with Phenotype as a binary value designing 
the two group from a pairwise comparison) from the R2 of a base model only including 
covariates (Phenotype ~ covariates). Covariates include the first 20 principal components 
to account for population stratification and gender. P-values represent the association of 
the PRS with phenotype for each p-value threshold pT tested. 
Schizophrenia odds ratios and 95% confidence intervals have been calculated to 
represent the effect of PRS on schizophrenia risk, between 22q11.2 samples with or 
without schizophrenia as well as between idiopathic schizophrenia and controls. They 
were calculated using an adapted version of the corresponding function from the PRSice 
software R script, after dividing the samples into different PRS quantiles. Odds ratio and 
confidence intervals have been calculated with a logistic regression of phenotype on PRS 
decile that include gender and 20 principal components as covariates to correct for 
population stratification. Statistical comparison of odds ratio between studies, for each 
quantile tested, was performed with the rma() function of the metaphor package in R 241 
(comparison of the log odd ratios). 
No correction for multiple comparisons has been done to account for the multiple p-
value thresholds pT used due to the high correlation of results between thresholds. No 
correction was applied either to correct for the multiple group pairwise comparisons. 
However, a permutation resampling analysis was performed to control for Type I error. 
For each pairwise comparison, the phenotypes were randomised while keeping the same 
case/control ratio. The p-values shown Supplementary figure 2-4 represent the probability 
of obtaining a smaller p-value by chance after random sampling (N = 10,000 resampling). 
These p-values are described below as Pperm, while the p-values represented in Figure 
2-4.A and described as P below are obtained from the logistic regression analysis.  
Plots were generated with the ggplot2 package 242.  
 
2.4. Results  
2.4.1. Proportion of variance explained by polygenic risk score 
 Following quality control analysis, the study was left with 105 schizophrenics who 
carried a 22q11.2 deletion (22q11.2 IBBC cases), 171 deletion carriers without 
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schizophrenia (22q11.2 IBBC controls), 10,755 samples with idiopathic schizophrenia 
(CLOZUK cases) and 24,295 population controls (CLOZUK population controls) (Figure 
2-2). Pairwise-comparison of polygenic risk scores was performed between the samples 
of the 4 groups. The proportion of variance in schizophrenia explained by the PRS in the 
model between two groups is defined by the Nagelkerke’s R2, as represented Figure 
2-4.A.  
 
Figure 2-4. Proportion of variance in schizophrenia explained by polygenic risk score 
(PRS). (A) Plots of Nagelkerke’s R2 for each pairwise comparison and different p-value 
thresholds. Nagelkerke’s R2 represent the proportion of variance in schizophrenia explained 
by the polygenic risk score and is calculated by substracting the R2 of a regression model 
including PRS and covariates from the R2 of a model including covariates only (gender and 
20 principal components to control for population stratification). The p-value represented on 
top of bars represent the association of PRS with the phenotype in the model for each p-value 
threshold (shown by colors, cf. legend on top). For each “Group A – Group B” comparison, a 
positive R2 indicate that Group A is associated with an increased risk for schizophrenia. n.s.: 
non-significant. (B) Number of independent SNPs included in the analysis for each p-
value threshold pT. 
A 
B 
pT 0.0001 0.001 0.005 0.01 0.05 0.1 0.2 0.3 0.4 0.5 1
# SNPs 342 952 2226 3244 8379 12712 19360 24684 29138 32941 45713
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2.4.1.1. Comparison of schizophrenia PRS between idiopathic CLOZUK cases and 
CLOZUK population controls 
First, individuals with idiopathic schizophrenia and no 22q11.2 deletion (CLOZUK 
cases) had a significantly higher polygenic risk score than the CLOZUK population 
controls. This was obtained at all pT thresholds and is consistent with what has been 
reported previously 92 (Figure 4). At the p-value threshold pT < 0.1 (used for the following 
descriptions as the representative threshold), the PRS explained 11% of the variance 
between idiopathic schizophrenia and controls samples (pT < 0.1: R2 = 0.11, P = 0, Pperm 
< 1*10-4) (Note: p = 0 means that the P-value is too small to be computed by the R script 
used; p < 10*10-300).  
 
2.4.1.2. Comparison of schizophrenia PRS between 22q11.2 IBBC cases, 22q11.2 
IBBC controls and CLOZUK population controls 
The 22q11.2 deletion carriers with schizophrenia (22q11.2 IBBC cases) had a 
significantly higher schizophrenia PRS than the 22q11.2 deletion carriers who did not 
have schizophrenia (22q11.2 IBBC controls) (pT < 0.1: R2 = 0.065, p = 2.5*10-4, Pperm = 
2*10-4). Similarly, the 22q11.2 IBBC cases also had a significantly higher PRS than the 
CLOZUK population controls who do not carry the 22q11.2 deletion (pT < 0.1: R2 = 
0.014, p = 1.9*10-5, Pperm < 1*10
-4). Schizophrenia PRS was therefore able to significantly 
distinguish the 22q11.2 carriers with schizophrenia (22q11.2 IBBC cases) and both non-
schizophrenic groups (22q11.2 IBBC controls and CLOZUK population controls). No 
differences were observed between the two groups of non-psychotic individuals (pT < 
0.1: R2 = -5.7*10-5, p = 0.74, Pperm = 0.73). 
 
2.4.1.3. Comparison of schizophrenia PRS between CLOZUK cases and 22q11.2 
IBBC cases and 22q11.2 IBBC controls 
The CLOZUK cases had a greater PRS than both groups that carried a 22q11.2 deletion 
(IBBC cases and controls). The difference was highly significant when comparing to the 
IBBC controls (pT < 0.1: R2 = 0.041, p = 3.7*10-16, Pperm < 1*10
-4), but much less when 
comparing to IBBC cases (pT < 0.1: R2 = 0.0066, p = 6.0*10-3, Pperm = 5.4*10
-3). 
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2.4.2. Estimating the odds ratio for schizophrenia conferred by the polygenic risk 
score 
22q11.2 deletion carriers (IBBC cases and controls), idiopathic schizophrenics and 
population controls (CLOZUK cases and controls) were grouped and ranked into 
polygenic risk score quintiles and, with reference to the lowest quintile, the odds ratio for 
schizophrenia was calculated for each quintile. Only the p-value threshold pT < 0.1 has 
been tested, as it’s the threshold for which IBBC cases and IBBC controls are the most 
significantly discriminated (Cf. Figure 2-4). As it has been published previously 92, the 
odds ratios seen in idiopathic schizophrenics were greater in samples that had a higher 
PRS (i.e. those who carry a greater number of common variants associated with an 
increased risk for schizophrenia) (Figure 2-5). There was a similar trend in the IBBC 
cases; however, compared to the CLOZUK cases, the odds ratio means were greater for 
individuals with PRS in intermediates quantiles (3rd and 4th quintiles), i.e. lower PRS 
Figure 2-5. Odds ratio by polygenic risk score. Plots of odds ratio for schizophrenia by 
polygenic risk score (PRS) quantile with or without the presence of 22q11.2 deletion for p-
value threshold pT < 0.1. Odds ratio are presented by PRS quintiles. Odds ratio for 
schizophrenia calculated for samples that have the 22q11.2 deletion (with or without 
schizophrenia) are represented in red while those calculated for samples without it 
(CLOZUK/WTCCC cohorts) are represented in blue. Bars represent the 95% confidence 
interval. Odds ratio and confidence intervals have been calculated with a logistic regression of 
phenotype on PRS decile that include gender and 20 principal components as covariates to 
correct for population stratification. Significance for difference from the 1st decile is 
represented above confidence interval bars (for each study separately). The number of 
independent SNPs included at each p-value threshold is detailed in Figure 2-4.B. 
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result in larger odds ratios for schizophrenia in 22q11.2 deletion carriers compared to 
idiopathic schizophrenics (Figure 2-5). For example, at the p-value threshold pT < 0.1, 
the odd ratios for the fourth PRS quintile (Figure 2-5) is 5.01 (95% CI [2.18-11.48]) for 
the IBBC samples and 3.69 (95% CI [3.39-4.02]) for the CLOZUK samples. However, 
confidence intervals are overlapping between odd ratios for CLOZUK and IBBC samples 
and their difference is not significant (p=1 for each quintile).  
 
2.5. Discussion 
This study presents a polygenic risk score analysis for schizophrenia risk in the largest 
cohort of 22q11.2 deletion syndrome patients available to date. The goal was to determine 
if common variants previously associated with schizophrenia in genome-wide 
associations studies were involved in the aetiology of this psychiatric disorder in 
22q11.2DS. Results show that, indeed, 22q11.2 deletion carriers with schizophrenia have 
on average a greater polygenic risk score than 22q11.2 deletion carriers without psychosis 
(pT < 0.1: R2 = 0.065, p = 2.5*10-4, Pperm = 2*10
-4). The polygenic risk score explains 
around 6% of the variance in schizophrenia in 22q11.2DS patients in the model studied, 
with a mean Nagelkerke’s R2 of 0.051 between all p-value thresholds tested. 
The CLOZUK1/2 dataset is to our knowledge currently the largest available dataset of 
idiopathic schizophrenia patients and controls independent from the PGC meta-analysis 
(CLOZUK1 were included in the original PGC meta-analysis 92 but new summary 
statistics have been generated without them while CLOZUK2 samples were not in the 
original dataset). This cohort was used to assess the relative contribution of schizophrenia 
PRS in 22q11.2 deletion carriers to that seen in idiopathic schizophrenics and unscreened 
population controls. The results show that the 22q11.2 deletion carriers with 
schizophrenia had a PRS significantly higher than the control population (pT < 0.1: R2 = 
0.014, p = 1.9*10-5, Pperm < 1*10
-4) and significantly lower than the idiopathic 
schizophrenia patients (pT < 0.1: R2 = 0.0066, p = 6.0*10-3, Pperm = 5.4*10
-3). This 
observation is consistent with an additive model where both the 22q11.2 deletion and 
schizophrenia polygenic risk contribute to the overall genetic liability of the increased 
rate of schizophrenia in 22q11.2DS. 
In such a model, individuals carrying the deletion, a known risk factor for 
schizophrenia 223, require a lower polygenic risk score (relative to idiopathic 
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schizophrenics) to exceed the liability threshold required to develop schizophrenia 
(Figure 2-6). This is further supported by a comparison of the odds ratios for 
schizophrenia conferred by the PRS in 22q11.2 deletion carriers (IBBC cases) and 
idiopathic schizophrenics (CLOZUK cases). As presented in Figure 2-5 the odds ratios 
for intermediate PRS quantiles are greater for 22q11.2 deletion carriers relative to 
idiopathic schizophrenics, implying that relatively lower polygenic risk scores can confer 
a greater risk to schizophrenia in the presence of the 22q11.2 deletion. However, the odds 
ratios confidence intervals are overlapping, and the difference isn’t significant; greater 
sample size for the 22q11.2DS population would reduce the confidence intervals and help 
further comparisons of both groups. 
As high-to-intermediate PRS values could therefore be sufficient to cause 
schizophrenia in 22q11.2 deletion carriers, conversely it might also be expected that 
22q11.2 deletion carriers who do not develop schizophrenia to have on average a lower 
PRS than that seen in population controls. However, this study was not able to 
demonstrate a significant difference between the IBBC controls and the CLOZUK 
population controls (pT < 0.1: R2 = -5.7*10-5, p = 0.74, Pperm = 0.73). It is possible that 
this could be due to insufficient power, and if so then an increased sample size will be 
needed in the future to determine if it is possible to demonstrate a significant difference 
in schizophrenia PRS between non-schizophrenic individuals carrying a 22q11.2 deletion 
and population controls.  
Figure 2-6. Effect of 22q11.2 deletion on genetic liability. The 22q11.2 deletion participate 
to the genetic liability and will lead to a shift of the population curve. In consequence, 
polygenic risk score will pass the threshold with lower values than in a population with 
individuals that do not have the deletion. The minimum genetic liability sufficient to cause the 
disorder (liability threshold) is represented by a red dotted bar. 
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Schizophrenia PRS explained a higher percentage of the variance in this model when 
comparing the IBBC cases and IBBC controls (pT < 0.1: R2 = 0.065, p = 2.5*10-4, Pperm 
= 2*10-4) than when the IBBC cases and CLOZUK population controls were compared 
(pT < 0.1: R2 = 0.014, p = 1.9*10-5, Pperm < 1*10
-4) (Figure 2-4, Supplementary figure 
2-4). The difference in variance in schizophrenia explained by PRS in this model could 
be due to the deletion, as in one comparison (IBBC cases and CLOZUK population 
controls) some of the variance in schizophrenia will be explained by the effect of the 
deletion itself. This difference could be due to a direct effect of the deletion but also to an 
interaction effect between the deletion and common variants. 
The PRS explained a lower percentage of the variance in this model when comparing 
the IBBC cases and IBBC controls (pT < 0.1: R2 = 0.065, p = 2.5*10-4, Pperm = 2*10
-4) 
than that seen when the CLOZUK cases and CLOZUK population controls (pT < 0.1: R2 
= 0.11, P = 0, Pperm < 1*10
-4) were compared (Figure 2-4, Supplementary figure 2-4). As 
one test compares both groups with a 22q11.2 deletion and the other includes no deletion 
carriers, the difference in variance in schizophrenia might be due to an interaction effect 
of the 22q11.2 deletion with common variants, rather than a direct effect. Indeed, in the 
comparison of IBBC cases and IBBC controls the deletion is not part of the variance in 
schizophrenia as it is present in both cases and controls. In consequence, it is possible that 
an epistatic effect between PRS and deletion is taking place (interaction between the 
deletion and common variants). 
Careful interpretation of these results is needed; however, they support an additive 
model where both the deletion and common variants are part of the genetic liability. This 
observation is concordant with an earlier study of PRS in schizophrenia-related CNVs (as 
a group) 161.  
 
There are differences in gender ratios (male/female) between the 4 groups tested, as 
shown Figure 2-2. However, performing permutation analysis while keeping similar 
gender ratio between groups shows that it does not seem to affect the results 
(Supplementary figure 2-3). Furthermore, despite unequal sample sizes between the 
groups, the R2 values and their differences between pairwise comparison is consistent 
when performing random sampling of equal sample size in each group, as shown in 
Supplementary figure 2-5.  
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The number of SNPs used to detect PRS differences between the IBBC cases and 
controls was relatively low (Figure 2-4.B) due to the joint data processing and quality 
control with the CLOZUK data cohort, which was genotyped using different array 
technology. While genotype imputation helped to improve the number of overlapping 
variants between the different types of arrays used in the two cohorts (CLOZUK/22q11.2 
IBBC), the number of high quality imputed SNPs remained low after QC. Processing the 
22q11.2 IBBC data separately yielded around twice as many SNPs tested at each p-value 
threshold (Supplementary figure 2-6.C) and resulted in similar levels of variance 
explained by the PRS (Supplementary figure 2-6.A). Another possible concern would be 
the multiple origins of the samples collected within the 22q11.2 IBBC cohort, that could 
lead to an ascertainment bias. For this reason, the sample origin has been added to the 
regression model to compare 22q11.2DS samples with or without schizophrenia (for the 
22q11.2 dataset processed independently). No major differences were observed when 
correcting for this potential bias (Supplementary figure 2-6.B).  
 
Increased sample sizes and further investigation will be needed to characterise the 
difference in variance in schizophrenia explained by PRS with or without the presence of 
the deletion. The polygenic risk score tends to underestimate the total variation in liability 
explained by the PRS because of errors in the estimation of variants effects 243,244. For 
this reason, it is different than the Nagelkerke’s R2 calculated in the present study. Future 
work will focus on trying to estimate this variance explained by all schizophrenia-
associated SNPs in 22q11.2 by using software such as GCTA 245. Another future goal will 
be to try and explore possible epistatic interactions between the deletion and other 
variants. Some genes located within the 22q11.2 deletion could play a role in such 
interactions, such as DGCR8, a protein involved in genetic regulation (cf. Chapter 4 
(p.81)). 
 
 
 
 
 
 49 
 
 Effect of the 22q11.2 deletion on DNA methylation 
3. Effect of the 22q11.2 deletion on DNA methylation 
3.1. Introduction 
3.1.1. DNA methylation and gene expression 
DNA methylation involves a chemical modification of DNA bases and is one of the 
most studied epigenetic modifications in animals, yet it is still not well understood despite 
having been discovered more than 60 years ago 246. The most common type of DNA 
methylation mark is the 5-methylcytosine (5mC) (Figure 3-1.A); it occurs on cytosine 
bases (C) that are followed by a guanine (G), or CpG sites. In animals, the methylation 
pattern is bimodal with the vast majority of CpG sites having high levels of methylation 
(>80%) while particular sites, which are termed “CpG islands”, have low levels of 
methylation (<20%).  
As around 70% of gene promoters have CpG islands (CGIs) they have been one of the 
first and most studied feature of 5mC methylation 247. Most CGIs are in a nonmethylated 
state, in particular those located in promoter regions where methylation is often associated 
with long-term silencing of the gene (as reviewed in Deaton & Bird 2011 248). The effect 
of methylation on expression is context dependent: they are negatively correlated in CpGs 
close to the transcription start site (TSS) while they are positively correlated in gene body 
CpGs 249 (Figure 3-1.B).  
 
3.1.2. DNA methylase enzymes 
There are three known DNA methylase: DNMT1, DNMT3a and DNMT3b. DNMT1 
is commonly considered as a maintenance methylase due to its ability to preferentially 
process hemimethylated (or asymmetric) CpG sites 250. This allows the preservation of 
DNA methylation patterns in a cell lineage despite DNA replication (Figure 3-1.C.1). 
DNMT3a/b on the other hand are mainly (but not exclusively) involved in de novo DNA 
methylation and can introduce methylation at non-methylated CpG sites 251 (Figure 
3-1.C.2). DNMT3l is a fourth member of the DNMT family but is not a methylase per se 
due to its lack of catalytic domain. It is thought to interact with the other DNMT proteins, 
in particular DNMT3a/b in the establishment of genomic imprints 252, a specific case of 
DNA methylation leading to a parent-of-origin specific allelic expression. DNA 
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demethylation can occur in either a passive or active manner. DNMTs dysfunction or 
inhibition can lead to altered DNA methylation patterns in dividing cells due to a lack of 
maintenance. Even though there is no known DNA demethylase enzyme, active 
demethylation has been observed via repeated oxidisation and removal of the methyl 
group (as reviewed in Kohli & Zhang 2013 253) (Figure 3-1.C.3). The biological function 
of DNA methylation and its correlation with gene expression is still unclear and under 
investigation. In particular, the relation between transcription factor binding and DNA 
methylation is subject to debate and seems to be context dependent (Figure 1.D). It is 
however clear that DNA methylation is essential for development; DNMT1, DNMT3a 
and DNMT3b homozygous knock-outs are lethal in mice (pre-natal death for DNMT1 
and DNMT3b, post-natal for DNMT3a) 251,254. 
 
Figure 3-1. Overview of DNA methylation biology. (Legend on next page) 
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3.1.3. DNA methylation in neurodevelopment 
Spiers et al. have observed widespread changes in DNA methylation during the 
development of the human foetal brain 255. The assessed CpGs showed a significant 
reduction of methylation over time, with an enrichment of differentially methylated sites 
in gene bodies, CGI shores and shelves (regions flanking the CGIs). CGIs seemed to be 
less dynamic than other genomic regions, which reflects their strong presence over the 
transcription start site of housekeeping genes 256,257. Jaffe et al. confirmed this global 
remodelling of the epigenome during brain development, more specifically during the 
transition from foetal to postnatal life 258. It might be due to changes in neuronal 
Figure 3-1. Overview of DNA methylation biology. (A) Chemical structures of cytosine 
and 5-methylcytosine (5mC). (B) Genomic distribution of methylated cytosine in a 
typical vertebrate genome (shown by level of 5-methylcytosine). The representative 
genomic region includes an example of an active and an inactive gene with proximal 
(promoter) and distal (enhancer) regulatory regions. CpG islands, which often overlap with 
promoter regions, generally remain unmethylated, whereas CG-poor promoters are 
methylated when not active. (C) Setting and erasing cytosine methylation. A family of 
DNA methyltransferases (DNMTs) catalyses the transfer of a methyl group from S-adenyl 
methionine (SAM) to the fifth carbon of cytosine residue to form 5-methylcytosine. (C.1) 
DNMT3a and DNMT 3b are the de novo DNMTs and transfer methyl groups (red) onto naked 
DNA. (C.2) DNMT1 is the maintenance DNMT and maintains DNA methylation pattern 
during replication. When DNA undergoes semiconservative replication, the parental DNA 
strand retains the original DNA methylation pattern (grey). DNMT1 associates at the 
replication foci and precisely replicates the original DNA methylation pattern by adding 
methyl groups (red) onto the newly formed daughter strand (blue). (C.3) Different methylation 
states of the CG dinucleotide and the enzymatic pathways that set, maintain and erase the 
mark. The pathways leading from the oxidized forms to the unmethylated state are under 
debate. (D) Potential scenarios for the interplay between cytosine methylation (shown by 
level of 5-methylcytosine) and transcription-factor binding. (D.1) A methylation-
insensitive transcription factor causes reduced methylation after binding. (D.2) A transcription 
factor binds specifically to the methylated state of its binding site. (D.3) A methylation-
sensitive transcription factor is blocked by 5-methylcytosine. (D.4) Methyl-CpG-binding 
domain (MBD) proteins bind to the methylated state, leading to indirect repression, which 
probably requires high local density of CGs (shading). (D.5) A methylation-insensitive 
transcription factor functions as a pioneer factor and creates a site of reduced methylation that 
allows a methylation-sensitive factor to bind. (C.1/2): reprinted by permission from Springer 
Nature: Neuropsychopharmacology, Moore & al., 2013 496, copyright (2012); (B,C.3,D) 
reprinted by permission from Springer Nature: Nature, Schübeler, 2015 497, copyright (2015). 
5mC(G), 5-methylcytosine(guanine); 5hmC(G), 5-hydroxymethylcytosine(guanine); 5fC(G), 
5-formylcytosine(guanine); 5caC(G), 5-carboxylcytosine(guanine); CGI, CpG Island; 
DNMT, DNA methyltransferase; MBD, Methyl-CpG-binding domain; SAM, S-adenyl 
methionine; TDG, thymine-DNA glycosylase; TET, ten-eleven translocation family of 
proteins.  
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composition during this time-period, tying in with the tissue-specific changes observed. 
Interestingly, both studies show that several schizophrenia-associated genomic loci 
contain sites that are differentially methylated during development. In fact, around 60% 
of published GWAS-positive schizophrenia loci are a significant methylation quantitative 
trait loci (meQTLs) in this developmental data 258. This supports the hypothesis that 
schizophrenia is a neurodevelopmental disorder 181. 
 
3.1.4. Genome wide DNA methylation analysis in Schizophrenia 
DNA methylation microarrays and Methylated DNA ImmunoPrecipitation sequencing 
(MeDIP-seq) have allowed the study of genome-wide methylation in large case-control 
studies. The first genome-wide DNA methylation study of major psychosis, performed in 
2008 by Mill et al., revealed that DNA isolated from the post mortem frontal-cortex of 
schizophrenia patients was differentially methylated relative to controls 259. Some of the 
affected genes were involved in biologically relevant pathways, such as neurotransmitter 
pathways (e.g. GRIN3B and GRIA2 in glutamatergic transmission). More recent studies 
in larger cohorts have since been performed and report differential methylation in many 
genes previously associated with schizophrenia as well as potential new candidates 258,260–
266.  
Due to its better availability than brain tissue, many studies have been using peripheral 
blood to try and detect methylomic changes due to psychosis. It has been reported that 
DNMT1 and TET1, both involved in methylation pathways (cf. Figure 3-1.C.3), have 
increased levels both in brain tissue 267,268 and peripheral blood lymphocytes 268,269 of 
schizophrenia patients. This suggests a possible alteration of DNA methylation patterns 
in schizophrenia and that changes observed in the brain could potentially also be observed 
in other tissues. Methylation changes have indeed been observed in blood from patients 
with first-episode psychosis 270, including in antipsychotic-naïve patients 271. This suggest 
that the DNA methylation changes, whether they are the cause or consequences of 
changes in gene expression, might have a diagnostic value. 
Multiple schizophrenia EWAS from peripheral blood have reported differences in 
methylation affecting genes involved in pathways relevant to the disorder, such as 
neuronal development and differentiation 272–274. Results of longitudinal studies of 
genomic DNA methylation during psychotic transition such as performed by Kebir et al 
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274 will also help to understand what are the changes occurring during the conversion from 
the prodromal phase to psychosis.   
 
3.1.5. Considerations when interpreting differential DNA methylation 
It has been shown that intra-individual differences between blood and brain tissue are 
greater than between-individuals differences 275. Moreover, methylation patterns can be 
different between brain regions, with sometimes greater differences within subjects than 
between study groups 264,266. Consequently, despite there being evidence for a partial 
overlap (although minor) between the results of schizophrenia EWAS using different 
tissues 261,276, linking the results of DNA methylation in peripheral tissue to the pathology 
of psychiatric disease needs to be done with caution. To facilitate this, recent studies have 
been performed to find which CpG sites methylation levels are correlated between blood 
and brain tissues 277,278. This information will provide a great help to interpret peripheral 
tissue EWAS in the context of psychiatric disease.  
Another issue to ponder is the impact of the cell composition of the tissue considered. 
As the methylation of some CpGs can be specific to their cell-type then when DNAm is 
measured in DNA extracted from tissue composed of heterogenous cells, it is possible 
that the variation in cell-type proportions between the samples may result in false 
observations of differential methylation (or even mask true differential methylation in 
disease relevant cell types). In blood, the proportions of leukocytes varies with age and 
immune status; and in the context of schizophrenia it has been shown that antipsychotics 
such as clozapine induce neutropenia (deficit in neutrophils) 279. Brain tissue samples are 
Table 3-1. Replication of significant case-control differences. “Probes” refer to the exact 
Illumina 450 k probe by “cg” identifier; “Genes” refer to the nearest gene to each probe or 
those listed in the tables of the cited papers. Table and legend adapted from Jaffe & Kleinman, 
2016 498, used under CC BY 4.0 license. References: Hannon et al.486; Montano et al.273 ; 
Alberg et al.499 ;Jaffe et al.258. 
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also heterogeneous and cell composition can vary between patients. Moreover deficits in 
parvalbumin-positive GABAergic interneurons have been observed in schizophrenia 
patients 280.  
Genome wide analysis of DNAm has resulted in new methods that allow us to use the 
methylation data to adjust for estimated cellular proportion 281–283. These have shown that 
it is essential to use these estimation (or real cell type counts if available) to correct any 
possibly associated bias 284. Finally, unlike in certain cancer types were global changes 
of methylation are observed 285, schizophrenia seems to be associated with more moderate 
changes for which only larger cohorts will provide enough power to detect properly. 
Tissue heterogeneity, differences in statistical methods and covariates accounted for as 
well as lack of power probably explain the low replication rate observed in most studies 
so far such as described Table 3-1. 
  
3.1.6. The potential influence of deletions at 22q11.2 on DNA methylation 
Deletions at chromosome 22q11.2 are the highest known schizophrenia risk factor 
identified to date, with about one third of patients with the deletion developing the 
disorder 57. However, the deletion itself is not fully penetrant and suggests, as in idiopathic 
schizophrenia, the presence of other risk variants (Cf. Chapter 2 (p.31)), gene-gene 
interactions or gene-environment interactions. Epigenetic studies on twins, in particular 
monozygotic twins, is an elegant method to investigate such gene-environment 
interactions 286. Despite sharing the same genotype, monozygotic twins have phenotypic 
differences, from minor traits to being discordant for certain disorders. It has been shown 
that during their lifetime, their epigenome accumulate changes, leading to significantly 
different transcriptomes 287. Investigations of the methylome of monozygotic twins 
discordant for schizophrenia have revealed such epigenetic changes in genes and 
pathways relevant for the disorder 276,288,289. Case reports of monozygotic twins with the 
22q11.2DS have described discordant phenotypes, including congenital features (mainly 
congenital heart defects) 162–165,290,291. One author reported different sizes of the deletion 
of 22q11.2 between two twins by using genomic DNA microarray analysis rather than 
the less precise techniques used in the other reports (fluorescence in situ hybridisation, 
qPCR). It suggests that this could be one reason for the phenotypic variability between 
them (non-psychiatric symptoms) 165. As they share the same intrauterine environment, 
gene-environment interactions differences between twins would arguably be minimal 
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prenatally. It is therefore unlikely that any congenital defects that are discordant between 
a pair of twins with 22q11.2DS would be due to major environmental changes. On the 
other hand, neuropsychiatric symptoms in 22q11.2 appears later during lifetime, and are 
more likely to be affected by differences in DNA methylation.  
No studies published so far have investigated genome-wide DNA methylation changes 
in 22q11.2 deletion patients, but certain genes within the 22q11.2 region are of particular 
interest in the context of methylation. The Catechol-O-Methyltransferase (COMT) gene, 
implicated in neurotransmitter inactivation, has been shown to have abnormal 
methylation in schizophrenia patients. In particular, in these patients the membrane-
bound COMT (MB-COMT) gene promoter appears to be hypomethylated (in saliva 94 and 
brain tissue 95) while the soluble COMT isoform (S-COMT) promoter is hypermethylated 
(in leukocytes 96). Olanzapine, an atypical antipsychotic structurally similar to clozapine, 
has been shown to induce DNA methylation changes in rats cerebellum, hippocampus 
and liver 292. Interestingly, when looking specifically at gene promoters inside the 
genomic region homologous to 22q11.2 in rats (59 genes), 34 showed altered methylation 
in response to treatment in at least one tissue type. These results suggest that changes in 
methylation and/or gene expression of genes within the deletion might influence the 
schizophrenia phenotype. 
Two genes located within the common minimal 1.5mb deletion shared by all typical 
22q11.2 deletion patients can potentially affect DNA methylation changes indirectly: 
HIRA and DGCR8. HIRA is a histone chaperone protein that has been shown to be 
essential for histone assembly and de novo DNA methylation in gametes/gametocytes 
293,294. The hemizygous deletion of DGCR8, involved in microRNA pre-processing (see 
Chapter 3 (p.49)), could potentially alter DNA methylation due to the transcriptome 
changes caused by abnormal microRNA levels. DGCR8 is part of the microprocessor 
complex acting in the canonical microRNA biogenesis pathway and its deletion leads to 
decreased microRNA levels 78,128. It could affect mRNA and protein levels of genes 
involved in DNA methylation pathways; or it could affect transcription factors levels and 
thus change DNA methylation at certain genes promoters and enhancers (see Figure 3-1). 
In the former hypothesis, one could expect global and unspecific changes in DNA 
methylation, while in the latter it could lead to more targeted changes. 
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3.1.7. miRNAs and DNA Methylation 
There is an interplay between microRNA and DNA methylation and that could be of 
importance in the context of the 22q11.2 deletion syndrome. First, the expression level of 
a microRNA is controlled by the promoter of the host gene or its precursor microRNA. 
Methylation levels at their respective promoter, enhancer regions, transcription start sites 
and/or gene bodies are therefore likely to affect the transcription of a microRNA. 
Accordingly, Dnmt1/Dnmt3b knock-out cell lines have shown that around 10% of all 
miRNAs tested were regulated by DNA methylation 295. Haploinsufficient miRNAs 
spanned by the 22q11.2 deletion could be further affected by DNA methylation changes.  
On the other hand, microRNAs have also been shown to mediate DNA methylation. 
Dicer (part of the microRNA biogenesis pathway, cf. Figure 4-1, Chapter 4 p.82) 
knockouts in embryonic stem cells (mESCs) have been shown to have a down-regulation 
of de novo DNA methyltransferase and methylation defects that can be rescued by the 
transfection of the miR-290 cluster miRNAs 296,297. Similarly, Dgcr8 mESCs knock-outs 
have reduced levels of Dnmt3a, Dnmt3b and Dnmt3l 298, with transfection experiments 
reporting that Dnmt3b and Dnmt3l levels are upregulated by miR-294 transfection and 
downregulated by let-7/miR-152 transfections 298,299. Another microRNA, miR-185, has 
been shown to target DNMT1 in cancer lines, including gliomas 177,178. It is of particular 
interest in the context of 22q11.2 deletion syndrome for two reasons. First, it is processed 
by DGCR8 and its level is decreased by around 20% the hippocampus of mice carrying 
a Dgcr8 hemizygous deletion 176. Secondly, miR-185 is located within the minimal 1.5Mb 
deletion at 22q11.2 and also in the syntenic region on mouse chromosome 16. A mouse 
model with a hemizygous deletion in this syntenic region (Df(16)A+/-) has shown a 70 to 
80% decrease of miR-185 in the hippocampus and prefrontal cortex 176, an effect 
potentially due to the hemizygous deletion of both miR-185 and Dgcr8.  
A significant decrease of miR-185 levels can be found in blood samples of 22q11.2 
deletion syndrome patients 129 and was associated with significant decrease in 
hippocampal volume. A previous study reporting that mice with conditional Dnmt1 
and/or Dnmt3a knock-out have smaller hippocampi volumes 300, which is also a feature 
observed in 22q11.2 deletion syndrome patients 301–303. However, decreased levels of 
miR-185 should result in increased levels of Dnmt1 and Dnmt3a/b, thus potentially not 
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having the similar effect than a knock-out of these genes. Finally, it has been 
demonstrated that miRNAs preferentially target genes with low DNA methylation levels 
in their promoter regions 304, suggesting that the two mechanisms might be 
complementary.  
 
3.2. Aims of the chapter 
In this chapter, I investigate DNA methylation profiles of 22q11.2 deletion syndrome 
patients. This is, to our knowledge, the first epigenome-wide association study of this 
disorder. Our hypothesis is that the dysregulation of microRNA expression through the 
hemizygous deletion of DGCR8 and miR-185 will affect DNA methylation, potentially 
both in a direct way (dysregulation of methylation pathway enzymes levels) and indirect 
way (dysregulation of transcription factors levels). This hypothesis is summarised in 
Figure 3-2. The goals of the project are: 
- Determine if DNA methylation is affected in 22q11.2DS patients 
- Determine if genes that are differentially methylated and their related biological 
pathways have been previously shown to be associated with schizophrenia. 
 
Figure 3-2. Study hypothesis: deletion at 22q11.2 region affects DNA methylation 
patterns through microRNA dysregulation. The hemizygous deletion of DGCR8 gene 
change microRNA levels, possibly resulting in altered levels of proteins that affects DNA 
methylation. The possible consequences of the 22q11.2 deletion are depicted in red.  
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3.3. Methods 
3.3.1. Sample origin 
22q11.2DS samples analysed in this chapter are part of 2 independent cohorts: 
- ECHO cohort: ExperienCes of people witH cOpy number variants cohort. The Cardiff 
ECHO study of children with copy number variations is led by Prof. Marianne van den 
Bree and Prof. Michael Owen at Cardiff University. Participants were referred by UK 
genetics clinics and charities. Blood samples from 22q11.2DS children and sibling 
controls were selected from the study 52. 
- BBAG cohort: Brain, Behaviour And Genetics in 22q11.2 deletion syndrome cohort. 
The BBAG study is led by Dr. Michael Craig at King’s College London. Blood samples 
provided were collected from 22q11.2DS patients and individual without the 22q11.2 
deletion that were recruited for brain imaging studies principally. 
 
3.3.2. Sample preparation 
Genomic DNA was extracted from whole blood with PAXgene Blood DNA kits 
(Qiagen) and quantified with Quant-it PicoGreen dsDNA Assays (ThermoFisher 
Scientific). 500 ng of purified genomic DNA from each sample was treated with sodium 
bisulfite with the EZ-96 DNA Methylation-Gold Kit (Zymo Research). Genome-wide 
methylation of bisulfite-converted DNA was assessed using either Illumina 
InfiniumHumanMethylation450 BeadChip (Illumina) or Infinium 
HumanMethylationEPIC BeadChip (Illumina) and scanned on an Illumina HiScan 
system (Illumina). Illumina InfiniumHumanMethylation450 BeadChip (450K array) 
interrogate methylation levels at over 485000 sites per sample that cover 99% of RefSeq 
genes; Infinium HumanMethylationEPIC BeadChip (EPIC array) is an upgraded version 
with over 850000 methylation loci assessed, with around 93% of loci also contained on 
the 450K array (correlation between arrays types: R2 > 0.98, information provided by 
Illumina). Genomic DNA was extracted by the MRC Centre for Neuropsychiatric 
Genetics and Genomics Core team. 450K arrays were prepared and run by Dr Afnan 
Salaka and Catherine Bresner (Cardiff University); EPIC arrays were prepared and run 
with the help of Catherine Bresner. 
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3.3.3. Data processing and quality control 
The data processing workflow is presented in Figure 3-3. All data processing was 
performed in R (Microsoft R Open 3.4.0 (Microsoft), based on R-3.4.0 (R Statistics)). 
The minfi package and its various integrated functions were used to process the data 
unless specified otherwise. Data (IDAT files) from 450K and EPIC arrays were loaded 
into the R environment separately. Samples were included if they had less than 1% of 
sites with a detection p-value greater than 0.01, and if they passed the standard array 
Illumina quality controls (bisulphite conversion I and II controls, extension controls, 
hybridization controls, non-polymorphic controls, specificity I and II controls and target 
removal controls). The methylation levels at each probe was characterised by a Beta 
value, which is the ratio of the methylated probe intensity and the sum of methylated and 
unmethylated probes intensities. Subsequently, data from 450K and EPIC arrays were 
combined and normalised using the single-sample normalisation method ssNoob (derived 
from the Noob method 305) as it has been shown to be the best method to date for joint 
analysis of data from 450K and EPIC arrays 306. Quality control of combined data before 
Figure 3-3. DNA methylation data processing pipeline. Dotted lines represent data used as 
covariate in the regression model fitted to detect DMP and DMR.450K: data from 450K arrays; 
EPIC: data from EPIC arrays; DMP/DMR: differentially methylated probes/regions; QC: quality 
control.  
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and after normalisation was assessed interactively with the ChAMP package (Beta value 
distributions shown in Supplementary figure 2-1). Low quality probes were then removed 
with the wateRmelon package (probes with at least 5% of samples with a beadcount < 3 
and a detection p-value < 0.01). Probes located on the X and Y chromosomes, as well as 
previously recognised underperforming probes (such as cross-hybridising probes or 
probes containing a single-nucleotide polymorphism within 5 bp of the probe 3’ end) 
were excluded from all analyses (Chen et al. 307, data available at 
http://www.sickkids.ca/MS-Office-Files/Research/WeksbergLab/48639-non-specific-
probes-Illumina450k.xlsx and Zhou et al. 308, GRCh37/hg19 annotation with suggested 
overall masking, data available at http://zwdzwd.github.io/InfiniumAnnotation). After 
quality control and filtering, 381,688 probes were subsequently used for analysis.  
 
3.3.4. Data-based phenotypic prediction and assessment of potential confounders 
Different data-based analyses have been performed to assess possible confounders in 
the dataset as well as avoiding additional sample issues. For instance, it has been shown 
that sex and ethnicity affect global methylation levels in DNA extracted from blood 309. 
- Methylation-based sex prediction was performed with the minfi package and 
compared to available phenotype information. 
- Probes are present in the Illumina arrays to detect single nucleotides 
polymorphisms (SNPs) and allow the discrimination of samples (59 probes present in 
both 450K and EPIC arrays); these probes were used to detect (and remove) any 
duplicated samples.  
- These “explicit” SNP probes have been previously used for race prediction and 
discriminate between African American and non-African American populations 273. 
Moreover, a subset of CpG probes have been shown to act as “implicit” SNP probes 
because they contain a SNP within the probe that leads to a colour switch on the array 
depending on base change 308. Joint use of “explicit” and “implicit” SNP probes have 
been shown to increase ethnicity prediction accuracy 308. Of the 59 “explicit” and the top 
30 most predictive (as described in the original paper) “implicit” probes, a total of 78 had 
beta values for all samples, and these were used to look for population stratification by 
principal component analysis (PCA). In order to increase discrimination by PCA, the data 
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was merged with publicly available DNA methylation from blood and lymphoblastoid 
cell lines from different ethnicity (GEO accession GSE36369: 96 Caucasian American, 
96 Han Chinese American and 96 African American LCL samples; 10 Caucasian, 10 
African American (GSE36064) and 10 Japanese blood samples.) (Figure 3-4.A). Outliers 
(samples further than 3 standard deviation away from the mean of the first two principal 
components) were excluded from the analysis (N=2) (Figure 3-4.B). The 4 first principal 
components were selected as covariates in the regression analysis, based on observation 
of PCA plots (Supplementary figure 3-3.A) and Scree plot (Supplementary figure 3-3.B), 
leading to a decrease in genomic inflation (Supplementary figure 3-3.C). 
- Blood cell-type sample compositions were estimated with the minfi 
estimateCellCounts function and compared between 22q11.2DS cases and controls with 
a Bonferonni-corrected Wilcoxon test (cf. results and Figure 3-6). The cell proportions 
Figure 3-4. Population stratification and outlier detection. (A) Principal component analysis 
discrimination of samples from different ethnicity (B) Outlier detection based on standard 
deviation (3 standard deviation away from the means of both principal components, represented 
in red dotted lines). 
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(CD4+ T-cells, CD8+ T-cells, Monocytes, Granulocytes, Natural Killers and B-cells) 
were used as covariates in the regression analysis.  
- Presence and size of deletion at locus 22q11.2DS have been assessed in all 
samples by copy number variant (CNV) detection with the conumee package, using as 
controls CNV-free samples from the CopyNumber450kData package (deprecated since 
04/2017). 
- Age outliers were removed (samples further than 4 standard deviation away from 
the mean age) (N=1) as well as samples without age information (N=1). 
- CpG sites known to be associated with active smoking exposure in blood samples 
and/or prenatal tobacco smoke exposure have been removed. Active smoking exposure 
associated probes were selected from a systematic review of DNA methylation studies by 
Gao et al. 310 (14 EWASs and 3 gene-specific methylation studies, N = 1460 probes) and 
a more recent EWAS 311 (N = 748 probes). Prenatal smoking exposure associated probes 
are from a study in which the maternal plasma level of a biomarker of smoking has been 
assessed 312 (N = 26 probes passing Bonferonni-corrected significance; however the top 
100 most significant probes were included) and a second study with self-reported 
maternal smoking during pregnancy 313 (N = 19). A total of 2058 probes associated with 
tobacco exposure have been removed prior to analysis; including these probes in the 
analysis shows that 27 of them are significantly differentially methylated between 
22q11.2DS cases and controls.  
The characteristics of sample groups are presented Figure 3-5.  
 
3.3.5. Statistical analysis and enrichment analysis 
Beta values were first transformed into M-values ( M = log2(Beta / (1 – Beta)) ), as 
their distributional properties make them more suitable for the statistics used in the 
differential methylation analysis 314. Detection of differentially methylated probes 
(DMPs) and regions (DMRs) was performed with the DMRcate package 315, based on the 
limma package that test association between case/control status and methylation levels 
with a linear regression model 316. The model was fitted to the M-values with Age, Sex, 
Slide (also accounting for array type (450K or EPIC)), Cell type proportion estimations 
(6 cell types), Cohort (ECHO or BBAG) and Ethnicity-based principal components (4 
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PC) as dependent variables. The model fit for each array has been determined with the 
limma function arrayWeights and the calculated weights were incorporated in the model. 
False discovery rate (FDR) was adjusted by Benjamini-Hochberg correction 317. 
Detection of DMRs was done with DMRcate default settings (Lambda = 1000, C = 2, 
Benjamini-Hochberg correction for multiple testing, p-value cutoff of 0.05). Each DMR 
contained 2 consecutive CpG probes or more, and CpGs separated by more than Lambda 
(1000 bp) were in separate DMRs. FDR-corrected p-values were combined within each 
DMR with the Stouffer method 318 and only DMR with a Stouffer(FDR) < 0.05 were 
retained and described in the results.  
KEGG and GO Enrichment analysis were done with the gometh function from the 
missMethyl package 319. This function performs an over-representation analysis using a 
hypergeometric test and takes into account the number of probes per gene to adjust the 
probability of significant differential expression (based on the GOseq method 320). Only 
CpG sites that passed filtering/quality control were used as the background set. The 
enrichment of DMPs within schizophrenia-GWAS associated regions was tested by 
Fisher’s exact test. Prof. Jonathan Mill provided correlation data between blood and brain 
methylation levels, a description of which was reported in Hannon 2015 321. A probe was 
considered as having a blood/brain correlation if it had a Pearson correlation coefficient 
r > 0.3 (low/moderate correlation) between blood methylation levels and at least one brain 
region tested in the original study (prefrontal cortex, entorhinal cortex, superior temporal 
gyrus, and cerebellum).  
Plots were been generated with the ggplot2 package 242 unless specified otherwise. 
 
Figure 3-5. Sample characteristics for cases (22q11.2 samples) and control groups. N: 
number of samples. 
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3.4. Results 
3.4.1. 22q11.2 samples altered cell-type composition lead to an important 
enrichment bias 
An initial analysis of probes that were differentially methylated in 22q11DS relative 
to non-deleted controls revealed that 69.2% of all of CpG sites tested genome-wide were 
differentially methylated (i.e. 25542 differentially methylated probes (DMPs) with FDR 
< 0.05). After exclusions of the DMPs within the 22q11.2 region (cf. next result), a Gene 
Ontology enrichment analysis (biological process ontology) of the top 1000 most 
significantly DMPs revealed one significant enrichment after FDR correction: immune 
system process (FDR = 3.4*10-4). Analysis of these DMPs with eForge, a tool to identify 
cell- and/or tissue-specific signal in DNA methylation data 322, showed that the most 
significant tissue-specific enrichment was “foetal thymus” (Q-value 1.7*10-34, 
Supplementary figure 3-2.A). 
Thymus aplasia is one of the most common feature of 22q11.2 deletion syndrome and 
is present in around 80% of patients 44. This organ is essential for T-cell development 323, 
Figure 3-6. Estimation of leukocytes proportion in 22q11.2 deletion syndrome patients 
and controls. CD8T: CD8+ T-cell; CD4T: CD4+ T-cell; NK: Natural Killer cell; Bcell: B-
cell; Mono: Monocyte; Gran: Granulocyte. Wilcoxon signed rank test, Bonferroni corrected 
for multiple comparisons. 
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and it has been shown that 22q11.2 patients have a significant deficit in this cell type, 
with differences decreasing during adulthood 43,44. A deficit in one cell type in the patients 
will lead to difference in the proportion of leukocyte subtypes between 22q11DS patients 
and controls and could adversely result in the observed differential DNA methylation 
levels 324. Koestler et al. have demonstrated in 2013 that it is possible to estimate the 
blood cell composition based on DNA methylation profiles 325 and studies have since 
demonstrated that adjusting for these estimates is essential 284,326.  
The R package minfi was used to obtain leukocytes proportions in the 22q11DS 
samples and non-deleted controls, based on reference DNA methylation data from FACS-
sorted adult blood 284. The results revealed a deficit in T-cells in 22q11.2 deletion 
syndrome patients (p = 2.2*10-5 (CD8T), p= 1.0*10-5 (CD4T)). There was also an 
increase in Natural Killer cells (p = 1.7*10-2) as well as Granulocytes (p = 1.3*10-3) which 
might reflect a proportion change due to the T-cell deficits (Figure 3-6). While it has been 
suggested that this method based on adult reference data may not be appropriate in new-
borns or young children 327, the mean age of the samples used in this study was 14.1, 
which is higher than the 12 years old patient group used in the study, for which the data 
correlate well with differential cell counts (=0.75-0.77). Other methods for correcting 
for cell proportion heterogeneity have been proposed, however reference-based methods 
such as the one implemented in minfi appears to be the most appropriate when tissue-
specific methylome data is available 282,328,329.  
Figure 3-7. Correction of the genomic inflation due to differences in leukocytes proportion. 
(A) Before correction for cell type composition, (B) After correction. P-values from DMPs within 
the 22q11.2 region are excluded. A lambda close to 1 indicate that results are not inflated by 
unaccounted variance. Lambda = genomic inflation factor. The red line represents the uniform 
distribution; red dotted lines represent the 95% confidence interval. 
A B 
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After adjustment for cell composition using cell type percentages as covariates in the 
regression model used to calculate differential methylation, only 662 DMPs remained 
significant. The quantitative-quantitative (Q-Q) plot in Figure 3-7 shows that adjusting 
for cell composition reduced the genomic inflation from Lambda = 1.57 to 1.06. Gene 
Ontology enrichment analysis of this adjusted data did not show significant enrichment 
in immune-related biological processes. Moreover, eForge analysis of the top 1000 most 
significant DMPs showed an important decrease in the significance of the enrichment in 
thymus and blood-specific CpGs sites (Supplementary figure 3-2.B). 
 
3.4.2. Hemizygous deletion of a genomic region leads to potential spurious 
associations 
Differentially methylated probes (DMPs) and differentially methylated regions 
(DMRs) were calculated after adjusting for cell composition. Analysis of the distribution 
revealed an important association of probes located within the 22q11.2 region (Figure 
3-8). In fact, around 42% of the probes in this region were differentially methylated, 
compared to only 0.2% of all other probes outside of the 22q11 deleted region. The 
window of differentially methylated probes on chromosome 22 is clearly delimited by the 
boundaries of the deletion (Figure 3-8.C.3 and Figure 3-8.C.4). In order to try and 
determine if these differences were due to a technical artefact or a true biological signal 
a number of tests were then conducted. 
 
3.4.3. Investigating the source of the increased rate of differential DNA 
methylation at 22q11 
If the differences were an artefact due to reduced probes intensities caused by 
hemizygosity at 22q11 in deletion carriers, it could be expected to result in a similar 
direction of effect for all affected probes. However, as can be seen in Figure 3-8.A.2 the 
DMPs spanning the 22q11 deletion can be either hypo- or hyper- methylated in 22q11DS 
patients relative to non-deleted controls. On the other hand, Figure 3-8.B.1 and Figure 
3-8.B.2 shows that DMPs and DMRs within this region have very low p-values, despite 
small differences in beta-values. It is therefore possible that hemizygosity has resulted in 
an inflation of the p-values for probes spanning the 22q11 deletion. 
In order to establish whether hemizygosity resulted in falsely inflated evidence for 
differential methylation, the data were compared to the only independent but comparable 
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CNV case-control study available to our knowledge, from Strong et al.330 (GEO accession 
A.1 A.2 
B.1 B.2 
C.1 
C.2 
C.3 
C.4 
Figure 3-8. Overview of differential methylation results and specific association at the 
22q11.2 region. (A) Comparison of methylation levels between cases (22q11.2 group) and 
controls for all (A.1) or only significant (A.2) probes. (B) volcano plots of DMP (B.1) and DMR 
(B.2). (C) Manhattan plots for all probes (C.1) and DMRs (C.2) ordered by chromosomal 
location, with a zoom-in on chromosome 22 (C.3 and C.4). The red dotted lines symbolize 
significance level (FDR < 0.05 or Stouffer < 0.05). 22q11.2 deletion breakpoints LCR A-B are 
the boundaries of the small 1.5 mb deletion; the large 3Mb deletion is between breakpoints LCR 
A-D, and the distal deletion is between breakpoints D-G. Hypermeth/hypometh: 
increased/decreased methylation in 22q11.2 patients; FDR: false discovery rate (Benjamini–
Hochberg procedure); Stouffer: Stouffer transformation of the group of FDRs value for CpGs part 
of DMRs.  
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GSE66552). This publicly available 450k methylation data included 15 control samples 
and 20 samples with Williams syndrome (WS). WS is a neurodevelopmental disorder 
caused by a 1.6mb hemizygous deletion on chromosomal region 7q11.23, causing various 
symptoms including cardiovascular abnormalities, characteristic facial features, growth 
retardation as well as cognitive and neuropsychiatric symptoms 331. The study data 
processing and analysis was relatively similar to that conducted for 22q11DS in this 
thesis, but no particular regional association have been reported for the 7q11.23 locus in 
the published study.  
However, analysis of the publicly available DNA methylation data of Strong et al. 
using the Stouffer method 318 which combined the FDR of all CpGs within the 7q11.23 
Figure 3-9. Manhattan plots of regional associations at hemizygously deleted locus for 
different sample size. (A.1) Association for probes on chromosome 22 for N=20 22q11.2DS 
cases and N=15 controls. (A.2) Association for probes on chromosome 22 for N=20 22q11.2DS 
cases and N=66 controls. (B.1) Association for probes on chromosome 7 for N=20 WS cases and 
N=15 controls. (B.2) Association for probes on chromosome 7 for N=20 WS cases and N=66 
controls. 7q11.3 deletion data is from GEO accession GSE66552. Probes within the hemizygously 
deleted region are in red. For (A.2) and (B.2), controls are a combination of controls from both 
studies. The red dotted lines symbolize significance level (FDR < 0.05). FDR: false discovery 
rate (Benjamini–Hochberg procedure).  
A.1 A.2 
B.1 B.2 
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deletion locus, revealed a highly significant excess of differential methylation in deletion 
carriers relative to non-deleted controls (Stouffer(FDR) = 1.62*10-50). In comparison, 
randomly selecting the same sample size in the 22q11DS/non-deleted control cohort (20 
22q11.2DS samples + 15 controls) did not show significant evidence for association 
(Stouffer(FDR) = 1). It is possible that this difference could be due to differences in the 
ratio signal/background between the two studies, which is likely to reduce the power of 
the 22q11DS study relative to the WS study. 
To address this, the sample size in both studies was increased by combining the control 
samples of both studies (N=66) and keeping the same number of cases (either 20 WS 
samples or 20 22q11.2DS samples). Analysis of these cohorts revealed that when probes 
that were spanned by either a 7q11.23 or a 22q11.2 deletion were tested for DNA 
methylation, highly significant evidence for differential methylation (relative to non-
deleted controls) was obtained (Stouffer(FDR) = 1.23*10-160 (WS), Stouffer(FDR) = 
4.26*10-39 (22q11.2DS)). Manhattan plots of the chromosomes containing these regions 
in these different scenarios are represented Figure 3-9. Random permutations over either 
the same number of CpGs than those included within the deletions or any CpGs included 
in genomic regions of same size than the deletions confirmed this significant association 
of these regions (p = 0; 10,000 permutations comparing Stouffer(FDR) values obtained 
through random sampling with the values obtained for N=66 controls and N = 20 cases 
in both cases).  
Further analyses of differential DNA methylation in sufficiently powered cohorts for 
different CNVs will be required to further confirm that the observation is a technical 
artefact caused by hemizygosity. However, as the available data is not able to rule out the 
possibility of this being an artefact and in order to be conservative, all probes contained 
within the 22q11.2 deletion locus were excluded from any of the following differential 
methylation analyses.  
 
3.4.4. Differential methylation analysis (DMP/DMR)  
After excluding probes within the 22q11.2 region and correcting for known bias, the 
comparison of DNA methylation between 22q11.2DS cases and non-deleted controls 
identified 662 significant differentially methylated probes (DMPs, FDR < 0.05, 357 and 
497 probes hypo- and hyper-methylated in 22q11.2 samples respectively) and 62 
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significant differentially methylated regions (DMRs including at least 2 DMPs, 
Stouffer(DMR) < 0.05, 32 and 30 regions hypo- and hyper-methylated in 22q11.2 
samples respectively). 66 significantly methylated probes were located at a CpG that has 
been shown previously to have methylation levels that are correlated between blood and 
brain tissue 321. The DMPs were further broken down according to their features (Figure 
3-10). This revealed that DMPs were significantly enriched in CGI shores (p = 2.8*10-4 
(North shores), p = 1.1*10-3 (South shores)). There was also an enrichment in DMPs in 
the promoter regions located within 1.5kb of the transcription start site (p = 4.5*10-5) but 
a deficit in the 5’UTR regions (p = 2.4*10-3).  
 
Figure 3-10. Differentially methylated probes (DMPs) features. (A.1/2) Relation to CpG 
islands for all probes versus significant probes (A.1) or significantly hypomethylated probes 
versus significantly hypermethylated probes (A.2). (B.1/2) Genomic location for all probes versus 
significant probes (B.1) or significantly hypomethylated probes versus significantly 
hypermethylated probes (B.2). A significant probe is a probe with a FDR-corrected p-value < 
0.05. Island: CpG island (CGI); N_Shore/S_Shore: North/South CGI shores (sites located within 
+/- 2 kb from a CGI); N_Shelf/S_Shelf: North/South CGI shelves (sites located within +/- 2 kb 
from a CGI shore); North/South: upstream/downstream; OpenSea: sites not located within an 
annotated CGI location; UTR: untranslated region; TSS200/1500: regions located 200/1500 bp 
upstream of a transcription start site; Multiple_loc: probes located within multiple annotated 
genomic regions. Cgi-square test, bonferonni corrected for the multiple features tested. Functional 
annotation from the Illumina HM450 annotation (with Multiple_loc feature added). 
A.1 A.2 
B.1 B.2 
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3.4.5. Pathway analysis  
Performing KEGG pathway enrichment analysis for all significant DMPs (N=662, 
FDR < 0.05, adjusting for the number of probes per genes) revealed significant evidence 
that 22 different biological pathways were enriched (Figure 3-11.A). Restricting this 
analysis to the DMPs with a difference in beta values |Beta| > 0.05 (5% difference in 
methylation levels between cases and controls, N=477) showed an enrichment in 11 
different pathways (Figure 3-11.B). The gene overlaps between pathways shown in 
Figure 3-11.A are represented in Supplementary figure 3-4 and Supplementary figure 3-5. 
Despite the majority of DMPs being hypermethylated rather than hypomethylated (380 
vs 281 respectively), the enriched pathways were due primarily to the DMPs that were 
less methylated in 22q11.2 patients relative to controls (Supplementary figure 3-6). 
Restricting to DMPs that have a correlated methylation levels between blood and brain 
tissue did not show significant KEGG pathways enrichments (data not shown). 
 
Figure 3-11. KEGG pathway enrichment analysis. (A) DMPs with FDR < 0.05 (NDMP = 662). 
(B) DMPs with FDR < 0.05 and |Beta| > 0.05 (NDMP = 401). N: number of gene in the pathway; 
NDMP: number of DMP tested; DE: number of genes associated with at least one DMP; FDR: false 
discovery rate (the number of probes per gene is taken into account to adjust the probability of 
significant differential expression). Only significant KEGG pathway enrichment (FDR < 0.05) 
are shown. 
A 
B 
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3.4.6. Differentially methylated regions 
Of the 62 differentially methylated regions, 57 were associated with the promoter 
region of an annotated gene (Figure 3-12.A). The most hypomethylated and 
hypermethylated regions are presented Figure 3-12.C and Figure 3-12.D. Changes in 
DNA methylation ranged from a 14% increase for the most hypermethylated region 
A 
B 
E D 
C 
Figure 3-12. Differentially methylated regions (DMRs) associated with a promoter region. 
(A) All DMRs, sorted by significance. (B) Top 10 most significant DMRs. (C) Top 10 DMRs 
with most significant probes. (D) Top 10 most hypomethylated DMRs. (E) Top 10 most 
hypermethylated DMRs. BloodBrain: presence of probes that have shown to be correlated 
between blood and brain tissue. DeltaBeta: average beta value differences for the probes 
(deltaBeta > 0: hypermethylation in 22q11.2DS samples); Genes: genes with a promoter region 
that contain the DMR; Location: genomic location. Stouffer: combined false discovery rates for 
the probes, with the Stouffer method; Width: DMR size. 
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(included within AC020934.1, MAST1 and HOOK2 genes promoter regions) to a 17% 
decrease for the most hypomethylated region (within NFIA promoter region). These 
regions included between 2 and 31 CpGs (for the DMR within the c6orf24 and LY6G6C 
gene promoter regions). 9 of the DMRs include at least one DMP for which methylation 
levels have been previously shown to be correlated between blood and brain tissue 321. 
The DMRs that were not associated with a gene promoter region are presented in 
Supplementary figure 3-7.  
 
3.4.7. DMP enrichment in schizophrenia-related genes 
A recent large-scale genome-wide association study has detected 128 genomic regions 
associated with schizophrenia 92. Some of these associations are overlapping, thus there 
are 108 different loci in total that are associated with the disorder. 2 DMPs were located 
within these regions (Figure 3-13.A), which was less than expected by chance (p = 0.029, 
Fisher’s exact test). The STAC3-associated DMP has been previously to have a correlation 
between DNA methylation in blood and in brain tissue. 
 
3.5. Discussion 
Comparison of DNA methylation between 22q11.2 deletion syndrome patients and 
controls revealed 662 significantly differentially methylated probes and 62 significantly 
differentially methylated regions containing at least two probes. DMPs were significantly 
enriched in CpG Islands shores (p = 2.8*10-4 (North shores), p = 1.1*10-3 (South shores)). 
This pattern may reflect differences in tissue/cell types but CGI shores are also strongly 
associated with gene expression 332. Furthermore, there was also an enrichment of 
Figure 3-13. DMPs linked to genes associated with schizophrenia in GWAS. DMPs 
overlapping a LD-independent genome-wide significant SNP associations for schizophrenia (N= 
108 regions tested). Location: Genomic location; deltaBeta: difference in beta values between 
controls and 22q11.2DS samples (deltaBeta > 0: hypermethylation in 22q11.2DS samples); FDR: 
False Discovery Rate; Dist.Prom: distance to the transcription start site (TSS) of the nearest gene; 
CGI: relation with CpG Islands; BloodBrain: probes that have shown to be correlated between 
blood and brain tissue. 
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methylation in the promoter region (located within 1500bp from the transcription start 
site, p = 4.5*10-5) which can be negatively correlated with gene expression 249. 
This study compared individuals with or without the 22q11.2 deletion, without 
controlling for individual phenotypes. This meant that it was not possible to test for 
particular pathways that were associated with specific phenotypes encountered in 22q11.2 
deletion syndrome patients. Nevertheless, it did generate data that can potentially help 
gain a better understanding of the biology behind this disorder, in particularly those with 
a high incidence in 22q11.2, such as schizophrenia. Differential methylation analysis of 
all DMPs (regardless of difference levels) implicated 22 KEGG pathways, 15 of which 
could be grouped into 4 main (overlapping) groups with a biological relevance to 
schizophrenia: metabolism, cell signalling, cell adhesion and intracellular vesicle 
trafficking ( 1: Metabolism: metabolic pathways, fatty acid metabolism, adipocytokine 
signalling pathway, insulin signalling pathway; 2: Cell adhesion: ECM-receptor 
interaction, focal adhesion, cell adhesion molecules (CAMs); 3: Vesicle trafficking: 
endocytosis, lysosome, phagosome, regulation of actin cytoskeleton; 4: Cell signalling: 
PI3K-Akt signalling pathway, MAPK signalling pathway, Ras signalling pathway, hippo 
signalling pathway, EGFR tyrosine kinase inhibitor resistance, insulin signalling 
pathway, adipocytokine signalling pathway). It is important to note that many of these 
pathways share common genes with other pathways within and between these 4 groups, 
as shown in Supplementary figure 3-4 and Supplementary figure 3-5. 
Early transcriptome analyses of schizophrenia brain compared to matched controls 
suggested that multiple metabolic pathways were affected in these patients 333, 
particularly energy metabolism which was later shown to be affected through 
mitochondria dysfunction 334. Glucose metabolism has been shown to be affected, as well 
as fatty acid metabolism, in response to the resulting oxidative stress 334. Metabolic 
changes have also been observed in 22q11.2DS patients, including increased fatty acid 
plasma concentration that has been suggested to be due to the haploinsufficiency of the 
mitochondrial citrate transporter SLC25A1 335. Moreover, another gene within the 
deletion, ZDHHC8, codes for a palmitoyltransferase. Palmitoylation is a posttranslational 
process that add fatty acids chains to proteins. Around 40% of synaptic proteins are 
palmitoylated 336 and ZDHHC8 function seems to be essential for brain and neuronal 
development 122. A study has shown that fatty acids such as long-chain ω-3 (omega-3) 
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polyunsaturated fatty acids could reduce the risk of transition to schizophrenia in high-
risk individuals 337, however this has not been replicated in a larger multi-center trial 338. 
Cell adhesion molecules (CAMs) are essential for synaptogenesis (as reviewed in 
Washbourne 2004 339), and synaptic dysfunction is suggested to have an important role 
in schizophrenia 340. The extra-cellular matrix (ECM) interact with the cells during this 
process, and it is also important for cell adhesion and migration which are altered in 
schizophrenia 341. In particular, a class of ECM molecules named proteoglycans (such as 
heparan and chondroitin sulfate proteoglycans) have been linked to neuron migration and 
associated with schizophrenia (as reviewed in Maeda 2015 342). Notably, the 22q11.2-
deleted gene DGCR2 is a putative adhesion receptor protein, and a murine model of 
22q11.2DS has been reported to present defects in interneuron migration 343. 
It has been suggested that endocytosis and protein trafficking are pathophysiological 
processes in schizophrenia, and that antipsychotic drugs interact with proteins involved 
in endocytosis 344. Moreover, transcriptomic and genome-wide association study analyses 
have showed an enrichment in schizophrenia patients of genes involved in a network 
centred on the regulation of actin cytoskeleton and lysosomal function, implying that 
intracellular vesicle trafficking is also relevant to this disease 345. In the context of 
22q11.2DS, it has been shown that miR-185, whose levels are decreased due to its 
presence in the deletion and its processing by DGCR8, have two validated targets (RhoA 
and Cdc42) involved in the regulation of actin cytoskeleton (as reviewed by Forstner 2013 
346). 
The PI3K-AKT-GSK3-mTor and the Ras-ERK (/Ras-MAPK) signalling pathways are 
two intracellular signalling pathways essential to cell survival and involved in many 
processes such as cell proliferation and differentiation. Both pathways are cross-regulated 
in a system of feedback circuits 347. HIPPO signalling pathway, which is significantly 
enriched in this study, has also been shown to be part of this complex signalling system 
and is indirectly regulated by EGFR-Ras-MAPK signalling 348. Due to their primordial 
functions, defects in these pathways have been involved in many disorders such as cancer 
but also schizophrenia 349,350. Analysis of DNA methylation differences between 
monozygotic twins discordant for schizophrenia has also shown an enrichment of 
differentially methylated genes involved in both MAPK and HIPPO signalling pathways 
289. CRKL is a protein whose gene is located at the 22q11.21 locus that mediates MAPK 
 76 
 
 Effect of the 22q11.2 deletion on DNA methylation 
signalling. Mouse knock-out models of CRKL have been shown to recapitulate some 
phenotypes observed in 22q11.2DS models 351, suggesting the importance of this pathway 
in this syndrome. It should however be noted that CRKL is located in a part of the deletion 
not shared by every patient. ZDHHC8 on the other hand is within the A-B deleted region 
at 22q11.2 and its protein has an effect on the AKT/GSK3 pathway through 
palmytoilation of CDC42 121. Both single gene mouse knock-out models of ZDHHC8 and 
a murine model of 22q11.2DS have been reported to result in phenotypes such as 
abnormal neuromorphogenesis and behaviour that can be rescued by downregulating 
GSK3 during development 121,352. 
Finally, GSK3 have been shown to be involved in arrhythmogenic cardiomyopathy 
353, one of the KEGG pathway enriched in the present analysis. Moreover, Gsk3-/- knock-
out mice exhibit different cardiac defects354, including ventricular septal defects, which 
are common in 22q11.2DS. 
Performing pathway analysis on individual significantly differentially methylated 
probes can help provide an overview of the DNA methylation changes associated with 
the observed phenotypes, it is potentially more informative to focus on differentially 
methylated regions (DMRs) composed of multiple adjacent probes; potentially providing 
more confidence in the results. In this study 66 DMRs were detected, of which 48 were 
located in the promoter region of a gene and thus potentially having methylation levels 
directly correlated with its expression. Genes associated with these DMR are marked * 
below. Multiple DMRs are of particular interest here in the context of 22q11.2DS and its 
neuropsychiatric symptoms. MIB2*, associated with the most significant DMR in this 
study, is involved in NOTCH signalling 355 which is associated with schizophrenia 356. 
NBEA* 357, SORBS2* 357, FILIP1* 358 and TRAK1* 359 have been shown to have de novo 
mutations in schizophrenia patients. Deleterious variants in TRAK1* also lead to lethal 
neurodevelopmental defects 360 and the protein product forms a complex with DISC1 361, 
a gene whose disruption has been shown to be associated with schizophrenia 362. DISC1 
regulates the GSK3 pathway and appears to control AXIN2* levels 363. Finally, DPPA5* 
has also been found to contain a DMR in schizophrenia patients, but with the opposite 
direction of effect than that observed in 22q11.2DS patients 263. No DMR, but two DMPs, 
are located within regions associated with schizophrenia in the largest GWAS study to 
date 92 (Figure 3-13). 
 77 
 
 Effect of the 22q11.2 deletion on DNA methylation 
NFIA and NFIX are the two most hypomethylated regions in the 22q11.2DS patients 
(Figure 3-12.D). They are both part of the transcription factor family of nuclear factor I 
(NFI) proteins, and mouse knock-out models of these genes present with abnormal brain 
development 364,365. In humans, both genes are spanned by CNVs (1p31.3-p32.2 deletion 
for NFIA and 19p13.13 deletion for NFIX) that have been associated with brain 
malformations among other phenotypes 366,367. Interestingly, 3 DMRs identified in this 
study are detected within the 19p13.13 deletion locus, overlapping the promoter regions 
of NFIX, MAST1, AC02093.1, HOOK2 and CTD6L21.1 genes. 8 probes are also 
individually significantly differentially methylated, and are associated with the genes 
ZNF136, MAST1, DNASE2 and NFIX. It is however worth noting that no 19p13.13 
deletion has been detected (methylation-array based detection) in any of the samples 
analysed in this study. Other DMR-associated genes that could be relevant to other 
22q11.2DS phenotypes include PLEKHB1 (ADHD candidate gene 368), HIC1 369 and 
HOXA2 370 (developmental defects in mouse model, including palatal malformation for 
both genes), DEAF1 (abnormal brain development and intellectual disability 371,372), 
SORBS2 (candidate gene within an intellectual disability causing CNV at locus 4q35.1 
373 and involved in dendritic development 374), RNF19A/DORFIN (abnormal 
neurogenesis, memory and behaviour in mice knockout 375) and NBEA (involved in 
synaptogenesis 376 and a candidate gene for autism 377). 
In this study, the DMPs within the A-D deleted region at 22q11.2 have been excluded 
due to the very strong differential methylation observed at the entire region. This 
potentially poses a problem of knowing if this window of association is due to a true 
biological signal or a technical artefact. To our knowledge, no such window of association 
around a hemizygous deletion has been previously reported, however it seems that only 
one other epigenome-wide epigenome case-control study of a CNV disorder has been 
reported. Analysis of the data from this study, looking at methylation changes in Williams 
Syndrome patients (7q11.23 deletion), revealed that a similar association is present at the 
hemizygously deleted locus. This association could result from a biological process either 
not known or not studied in this context. For example, biological mechanisms could 
compensate the reduced expression levels by decreasing DNA methylation levels at 
enhancer and promoter regions. That would imply a global hypomethylation of the 
hemizygously deleted region, but that does not seem to be the case at the 22q11.2 and 
7q11.23 loci, where both hypo- and hyper-methylated probes were found. The deletion 
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of one chromosomal copy of these regions could have led to a difference in observed 
methylation levels if the regions were imprinted. Genomic imprinting is a mechanism that 
leads to genes being expressed differently on maternal and paternal chromosomes as a 
result of DNA methylation-mediated gene silencing 378. The preferential deletion of the 
maternal (or paternal) copy of the 22q11.2 region could have led to such a bias in DNA 
methylation levels, depending on whether the silenced or expressed copy of the genes 
was present. While a number of studies have reported an increased maternal origin of the 
22q11.2 deletion (~55%) 10,11, parent-of-origin specific expression studies of 22q11.2 
orthologues in a mouse model (brain tissue) did not reveal any allelic specific expression 
of genes included within the smaller A-B deletion 379. Moreover, no differences in 
parental origins of the deletion at 7q11.23 have been observed 10. Together, these results 
and the findings from the current methylation study would suggest that the association 
observed at these deleted loci could be a technical artefact. It could potentially be caused 
by lower signal intensities of probes targeting CpGs at these hemizygously deleted 
regions, leading to an overestimation of the significance of small differences. Other DNA-
methylation analysis techniques such as pyrosequencing or reduced representation 
bisulfite sequencing could potentially to explore this issue further and try to investigate 
the origin of the signal (biological or technical). It needs to be addressed because recent 
estimations have shown that up to 10% of the genome could contribute to copy number 
variants (CNVs) 155. The presence of CNVs is commonly checked in genome-wide 
associations studies (GWAS), but mainly for CNVs known to affect the 
phenotype/disorder tested in the GWAS. This is less common in EWAS studies, due to 
the potential lack of genotyping information for the samples. The present study would 
imply that potentially any CNV, associated with the phenotype of interest or not, could 
have an impact on DNA methylation and potentially introduce a bias if its presence is 
unbalanced between cases and controls. For this reason, it is important to investigate this 
issue by performing CNV case-control epigenome wide association study (EWAS) of 
different CNVs and using different techniques of DNA methylation measurement. 
The changes in DNA methylation levels observed in this study outside of 22q11.2 are 
likely due to the transcriptome changes caused by the 22q11.2 deletion. Changes in the 
expression of genes coding for proteins such DNMTs or transcription factors could 
impact on DNA methylation (cf. Figure 3-2) indirectly. However, these changes would 
not be specifically associated to schizophrenia. In order to explore this association a case 
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control EWAS comparing DNA methylation levels of 22q11.2DS patients with or without 
schizophrenia would need to be performed. Possible differences in DNA methylation 
between these two groups could be due to variants outside the 22q11.2 associated with 
schizophrenia and affecting DNA methylation directly or indirectly; they could also be 
due to gene-environment interaction altering DNA methylation. These interactions could 
be potentially causative in the increased the risk to schizophrenia. It has been shown that 
environmental factors such as stress or cannabis use could have an effect on schizophrenia 
symptoms and endophenotypes 380. The gene-environment interactions leading to changes 
in DNA methylation could however also be a consequence of schizophrenia. For instance, 
Olanzapine, an atypical antipsychotic, leads to an alteration of DNA methylation levels 
of genes within the 22q11.2 deletion in different tissues 292. For this reason, it would be 
important to assess any potential confounder, such as drug use/treatments and correct for 
it in such an EWAS.  
Finally, despite the advantage of easy availability and the potential for disease 
biomarker discovery, the use of DNA extracted from blood has two major disadvantages 
in the context of 22q11.2DS. First, the deficit in T-cell observed in the 22q11.2DS 
patients led to an imbalance in cell-type proportion that is reflected at the DNA 
methylation levels. This introduced an important bias, and while it was corrected, this 
correction could have resulted in an increased rate of false-negative associations (due to 
overcorrection) while still retaining false-positive associations (imperfect correction, as 
the KEGG pathway enrichment in Hematopoietic cell lineage genes might suggest 
(Figure 3-11)). Secondly, the main phenotype of interest in this study was schizophrenia 
and as such, DNA extracted from brain tissue would have been more biologically 
relevant. While a correction for neuronal specific cell-type composition would still be 
needed, it is more likely that schizophrenia-associated DMPs and DMRs from brain tissue 
are linked to relevant gene pathways. However, despite these limitations it is encouraging 
that this study has identified DMPs that have been previously shown to have correlated 
methylation levels between blood and brain tissue 321. 
The present study is the first EWAS of 22q11.2 deletion syndrome patients. The results 
show enrichments in pathways that are biologically relevant, in particular for 
schizophrenia, and differentially methylated regions in promoter regions of genes that 
could have an effect in this neurodevelopmental disorder. Replication studies with 
increased sample size, correlation with gene expression data and use of brain tissue will 
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help to provide a better insight into the biology of this syndrome. This will hopefully lead 
to the discovery of an epigenetic signature that might lead to better symptom prediction 
and/or treatments.  
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4. CRISPR/Cas9 genome editing of DGCR8 in human 
embryonic stem cells 
4.1. Introduction  
4.1.1. DGCR8, the microprocessor complex and microRNA processing 
Among the genes deleted in the 1.5 mb-long 22q11.2 deletion – also called “DiGeorge 
syndrome chromosomal region (DGCR)” – DGCR8 is of particular interest. Its 
hemizygous deletion may explain the wide range of symptoms observed in patients with 
22q11.2 syndrome. First discovered in 2003 by Shiohama et al., DGCR8 has been shown 
to have a restricted expression pattern during development in tissues relevant to 
22q11.2DS symptoms, such as the embryonic neuroepithelium, thymus and palate 381. 
The DGCR8 protein was shown to interact with DROSHA, a nuclear RNAse (RNAse III 
protein). Together they form the microprocessor complex, an important component of the 
canonical microRNA biogenesis pathway 126 (Figure 4-1.A). MicroRNAs 
(miRNAs/miRs) are small non-coding RNAs (~22 nucleotides) involved in the regulation 
of gene expression. They are derived from primary microRNA (pri-miRNA) transcripts 
produced by the RNA polymerase II. These pri-miRNAs have a particular hairpin 
structure (also called RNA stem-loop) that is processed by the microprocessor complex 
into shorter precursor microRNAs (pre-miRNAs). These pre-miRNAs are transported out 
of the nucleus by the Exportin-5 (XPO5) protein. They are then trimmed by the 
endoribonuclease Dicer into double stranded miRNA/miRNA duplexes leading to the 
mature form of the miRNAs. miRNAs activate the RNA-induced silencing complex 
(RISC) in which the Argonaute II protein form a duplex between the miRNAs and a 
complementary mRNA. This leads to a regulation of gene expression through different 
repression mechanisms such as mRNA degradation or translational repression (as 
reviewed in Nilsen 2007 382). Some miRNAs are however also generated in 
microprocessor-independent pathways, for instance as a product of RNA splicing in 
which hairpin-containing introns (named mirtrons) generate pre-mRNAs 383. 
DGCR8 protein is localised mainly in the nucleus – more particularly the nucleolus – 
but has also been found in the cytoplasm 384,385. It contains two double-strand RNA 
binding domains (dsRBDs) that interacts with pri-miRNAs and are essential to the 
function of the microprocessor complex 386. Its other domains include a nuclear 
localisation signal (NLS), a heme-binding / dimerization domain (WW / Rhed) and a 
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domain on its C-terminal region that interacts with DROSHA 386,387 (Figure 4-1.B). The 
A 
B 
C 
Figure 4-1. DGCR8 structure and activity. (A) Canonical microRNA biogenesis pathway. 
Proteins involved are represented in colored ovals. The blue circle represents the cell nucleus. (B) 
DGCR8 genomic DNA (gDNA) and protein structure. Names of protein functional domains 
are indicated in boxes, with their function on top. Protein domains are depicted in rectangles 
mapped to the corresponding exons, with their function on top. Exons are depicted in full 
rectangles (coding exons) or empty rectangles (non-coding exons). dsRBD domain: double-
stranded RNA-binding domain; gDNA: genomic DNA; NLS: nuclear localization signal; Rhed 
domain: RNA-binding heme domain. (C) The DGCR8 RNA-Binding heme domain recognizes 
primary microRNAs by clamping the hairpin. The DGCR8 subunits in a dimer are shown in 
red and cyan. The thick avocado strands represent 5′ and 3′ mature miRNAs. Figure (A) adapted 
from Brzustowicz 2012 480, used under CC BY 3.0 license. Figure (C) from Quick-Cleveland 
2014 388, used under CC BY-NC-ND 3.0 licence. 
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Rhed domain (RNA-binding heme domain) is essential for forming a DGCR8 dimer that 
clamps to the apical or the basal junction of the primary microRNA to activate its cleavage 
by DROSHA 388 (Figure 4-1.C). It is worth noting that additional cofactors can bind to 
the microprocessor complex to regulate its activity as well as affecting which miRNAs 
are processed, as reviewed in Ha 2014 389.  
Despite being mostly known for its involvement in primary-microRNA processing, 
DGCR8 can also bind to other stem-loop containing RNAs that will be cleaved by 
DROSHA 390–393; cross-linking immunoprecipitation experiments have shown that 
DGCR8 can bind to many classes of RNAs such as messenger RNAs (mRNAs) 390,392. 
This extend further the capacity of DGCR8 to affect gene expression and as a 
consequence it potentiates the effects of gene dysregulation when DGCR8 is 
hemizygously deleted such as in 22q11.2 deletion syndrome. 
 
4.1.2. Animal models 
The DGCR8 gene appears to be relatively well-conserved and have orthologues in 
most species (Supplementary figure 4-1). Multiple animal models have been generated to 
study the impact of DGCR8 deficiency, for instance in C.elegans, D.melanogaster, 
D.rerio and M.musculus as reviewed in Guna 2015 74. Homozygous knock-outs (KO) of 
Dgcr8 is lethal before the end of pupal stage in D.melanogaster and during 
embryogenesis in M.musculus 74; however the use of heterozygous and/or conditional 
KOs have allowed investigations into the impact of Dgcr8 deletion in various aspect of 
development. The loss of microRNAs due to the deletion of Dgcr8 has been shown to 
have an effect on tissues linked to 22q11.2 deletion syndrome symptoms, for instance 
DGCR8 KO in kidney epithelial cells leads to hydrophrenosis and kidney cysts 394 and to 
dilated cardiomyopathy when targeting cardiac myocytes 395. 
Dgcr8 and Drosha conditional knock-out or knock-down in mice have previously 
shown that the microprocessor complex is essential for embryonic neurogenesis. It leads 
to precocious differentiation of neural progenitor cells (NPC) from the ventricular zone 
396. The microprocessor complex maintain the neural stem cell status and self-renewal by 
regulating pro-neuronal transcription factors’ mRNA levels such as Neurog2 396 and Tbr1 
397. This effect seems to be mostly miRNA independent, as Dicer KO results in less 
impairment of corticogenesis than DGCR8 KO 397. Consistent with these results, Ouchi 
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et al. reported that DGCR8 heterozygous KO mice exhibit reduced neural progenitor cell 
proliferation as well as cognitive and behavioural deficits 398. These hippocampal NPCs 
proliferation and behavioural deficits can be rescued with Insulin-like growth factor 2 
(IGF-2). Deletion of Dgcr8 seems to also have an effect on mature neurons. Conditional 
deletion of Dgcr8 in cortical pyramidal neurons leads to smaller neuronal size (resulting 
in loss in cortical thickness), deficits in inhibitory postsynaptic currents and a decreased 
abundance of parvalbumin interneurons in the prefrontal cortex 399. Dgcr8 heterozygous 
deficiency in mice results in impairment in short-term synaptic plasticity in the medial 
pre-frontal cortex (greater level of short-term depression) 400.  
Importantly, Dgcr8 knock-out mice seem to recapitulate some of the phenotypes 
observed in mouse models of the 22q11.2 deletion. Firstly, miRNA biogenesis seems to 
be altered in both Dgcr8+/- mice and Df(16)A+/- mice, a mouse model that mimic the 1.5 
mb human 22q11.2 deletion (LCR A to LCR B) with the hemizygous deficiency of 27 
genes 78. Even though Dgcr8+/- mice did not show the exact same behavioural and 
cognitive deficits compared to the 22q11.2DS model, they both have deficits in the pre-
pulse inhibition task which is considered to be an endophenotype of schizophrenia in 
human and mice 79. They both also present altered spatial working memory–dependent 
learning. Dgcr8+/- mice and 22q11.2DS models Df(16)1/+ and Df(16)2/+ have an age-
dependent long-term potentiation (LTP) increase which can be rescued in Dgcr8+/- by 
reintroducing microRNAs miR-25 and miR-185 that regulate Serca2 mRNA levels 
(coding for a Ca2+ ATPase) 83. Cortical interneurons and hippocampal dentate precursors 
have been shown to have a altered migration in both Df1/+ and Dgcr8+/- mice, due to 
abnormal Cxcr4/Cxcl12 signalling 401. This phenotype can be partly rescued in Df1/+ 
mice by reintroducing DGCR8 (lentiviral expression) in medial ganglionic eminence 
(MGE)-derived cells 401. Finally, Df(16)1/+ and Dgcr8+/- mice auditory thalamus have 
increased levels of D2 dopamine receptor Drd2, an antipsychotic molecular target, and 
their auditory thalamocortical projections are hypersensitive to antipsychotics 402. Taken 
together, these evidences support the relevance of DGCR8 haploinsufficiency as a model 
to investigate the aetiology of neuropsychiatric symptoms in 22q11.2 deletion syndrome. 
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4.1.3. Pluripotent stem cell models 
Advances in genome editing techniques and in-vitro cell differentiation protocol have 
made disease modelling with human embryonic stem cells an attractive method to 
elucidate the underlying mechanisms leading to human disease 184. Dgcr8 knock-out 
mouse embryonic stem cell (mESC) have previously been generated and studied. 
Consistent with DGCR8’s role in the microprocessor complex, Dgcr8 KO mESCs have 
an altered microRNA biogenesis. A subset of precursor and mature microRNAs are 
Figure 4-2. CRISPR/Cas9 system. (A) Schematic of the RNA-guided Cas9 nuclease. The 
Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown for example is 
the human EMX1 locus) by an sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold 
(red). The guide sequence pairs with the DNA target (blue bar on top strand), directly upstream 
of a requisite 5′-NGG adjacent motif (PAM; pink). Cas9 mediates a DSB ~3 bp upstream of the 
PAM (red triangle). (B) Double Strand Break (DSB) repair promotes gene editing. DSBs 
induced by Cas9 (yellow) can be repaired in one of two ways. In the error-prone NHEJ pathway, 
the ends of a DSB are processed by endogenous DNA repair machinery and rejoined, which can 
result in random indel mutations at the site of junction. Indel mutations occurring within the 
coding region of a gene can result in frameshifts and the creation of a premature stop codon, 
resulting in gene knockout. Alternatively, a repair template in the form of a plasmid or ssODN 
can be supplied to leverage the HDR pathway, which allows high fidelity and precise editing. 
Single-stranded nicks to the DNA can also induce HDR. HDR: homology-directed repair; NHEJ: 
non-homologous end-joining; PAM: Protospacer adjacent motif; sgRNA: single-guide RNA; 
ssODN: single-stranded oligodeoxynucleotides. Figures and legends reprinted with permission 
from Springer Nature: Nature, Ran 2013 406, copyright (2013). 
A 
B 
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absent in Dgcr8 -/- cells compared in Dgcr8 +/- and wild-type cells; and more generally a 
global reduction of miRNA levels is observed in Dgcr8 KO cells 128,403. Moreover, Dgcr8 
KO hESCs have a deficit in proliferation characterised by an accumulation in the G1 
phase of the cell cycle. They also exhibited an abnormal differentiation and do not silence 
entirely pluripotency markers such as Oct4 or Nanog. Reintroducing embryonic stem cell 
specific miRNAs that are part of the miR-290 family can rescue the proliferation 
phenotype, possibly by interacting with genes of the cyclin E–Cdk2 pathway such as 
Cdkn1a or Rlb2 404. More miRNAs have since been similarly implicated in embryonic 
stem cell self-renewal by studying Dgcr8 KO mESCs; in particular miR-27a and miR-24 
405. The dysregulation of gene expression in Dgcr8 KO mESCs is discussed in in more 
details in Chapter 5 (p.106). 
No DGCR8 KO in human embryonic stem cell have been published to date. The 
development of CRISPR/Cas9 genome editing system now permits to generate knock-
out in human cells an efficient and cost-effective way. This system is derived from the 
bacterial S.pyogenes Cas9 nuclease and allows precise genome editing by inducing 
targeted double-strand DNA break directed by specifically designed guideRNAs 406,407 
(Figure 4-2). 
 
4.2. Aims of the chapter 
In this chapter, I present the generation of DGCR8 KO lines in human embryonic stem 
cells (hESCs) using the CRISPR/Cas9 technology. The goals of this project are: 
- To obtain stable DGCR8 KO hESCs. 
- Determine how DGCR8-deficiency affects RNA processing ability.  
This works will serve as the basis of future transcriptomic studies to investigate the 
extent of DGCR8 contribution to the dysregulation of gene expression in 22q11.2 deletion 
syndrome. 
 
4.3. Methods   
4.3.1. Cell lines 
The H7 (WA07) human embryonic stem cell (hESC) line has been used in this study 
(WiCell Research Institute, Inc.). This cell line was derived from a female subject with a 
 87 
 
 CRISPR/Cas9 genome editing of DGCR8 in human embryonic stem cells 
karyotype of 46XX, European ethnicity (closest reference population: Tuscan/Palestine), 
B blood type, MHC class I antigens positive, MHC class II antigens negative). This line 
is also referred to as Wild-Type (WT) in this thesis. 
 
4.3.2. hESC culture and neural differentiation 
hESCs were cultured in Matrigel matrix-coated plates (Corning) and TeSR-E8 feeder-
free medium (Stemcell technologies) changed every day and passaged with Gentle Cell 
Dissociation Reagent (Stemcell technologies) at ~80% confluency. Neural differentiation 
was induced using a modified version of the dual inhibition SMAD signalling protocols 
developed and described by Chambers et al. 185 (similar to the control condition in Arber 
et al. 408). The differentiation medium used, N2B27, was composed of 1/3 Neurobasal 
medium, 2/3 DMEM/F-12, 1X N-2 supplement, 1X B-27 supplement, 20 mM L-
glutamine, 20 µm β-mercaptoethanol (all from ThermoFisher Scientific) and 1X 
MycoZap Plus-CL antibiotics (Lonza). Neural differentiation media was changed every 
other day. Briefly, cells were plated in E8 medium in 12-wells plates coated with growth 
factor reduced (GFR) matrigel (Corning). After 24-48h, media was replaced with N2B27 
medium supplemented with 10 µM SB-431542 (SB, TGF-B inhibitor) (StemCell 
technologies) and 100 nM LDN-193189 (LDN, BMP4 inhibitor) (Sigma-Aldrich) till day 
12; cells were passaged to fibronectin-coated 12-wells plates (15μg/mL) at around day 9-
10. Neural progenitor cells were collected at days 18 to 20. A summary of this 
differentiation protocol can be seen in Figure 4-3.  
  
Figure 4-3. Neural differentiation protocol. Dual-SMAD signalling inhibition has been used to 
obtain neural progenitor cells, following a cortical neurodifferentiation protocol. Media and 
coating compositions are detailed in the methods. 
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4.3.3. Genome editing 
Editing of DGCR8 gene has been performed using Zhang lab CRISPR/CAS9 protocol 
rev20140509, plasmid pX330 (pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene 
plasmid #42230, deposited by Pr. Feng Zhang)) 406. Two guide RNAs (gRNAs) were 
designed with an online CRISPR design tool (crispr.mit.edu, Zhang lab) (quality score > 
90, guide sequences CACTACAGTTCGGGTCTATG (AGG) and 
CTCATAGACCCGAACTGTAG (TGG), confirmed with CRISPR/Cas9 target online 
predictor CCTop 409). Two extra Guanine have been added at the 5' end to reduce off-
target activity 410. The guideRNAs (gRNAs) were then inserted into pX330 plasmids. 
gRNA efficiency was tested in HEK293 cells by transfection of the modified pX330 
plasmids with lipofectamine 3000 (ThermoFisher Scientific)). The region targeted by the 
gRNAs were amplified by PCR, sequenced and subsequently analysed with the Tracking 
of Indels by Decomposition TIDE online tool (tide.nki.nl 411) to assess gRNA efficiency 
(results not shown). Repair template for homology-directed repair (HDR) has been 
created using a pPGKpuro backbone (Addgene plasmid #11349, constructed by Peter W. 
Laird, deposited by Rudolf Jaenisch) to insert a puromycine resistance cassette at the 
targeted site and allow selection of recombinant clones. Briefly, two homology sequences 
of around 900 bp on both sides of the locus targeted by the gRNAs were amplified by 
PCR and inserted directionally with double digests/ligations. Details of pX330 and 
pPGKpuro plasmids and their editing can be seen in Figure 4-4.B/C. Restriction digests 
were performed using New England Biolabs restriction enzymes and reagents. Plasmid 
transformation was done in homemade chemically competent E. coli cells by heat shock 
following Invitrogen’s One Shot TOP10 protocol. Double transfection (pX330 + 
pPGKpuro) was performed on H7 cells using a 4D-Nucleofector system (Lonza). Various 
plasmid ratios and total input DNA amount have been used. H7 cells (WT) were disrupted 
to single cells before nucleofection and then plated into 6-well plates. Cell survival was 
increased by using the RevitaCell supplement (ThermoFisher Scientific). After 24 to 48h, 
puromycine (Sigma-Aldrich) was added at 0.5 µg/ml then 0.1 µg/ml after 3 days. Cell 
colonies were subsequently picked manually and cultured in 48-well plates. PCR 
screening strategy is described Figure 4-4.D/E.; for clones with single-allelic insertion of 
the resistance cassette, the second allele was sequenced by GATC Biotech. PCR was 
performed using either HotStarTaq DNA polymerase (Qiagen) for cloning and 
sequencing or MyTaq DNA polymerase (Bioline) for PCR screening. 
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4.3.4. RNA extraction and qRT-PCR 
Cells were lysed with TRI reagent (Sigma-Aldrich); then RNA was extracted by 
addition of 0.2 vol. chloroform, precipitation with 0.7 vol. isopropanol followed by two 
70% ethanol washes/precipitation. RNA pellets were air-dried then resuspended in 
A 
B C 
D E 
Figure 4-4. Genome editing strategy using CRISPR/CAS9 technology. Legend on next 
page.  
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DEPC-treated water and quantified/qualified with an Eppendorf BioSpectrometer. 
Samples with a 260/280 ratio of 1.8-2.2 were kept for subsequent analyses. Some samples 
used in Figure 4-9 (A) and (B) had 260/280 ratio < 1.8; visual inspection of qPCR 
amplification and melting curves was performed for these samples. RNA was treated by 
Turbo DNAse digestion (Ambion, Life Technologies) (Figure 4-6, Figure 4-7 and Figure 
4-8) or by PerfeCTa DNAse I (Quantabio) (Figure 4-9) then retrotranscription was 
performed with the qScript cDNA Synthesis Kit (Quantabio) (Figure 4-6, Figure 4-7 and 
Figure 4-8) or qScript cDNA SuperMix kit (Quantabio) (Figure 4-9). Samples were 
diluted 1:100 final in nuclease-free water and 1X MESA GREEN qPCR MasterMix Plus 
for SYBR Assay (Applied Biosystem, Life Technologies) with 1 µM primers (primer list 
in Supplementary table 4-1). Quantitative real-time PCR was executed on a CFX Connect 
Real-Time PCR Detection System (Bio-Rad) and analysed with the CFX Manager 
Software (Bio-Rad). PCR primers were designed with Primer3Plus (unless specified 
otherwise in Supplementary table 4-1) and produced by Sigma-Aldrich. The number of 
technical and biological replicates used are detailed in each figure. Calculations of relative 
expression were performed using the 2-CT method 412 using a custom R-script (Microsoft 
R Open 3.4.0 (Microsoft), based on R-3.4.0 (R Statistics)). Statistical analysis was 
performed on Ct values with the Mann-Whitney-Wilcoxon Test (wilcox.test from R 
package Stats). qPCR plots were generated with the R package ggplot2 242. 
Figure 4-4. Genome editing strategy using CRISPR/CAS9 technology. (A) DGCR8 
genomic DNA (gDNA) and protein structure. (B) Plasmid pX330 (Addgene, Zhang lab) 
containing Cas9 sequence and insertion of guideRNA at the BbsI restriction sites. (C) Plasmid 
PGKPurobpA and insertion of 5’ and 3’ homology arms for homology-directed repair (HDR) 
on exon 2 of DGCR8 (873bp and 892bp respectively). (D) Genome editing and PCR screening 
strategy. The nuclease Cas9 induces a double-strand break at the target site recognised by the 
gRNA that will be repaired by HDR with the targeting vector, allowing insertion of a selection 
cassette (puromycine resistance, PAC gene). Arrows labelled A to E represent the primers set 
used for PCR screening. Correct cassette integration was detected using forward primer A and 
reverse primer B, then confirmed with primer sets A to D. Primer set E was used to determine 
zygosity status. (E) Example of PCR screening results for a heterozygous recombinant clone. 
Expected sizes for primers sets A to D: 996bp, 971bp, 992bp, 997bp respectively; primer set 
E: 1748bp with cassette insertion (band 1), 248 bp without (band 2). The band 2 was then 
sequenced to determine possible insertion/deletion mutations due to non-homologous end 
joining repair errors. Abbreviations: 5’/3’ arms: homology arms for HDR at DGCR8 exon2 
locus AmpR: ampicillin resistance. BbsI, EcoRI, NotI, PspXI, SalI: restriction enzyme sites. 
bGHpA: Bovine Growth Hormone Polyadenylation Signal (termination signal). CbH: CBA 
promoter. dsRBD: double-stranded RNA-binding domain.gRNA: guide RNA. hSpCas9: 
humanized S.pyogenes Cas9. hU6: humanized U6 promoter. NLS: nuclear localization 
sequence. Pac: Puromycin resistance gene. PGK: PGK promoter. tracrRNA: transactivating 
RNA. WW: WW domain.  
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4.3.5. Immunostainings 
Cells were washed with PBS twice and fixed with 3.7% Paraformaldehyde for 20 
minutes at room temperature. Cells were then washed twice (5 min each) with PBST (PBS 
+ 0.3% Triton X-100 (ThermoFisher Scientific)) and blocked with 2% BSA (Bovin serum 
albumin, Sigma-Aldrich) and 5% donkey serum (Gentaur) in PBST (20 min). Primary 
antibodies were incubated in PBST + 5% donkey serum at 4C overnight, cells were then 
washed 3 times for 20 min in PBST at room temperature before being incubated with 
secondary antibodies for 2h at room temperature in the dark. After a PBST wash (10 min) 
cells were counterstained with DAPI (1:3000 in PBST) (ThermoFisher Scientifc)) for 5 
min. After 3 PBST wash (10 min each), all liquid was removed from the wells and cells 
were mounted with coverslips using Dako fluorescence mounting medium (Agilent). 
Primary antibodies and dilutions used were: OCT-3/4 goat Ab (Santa Cruz 
Biotechnologysc-86289, 1/500), TRA1-81 mouse Ab (Merck Millipore Chemicon 
MAB4381, 1/500), N-cadherin (NCAD) mouse Ab (Invitrogen 18-0224, 1/1000). 
Secondary antibodies were used at the dilution 1/500 (Alexa Fluor, ThermoFisher 
Scientific). 
 
4.4. Results  
4.4.1. Generation of DGCR8 knock-out human embryonic stem cells lines 
The CRISPR/Cas9 genome editing technology was used to knock-out DGCR8 in 
human embryonic stem cells. A custom donor plasmid was created to insert an antibiotic 
(puromycine) resistance gene in DGCR8 gene by directed homologous recombination. 
The goal was to disrupt DGCR8 and to be able to perform a positive selection on edited 
cells. DGCR8 Exon 2 was targeted, which is DGCR8 first coding exon (Figure 4-4.A/D). 
Two guideRNAs targeting the same region (on opposite strands) were designed to 
increase the chance of DNA cleavage. Nucleofection strategy was optimised by changing 
total quantity and ratio of donor vector and gRNA/Cas9 containing plasmids (gRNA1 
plasmid and/or gRNA2 plasmid) (data not shown). Use of linearized donor vector 
sequence (Cut by EcoRI and NotI, cf. Figure 4-4.C) led to more than 130 antibiotic-
resistant clones with integrated cassette; however PCR screening (cf. Figure 4-5) revealed 
around 95% of random integration of the cassette in other genomic loci. For this reason, 
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the circular form of the donor plasmid was used. This strategy led to a greater specificity 
of integration (around 20%, 40 clones tested) (Figure 4-5.B).  
Clones with the correct integration in one allele (cf. Figure 4-5.A potential genotype 
D-E) were sequenced to detect potential insertion/deletion mutation (INDEL) generated 
Figure 4-5. Results of genome editing and screening. (A) Schematic of possible genome 
editing results and resulting genotypes. INDEL: Insertion/deletion mutation (B) Results and 
comparison between uses of linearized or circular donor vector. (C) Sequencing results 
(from PCR amplicon with primer set E presented in Figure 4-4.E lane 2) of wild-type target 
sequence, example of one heterozygous knock-out and the two cell lines with INDEL mutations 
(Hom1 and Hom2 with 36bp and 12bp deletion respectively). (D) Amino-acid sequence of 
DGCR8 exon 2. In the box are presented the deleted amino-acids in Hom1, in bold those in 
Hom2. NHEJ: non-homologous end-joining. 
A 
B 
C 
D 
Donor vector Linearized Circular
Antibiotic resistant clones per transfection (~1-1.5* 106 cells per transfection) 15-30 1-3
Clones screened (B+C+D+E) 134 40
Clones with correct integration of donor vector (2 copy) (B) 0 0
Clones with correct integration of donor vector (1 copy) (C) 7 8
Clones with donor vector + NHEJ mutations (E) 0 2
Clones with donor vector + NHEJ mutations leading to a premature stop codon (E) 0 0
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via non-homologous end-joining repair in the other allele. The sequencing results for lines 
that are subsequently used in this thesis are presented in Figure 4-5.C. Two clones, named 
clone Hom1 and clone Hom2, had deletion mutations in the 2nd allele, which were 36bp 
and 12bp deletions respectively. However, no frameshift was generated by these 
mutations (as determined by ExPASy Translate Tool) (Figure 4-5.D). PROVEAN 
(Protein Variation Effect Analyzer 413) predicts a neutral effect of the mutation in clone 
Hom2 (score = -1.28) but deleterious in clone Hom1 (score = -7.57). Moreover, SNP id 
rs182736423 (Chr22:20086250, C/T), contained in amino-acid 96 (deleted in clone 
Hom1) is characterised on ENSEMBL.org as “deleterious – low confidence” (SIFT 
prediction) and “probably damaging” (Polyphen prediction). This could suggest that the 
allele containing this 36bp deletion potentially code for a protein with an altered function. 
For this reason, this clone was preferentially used (over the clone Hom2) in the following 
experiments; clone Hom1 is also referred to as DGCR8 MUT/- in this thesis.  
 
4.4.2. Validation of the model: preliminary study of expected results 
4.4.2.1. Posttranscriptional regulation of DGCR8 mRNA  
Recent studies have shown that DGCR8/DROSHA can bind and process RNAs that 
are not microRNAs, including hundreds of mRNAs 390–393. Interestingly, it has been 
shown in Drosophila and mouse models that Dgcr8 itself is among these mRNAs; there 
is a posttranscriptional control of Dgcr8 expression by the microprocessor complex 
391,414,415. The exon 2 of Dgcr8 contains two hairpins structures that are cleaved by the 
protein DROSHA to generate two microRNAs (miR-3618 and miR-1306), leading to a 
cross-regulation between DROSHA and DGCR8 (as DGCR8 protein stabilise DROSHA 
protein 415). Downregulation of DROSHA, and thus of the microprocessor complex, lead 
to increased levels of DGCR8 mRNA 415. This feedback loop is reflected at the protein 
levels; brain tissue from Dgcr8 heterozygous knock-out mouse have more than the 
expected 50% expression compared to controls (relative expression between 60%  and 
90% depending on brain regions and developmental time points) 78,416.  
Different sets of primers (A, B, C, D) have been designed (as depicted Figure 4-6.A) 
to investigate the effect of the generated DGCR8 mutations on this feedback loop by 
measuring RNA level at different DGCR8 gene sites. The primer set A targets exons 1 to 
2; primer set B spans the hairpin structure targeted by DGCR8; primer set C amplify the 
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region edited by CRISPR; primer set D targets exons 12 to 14. Three cell lines were 
Figure 4-6. Alteration of DGCR8 mRNA processing in embryonic stem cells. (A) 
Representation of precursor mRNA (before posttranscriptional processing), primer sets used to 
characterise mRNA levels and expected results. From top to bottom: mRNA secondary structure 
showing the hairpins contained in DGCR8 exon 2, leading to excision by the microprocessor of 
2 precursor microRNA; mRNA copies in Wild-type cells; Primer sets used for qPCR; mRNA 
copies in KO lines. (B) Table showing expected mRNA levels for the different primer sets 
depending on DGCR8 processing capacity in KO lines. (C) DGCR8 mRNA levels as determined 
by qPCR using the primers sets described in (A). Normalised to GAPDH levels. N = 3 (technical 
replicates) x 2 (biological replicates) for KO lines, 3 (technical replicates) x 1 (biological 
replicates) for WT. Bars represent standard deviation between biological replicates. No statistical 
test performed due to sample size. 
A 
B 
C 
A B C D
ABSENT in KO lines Hom1 = Het1 = WT Hom1 = Het1 = WT Hom1 = Het1 = ½ WT Hom1 = Het1 = ½ WT
PRESENT and ALTERED 
in KO lines
Hom1 ≥ Het1 > WT Hom1 ≥ Het1 > WT Hom1 ≥ Het1 > ½ WT Hom1 ≥ Het1 > ½ WT
Hypothetical situations leading to 
different mRNA levels
Primers sets
Posttranscriptional 
processing by DGCR8
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compared: Wild-Type (WT), Het1 (DGCR8 +/-) and Hom1 (DGCR8 MUT/-).  
Figure 4-6.B indicate the hypothetical relative mRNA levels between cell lines. It 
depends on the posttranscriptional ability of DGCR8 to process its own mRNA, which 
can be affected by the generated mutations. Primer sets A and B amplicons showed 
increased mRNA levels of around ~2- to ~2.5-fold between the heterozygous clone (Het1) 
and the control line (WT). This increase was greater for the lines Hom1 DGCR8 MUT/- 
(with a 36 bp deletion on second allele), with on average around ~5.5- to ~7.5-fold more 
mRNA detected compared to the control line. Primer sets C and D amplified regions on 
the other hand seemed to show less changes in mRNA levels. For the Het1 line, they 
indicated around ~30% average decrease and ~20% average increase respectively relative 
to WT. For the Hom1 line, there was a ~30% decrease for primer set C amplicon and a 
~40% decrease for the primer set D amplicon. 
The regions amplified by primer sets A and B were located upstream of the mutated 
sites; this increase possibly indicates an altered processing of DGCR8 mRNA by the 
microprocessor complex (Figure 4-6.B). The mRNA levels observed could be due to 
reduced DGCR8 mRNA degradation. The higher levels detected for the Hom1 line may 
indicate a further disruption of DGCR8-mediated processing. For the primer sets C and 
D amplicons only the intact allele is measured. In consequence, theoretically the mRNA 
changes compared to WT should be half of those measured for primer A and B amplicons. 
However observed levels are not concordant with this hypothesis. Alternative splicing of 
DGCR8 or qPCR variability due to small sample size could explain the results.  
 
4.4.2.2. microRNA processing  
The main expected phenotype upon single copy deletion of DGCR8 is an alteration of 
microRNA processing, as it has been shown in DGCR8 knock-out models in Drosophila 
417, mouse embryonic stem cells 128 and mice 78 as well as in 22q11.2 deletion syndrome 
mouse models and patients 129,418,419.  
To assess whether the DGCR8 KO lines had abnormal microRNA processing, a set of 
primary-microRNAs that were previously suggested to be processed by the 
microprocessor complex have been selected. These microRNAs include pri-miR 16-1, 
pri-let 7-a-1, pri-miR 185, pri-miR 20-19a and pri-miR 17. Pri-miR 16-1 and pri-let 7-a-
1 have increased levels after DROSHA depletion in HEK cells 415. Pri-miR 185 have been 
 96 
 
 CRISPR/Cas9 genome editing of DGCR8 in human embryonic stem cells 
selected due to the decreased levels of miR 185 in Dgcr8 KO mouse models 78. Pri-miR 
20-19a and pri-miR 17 are part of the miR 17~92 cluster that is affected by DGCR8 
deletion in vascular smooth muscle cells 420. Moreover, microRNAs from this cluster have 
been shown to be implicated in neuronal differentiation, neural progenitor cell 
proliferation and neurogenesis 421–423.  
These different primary microRNA have been tested in either undifferentiated hESCs 
(Figure 4-7.A) or neural progenitor cells at day 20 of differentiation (NPCs) (Figure 
4-7.B). I only tested Hom1 KO line against the control line due to the predicted effect of 
the mutation on DGCR8 function and the greater changes in DGCR8 mRNA levels (cf. 
Figure 4-6.C). The greatest effect observed was for pri-miR 16-1, with a ~2-fold increase 
in undifferentiated hESCs. Other tested pri-miRNAs showed minor differences or none.  
 
4.4.2.3. Neurogenin2 mRNA processing by the microprocessor complex 
As discussed previously, the microprocessor complex has been previously shown to 
process a subset of mRNAs. Among these, an interesting transcript in the context of 
neural differentiation is coded by Neurogenin 2 (NEUROG2). It has been shown that 
DROSHA can cleave hairpin structures in the 3’UTR of NEUROG2 mRNA and regulate 
its level 424,425. NEUROG2 is a pro-neural transcription factor upstream of NEUROD1 
(also regulated by the microprocessor complex). It has been shown that enforced 
Figure 4-7. Precursors levels of a subset of microRNAs. (A) RNA levels in human embryonic 
stem cells. N = 3 (technical replicates) x 3 (biological replicates). (B) RNA levels in Neural 
Progenitor Cells (Day 20). N = 3 (technical replicates) x 2 (biological replicates). Normalised to 
GAPDH levels. Bars represent standard deviation between biological replicates. No statistical test 
performed due to sample size. 
A B 
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expression of NEUROG2 in human and mouse embryonic stem cells induce the cells to 
differentiate into neurons 426,427. Furthermore, in human iPSC-derived neural progenitor 
cells, NEUROG2 induction causes a rapid maturation of the cells 428. Concordantly, 
inhibition of the microprocessor complex (Drosha inhibition) in forebrain neural 
progenitors lead to induction of NEUROG2, NEUROD1 and result in early differentiation 
424,425.  
Using the primer set A (cf. Figure 4-6.A), I firstly examined DGCR8 mRNA level 
corresponding to exons 1 to 2. It showed an ~3.5-fold increase in day 20 neural progenitor 
cells (NPCs) DGCR8 KO lines compared to wild-type NPCs, similarly to what has been 
found at the embryonic stem cell stage (Figure 4-6). I then determined mRNA levels of 
NEUROD1, NEUROG2 and different neural lineage markers in the Hom1 DGCR8 MUT/- 
line. I observed an increase of both NEUROD1 (~7.5-fold) and NEUROG2 (~19.5-fold) 
in NPCs (day 20), as well as TUJ-1 mRNA level (neuron-specific marker, ~2.5-fold). 
However, the transcript level of NESTIN and PAX6 (NPC and radial glia markers) were 
only slightly altered (~1.5- and ~1.2-fold increase respectively).  
 
Figure 4-8. Microprocessor-dependent control of pro-neural mRNAs. (A). RNA levels in 
Neural Progenitor Cells (Day 20). N = 3 (technical replicates) x 2 (biological replicates). 
Normalised to GAPDH levels. Bars represent standard deviation between biological replicates. 
No statistical test performed due to sample size. Marker used: Nestin: neural stem/progenitor cell 
marker; Pax-6: radial glia marker; TUJ1: Neuron-specific Class III β-tubulin (neuronal marker); 
NEUROD1, NEUROG2 (Neurogenin2): pro-neuronal transcription factors. (B) Involvement of 
the microprocessor complex in a regulatory cascade controlling neuronal differentiation (adapted 
from Di Carlo et al. 425).  
A B 
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4.4.3. Results reproducibility 
In order to assess the validity and reproducibility of the results, replications of the 
previous experiments have been done with a larger sample size (including different KO 
lines) and over multiple neural differentiation. Biological variation between independent 
neural differentiation and multiple cell lines is likely to introduce noise in the results; but 
the rationale of this experiment is to try and gain confidence on possible molecular 
phenotypes in the DGCR8 knock-out lines before pursuing with further experiments. 
While analysing results from single differentiation experiments independently could give 
a better picture of gene expression changes (such as what is shown in the preliminary 
results above), this will test the robustness of the results. 
For this, 7 different cell lines have been used. This include the homozygous KO Hom1 
(DGCR8 MUT/-), three distinct heterozygous knock-out lines Het1, Het2, Het3 (DGCR8 +/-
) and three control lines (DGCR8 +/+). The first control line is the parental H7 line (WT) 
as used previously. A second line, named WTcrispr1, is a DGCR8 wildtype sister clone 
of the above DGCR8 KO lines derived from the same CRISPR/Cas9 genome editing 
process. This line has integrated the antibiotic resistance cassette but at a random and 
non-determined locus (cf. Figure 4-5.A hypothesis D). A third line, named WTcrispr2, is 
another DGCR8 wildtype line of H7 background, derived from an independent 
CRISPR/Cas9 targeting study (provided by Dr. Lucia Cardo, Cardiff University). 3 
biological replicates have been collected for each cell lines, and results from samples from 
the same conditions (WT, Heterozygous KO, Homozygous KO) were pooled as replicates 
and analysed together.  
For the embryonic stem cell stage, 9 WT samples (3*3), 9 Heterozygous KO samples 
(3*3) and 3 Homozygous KO samples (1*3) have been collected. For the neural 
progenitor cell stage, three independent differentiations have been performed, resulting 
in 24 WT samples (9*3 minus 3 samples excluded due to abnormal melting curves/low 
cDNA levels), 27 Heterozygous KO samples (9*3) and 9 Homozygous KO samples 
(3*3). Due to other experimental constraints, NPCs were extracted at day 18 of 
differentiation, while samples for the preliminary qPCRs presented above were extracted 
at day 20. 
At the embryonic stem cell stage, the differences in DGCR8 mRNA levels previously 
observed were replicated (Figure 4-9.A), with increased RNA levels for the two primer 
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sets (A and B) located before the edited region but no significant changes for the primer 
sets situated after the mutations (C and D). These differences were significant for both 
heterozygous and homozygous KO for the primer set A that spans DGCR8 exons 1 to 2 
(~2-fold increase, p=0.04 and ~4.5-fold, p=0.0091 respectively) respectively. However, 
it was only significant for the Hom1 KO for the primer set B spanning the hairpins sites 
processed by the microprocessor complex (~2.8-fold increase, p = 0.036). This difference 
in DGCR8 mRNA level at the exons 1/2 locus was also significant in neural progenitor 
cells for the Hom1 clone (~2.2-fold increase, p = 0.0048) but not for the heterozygous 
KO lines (Figure 4-9.C).  
A B 
C D 
Figure 4-9. Results reproducibility. Quantitative PCR relative RNA levels for three controls 
lines (WT, WTcrispr1, WTcrispr2), three heterozygous DGCR8 knock-out lines (Het1, Het2, 
Het3) and one potential homozygous DGCR8 knock-out line (Hom1). For samples at day 0 
(embryonic stem cells, (A) and (B)) N = 9 biological replicates for Controls and Homozygous 
KO lines, N= 3 biological replicates for the Homozygous line (no technical replicates for any 
line). For samples at day 18 (neural progenitor cells cells, (C) and (D)) N = 24 biological replicates 
for Controls, N = 27 biological replicates for Homozygous KO lines, N= 9 biological replicates 
for the Homozygous line (no technical replicates for any line; samples from 3 independent 
differentiations). Normalised to GAPDH levels (2 technical replicates for each biological 
replicates). Statistical testing performed on Ct values with the Mann-Whitney-Wilcoxon Test, 
without correction for multiple comparison. Bars represent standard deviation between biological 
replicates. (A) Alteration of DGCR8 mRNA processing in embryonic stem cells (day 0) (cf. 
Figure 4-6). (B / D) Precursors levels of a subset of microRNAs at (B) day 0 (embryonic stem 
cells) and (C) day 18 (neural progenitor cells) (cf. Figure 4-7). (D) Microprocessor-dependent 
control of pro-neural mRNAs at day 18 (cf. Figure 4-8).  
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Three primary microRNAs had significantly higher RNA levels in undifferentiated 
DGCR8 KO lines (Figure 4-9.B): pri-miR 16-1 (~2.2-fold, p=0.036, Homozygous KO 
line) as well as pri-miRs 17-92a and 17-19a (~1.7-fold, p=0.031 and ~1.6-fold, p=0.04 
respectively, Heterozygous KO lines). Two other pri-miRNA, pri-miR 185 and 17-19a, 
seemed to have increased RNA levels in the KO lines (~2-fold and 1.9-fold respectively) 
but the difference was not significant. The direction of effect for these different pri-
miRNAs (increased levels) is consistent with a hypothetic disruption of DGCR8 function. 
At the neural progenitor cell stage however, no pri-miRNA appeared to be significantly 
impacted by the mutations in the different knock-out lines (Figure 4-9.D). 
In NPCs, the mRNA levels of NEUROG2 appeared to be increased in both 
heterozygous and homozygous lines. This difference was only significant in heterozygous 
KO lines (~2-fold, p=0.00097 and ~1.8-fold, p = 0.059 respectively) (Figure 4-9.C). None 
of the other transcript tested, NEUROD1, NESTIN, PAX6 and TUJ1, appeared to have 
different mRNA levels in the KO lines.  
 
4.4.4. Phenotypic observations 
I did not observe gross changes in DGCR8 knock-out KO cells at the embryonic stem 
cell stage (day 0). The KO cells did not appear to have increased level of spontaneous 
differentiation, or to exhibit deficit in cell viability or proliferation. The pluripotent cell 
markers OCT4 and TRA-1-81 were expressed by these cells in comparable proportion to 
that of the controls (cf. Figure 4-10).  
However, at the neural progenitor cell stage (day 18) the DGCR8 KO cells formed 
abnormal structures. At this stage of the differentiation there is presence of typical neural 
rosettes, which are 2-dimensional structures that are analogous to the neural tube that 
forms during development (cf. Figure 4-11.A). N-cadherin is commonly used to detect in 
vitro these round-shaped structures, as it marks their apical side. DGCR8 KO lines 
appeared to have relatively large and abnormal structures marked by N-cadherin (NCAD) 
(representative images shown Figure 4-11.B). Generally, differentiating DGCR8 KO 
cultures appeared more heterogeneous than the control cultures with spaces without 
NPCs. Moreover, the abnormal NCAD+ structures tended to appear on the border of these 
spaces. The effect seemed to be greater in the homozygous knock-out Hom1; and it has 
been observed for multiple heterozygous knock-out in multiple differentiation runs. 
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4.5. Discussion 
To my knowledge, this study presents the first DGCR8 knock-out out cell model 
generated in hESCs. The use of the CRISPR/Cas9 genome editing technology allowed 
the generation of multiple DGCR8 KO cell lines that have undergone homologous 
recombination in one chromosomal gene copy of the second exon of DGCR8. Two lines 
have been obtained that contains a deletion mutation in the second chromosomal copy of 
the DGCR8 gene. However, both mutations were in-frame deletions and thus are not 
Figure 4-10. Pluripotency markers expressed at the stem cell stage. DAPI: nuclear 
counterstain; OCT3/4: nuclear marker of pluripotency; TRA-1-81: surface marker of 
pluripotency. WT: Wild-Type. Het1: heterozygous DGCR8 KO line. Scale bar: 200 µm. 
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expected to cause a termination of translation. No true functional homozygous null mutant 
has been obtained. Multiple explanations could lead this result. First, it could be due to 
an insufficient number of clones screened for the mutation, combined with the low rate 
of effective homology-directed repair obtained. Secondly, DGCR8 null mutation may 
Figure 4-11. Neural rosette formation (A) hESC-derived neural rosettes in vitro bear 
striking resemblance to the neural tube. Apicobasal polarity is similar between rosettes and the 
neural tube, with tight junctions (indicated by N-cadherin expression, blue) at the apical surface 
forming a lumen. Radially arranged progenitors in the rosette, as well as the neural tube, express 
RC2 and BLBP (green). Figure adapted with permission from John Wiley and Sons: Journal of 
Cellular Biochemistry, Germain 2010 500, copyright (2010). (B) Abnormal N-cadherin 
organisation in DGCR8 KO lines at the embryonic stem cell stage (Day 18). DAPI: nuclear 
counterstains. NCAD: N-cadherin. Scale bar: 200 µm. 
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compromise self-renewal and hence reduce the chance of picking and screening such KO 
lines, for instance by reducing significantly the proliferation rate of the cells as it has been 
shown in mouse embryonic stem cells 128. Finally, it is possible that the homozygous 
knock-out of the DGCR8 gene is non-viable in human embryonic stem cells. It has 
however been shown to be viable in mouse embryonic stem cells 128. 
The generated KO lines appeared to have an altered DGCR8 protein activity. DGCR8 
has the ability to self-regulate its own mRNA levels by binding of the protein to 
microRNA-like hairpin structure located in the second exon of DGCR8 mRNA. These 
structures are then degraded by DROSHA and consequently controlling the protein levels 
78,391,414–416. Here the KO lines have shown to have increased mRNA levels for sequences 
that are located before the edited locus (Figure 4-6.C, Figure 4-9.A). This difference was 
significant when targeting the first two exons (before the edited region) in embryonic 
stem cells for the heterozygous knock-out lines (p = 0.04) and the homozygous knock-
out line tested (p = 0.0091). It was also significant in neural progenitor cells for the 
homozygous knock-out line (p = 0.0048) (Figure 4-8.A, Figure 4-9.C). This result might 
reflect an altered processing of the stem-loop structure contained in the second exon of 
DGCR8 mRNA by the microprocessor complex. The increased levels were probably not 
due to an increased transcription of the DGCR8 mRNA but rather to a reduced 
degradation of the mRNA due to lower microprocessor proteins levels and/or activity. 
The Hom1 cells, that contain a 36 bp in-frame deletion in the second allele (and 
homologous recombinant in first allele), showed a more significant difference (compared 
to wild-type) when amplifying these mRNA regions situated before the mutated site. This 
could indicate that the mutation affects the protein function, i.e. this second allele might 
be hypomorphic. However, the difference in mRNA levels when amplifying these regions 
was not significant when comparing the heterozygous knock-out lines to the homozygous 
line (data not shown). The presence of this homeostasis loop regulating DGCR8 mRNA 
could compensate partially or fully the absence of one chromosomal copy of the DGCR8 
gene. For this reason, future studies should determine the protein levels of DGCR8 in 
these KO lines. However, it is also possible to investigate this indirectly by looking at the 
levels of other RNAs targeted by DGCR8. 
The ability of DGCR8 to bind to other mRNA that contains stem-loop structure -and 
thus the ability to lead to their degradation through microprocessor complex activity- has 
also been indirectly tested by looking at the mRNA levels of NEUROG2. NEUROG2 
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mRNA contains such structure in its 3’ untranslated region and deficits in 
DROSHA/DGCR8 lead to increased levels of its mRNA 424,425. Concordantly, the 
DGCR8 heterozygous and Hom1 KO lines appeared to have increased levels of this 
mRNA (Figure 4-8.A, Figure 4-9.C). This difference was significant for the heterozygous 
knock-out lines (p = 0.00097) but not for the Hom1 clone (p = 0.059). There might have 
been a non-significant trend in Hom1 clone for an increase of NEUROD1 mRNA level, 
another pro-neuronal transcription factor downstream of NEUROG2 425. PAX6, a 
transcription factor interacting with NEUROG2 429 and a radial glia marker, did not have 
altered mRNA levels, and neither did NESTIN and TUJ-1 (neural progenitor cells- and 
neurons-specific markers). Further analysis of neuronal lineage specific genes by RNA-
sequencing could help to further investigate the effect of DGCR8 knock-out on 
NEUROG2 and neural differentiation. Nonetheless, these results suggest a reduced ability 
of DGCR8 in KO lines to bind and indirectly regulate the mRNA level of NEUROG2, 
containing microRNA-like structures. As NEUROG2 ectopic expression has been shown 
to induce a rapid neuro-differentiation and neuron maturation 426,428, this could potentially 
lead to specific cellular phenotypes in DGCR8 KO lines. 
The most studied function of DGCR8 is to bind to primary-microRNAs that are then 
processed by DROSHA into precursor-microRNA. DGCR8 KO lines have shown to have 
increased RNA levels for a small subset of pri-miRNA that have been previously shown 
to be regulated by the microprocessor complex (pri-miR 16-1 and 2 pri-miRNA which 
are part of the miR-17~92 gene cluster 415,420). However, the increase in mRNA levels 
appeared minimal compared to previously reported results in other cell lines, and the other 
tested pri-miRNA did not show changes in RNA levels. In particular, pri-miR 185, 
targeted by DGCR8 and part of the 22q11.2 deletion 78, did not seem altered in the 
DGCR8 KO lines. Multiple explanation would be possible, in the hypothesis that the 
DGCR8 KO lines are indeed hypomorphic. It could be due to biological variability 
between the different cell lines tested and between the multiple replicated differentiations 
used. Secondly, microRNA level changes observed in other cell types might not be 
reflected in the cell lines used.  
A large biological variability has been observed in the replication experiments, as 
shown by the standard deviations bars in Figure 4-9 and the non-reproducibility of some 
of the results presented in the preliminary experiments. Nonetheless, the levels of multiple 
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RNAs have been shown to be significantly altered. These results are indicating that the 
generated DGCR8 knock-out lines have an impaired RNA processing ability. 
Finally, phenotypic abnormalities have been observed during different runs of neural 
differentiation of the DGCR8 KO lines. Notably, large neural-rosette-like structure 
stained by N-cadherin were present in clones, with a seemingly more robust phenotype 
in the Hom1 DGCR8 MUT/- clone that contains a 36 bp deletion on the second allele. 
Further characterisation of these structures and the cells that compose and surround them 
is required. In particular, an analysis of earliest time points during differentiation will help 
to understand if these structures derive from neural rosettes that expand at an increased 
rate, or that they were the product of fusions of multiple rosettes or other unknown causes.  
 In summary, multiple DGCR8 heterozygous and homozygous knock-out cell lines 
have been generated in human embryonic stem cells. These cells exhibit abnormal 
molecular and cellular phenotypes. However, future work will be required to further 
characterise the cellular abnormalities and to elucidate the molecular mechanisms. In 
particular, mRNA-sequencing will permit to get a better understanding of the 
transcriptomic changes emerging from the hemizygous loss of DGCR8. This will 
hopefully also give hindsights into the defects in gene regulation occurring in 22q11.2 
patients who also suffer from the loss of one copy of the DGCR8 gene. 
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5. Transcriptome analysis of DGCR8 knock-out lines 
5.1. Introduction  
5.1.1. DGCR8 RNA targets and actions 
The DGCR8 protein, as a part of the microprocessor complex alongside DROSHA, is 
an essential component of the canonical microRNA biogenesis pathway (cf. Figure 4-1 
Chapter 4 p.82). As microRNAs regulate post-transcriptional expression, DGCR8 is a 
major player of genetic regulation. However, its involvement extends further due to its 
ability to bind to other type of RNAs. Kadener et al. in 2009 performed a genome-wide 
identification of microprocessor targets in D.melanogaster 430. It showed in a Drosha 
knock-down model that many RNAs were upregulated similarly to pri-miRNAs. These 
RNAs were not affected when knocking-down Dicer, another protein involved in the 
canonical microRNA biogenesis pathway. This suggested that the upregulated RNAs 
were due to Drosha knock-down directly and not indirectly through alteration of miRNA 
levels and their targets. These RNAs have the particularity to contain pri-microRNA-like 
hairpin secondary structure. They include several mRNAs such as Dgcr8 itself, and these 
results have been confirmed in mouse embryonic stem cells 431.  
By cross-linking DROSHA or DGCR8 proteins with UV light irradiation or 
formaldehyde exposure to their RNA partners, multiple studies have been able to 
sequence and identify these targets 390,432,433. These studies have shown that the 
microprocessor complex can bind to coding RNA (mRNA) as well as many subtypes of 
non-coding RNA, including for instance retrotransposon RNA, long-non-coding RNA 
(lncRNA), microRNAs (miRNA), small nucleolar RNA (snoRNA), ribosomal RNA 
(rRNA) and mitochondrial RNA (mtRNA). snoRNA are a class of non-coding RNA 
involved in guiding chemical modification of other RNA molecules (such as rRNA) 434, 
and are regulated by DGCR8 independently of DROSHA 390. It has been suggested that 
the DGCR8 protein can form a complex with the nuclear exosome and recruit it to induce 
the degradation of double stranded structured DNA such as these snoRNAs or the 
telomerase RNA component, essential for telomere replication 435.  
There is evidence that DROSHA and DGCR8 can affect gene expression in multiple 
ways. The first one is the most studied, through the regulation of microRNAs and thus 
mRNA targets levels. Secondly, it can directly alter the level of mRNAs that contain 
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exonic microRNAs by cleaving the secondary structure. This mechanism has been 
demonstrated for Dgcr8 mRNA 390,391,414,415,431, Neurog2 mRNA 424,425 , Aurkb 432 mRNA 
as well as Hoxa7, Dlg5 and Snx12 mRNAs 390. The microprocessor complex can also 
regulate gene expression independently of its RNA-cleavage function. It has been shown 
by chromatin immunoprecipitation analysis that both DROSHA and DGCR8 protein can 
bind to the promoter-proximal regions of large number of genes 436. DROSHA interacts 
with the RNA polymerase II protein and this activity correlates with gene expression 
levels 436. 
The two main proteins of the microprocessor complex (DROSHA/DGCR8) also have 
a role in splicing events. DGCR8 regulates the relative levels of alternatively spliced 
transcripts by binding to specific exons that can in turn (but not necessarily) be cleaved 
390. It has been for instance shown that the exon 5 of the eIF4H gene, which contains a 
predicted hairpin structure, is cleaved by DROSHA 437. Microprocessor-dependent 
alternative splicing can also occur due to the presence of hairpin structures located across 
exon-intron junctions 438. DGCR8 and DROSHA are found within the supraspliceosome 
complex, and it has been shown that the activity of either one of the microprocessor 
complex or spliceosome is negatively correlated with the activity (and protein levels) of 
the other 439.  
 
5.1.2. 22q11.2 deletion syndrome transcriptome and relation to DGCR8 
5.1.2.1. Mouse models 
The different processing activity of the microprocessor on a wide range of RNA 
subtypes suggests that the hemizygous deletion of Dgcr8 in knock-out models or in the 
context of 22q11.2 deletion syndrome is likely to lead to transcriptome changes. Stark et 
al. generated in 2008 the Df(16)A+/- mouse model that carry a hemizygous chromosomal 
deficiency spanning a region syntenic to the 1.5 mb A-B deletion at chromosome 22q11.2 
in humans 78. Analysis of the Df(16)A+/- transcriptome in the prefrontal cortex (PFC) and 
the hippocampus revealed changes at both mRNA and microRNA levels. Only a subset 
of the primary-microRNAs tested in the study were shown to have increased levels in the 
mutant compared to the wild-type mice and only some of their mature microRNAs were 
downregulated. Affected pri-miRNA and miRNAs were found to have similarly altered 
levels in Dgcr8-deficient mice, suggesting that this protein was the cause of these 
differences. In the Df(16)A+/- mice, more gene transcripts were significantly differentially 
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expressed in the PFC than the hippocampus, but a small subset of genes were dysregulated 
in both tissue type, including genes outside the 22q11.2 deleted region. Gene ontology 
analysis of dysregulated genes suggested that those affected in the PFC are related to 
energy metabolism while those affected in the hippocampus were related to synaptic 
functions. Interestingly, looking for miRNA target sites (seed sites) within the 
3’untranslated region (UTR) of the dysregulated genes identified an enrichment of seed 
sequences in upregulated genes. This suggests that part of the alteration of the 
transcriptome in the 22q11.2DS mice model is indeed due to decreased levels of DGCR8-
dependent microRNAs. Further analysis of this model showed that one microRNA in 
particular, miR-185, represses Mirta22. This is particularly relevant because miR-185 is 
a microRNA whose sequence is located within the 22q11.2 deletion, and is also processed 
by the microprocessor complex, thus resulting an important reduction in 22q11.2 mice 
176. This reduction of miR-185 leads to greater Mirta22 levels which in turn affects 
neuronal dendritic and spine growth in this 22q11.2DS mouse model 176. Interestingly, it 
has been shown that some of the genes with lower hippocampal mRNA levels in Dgcr8+/- 
mice (compared to wild-type) have also been shown previously to be downregulated in 
schizophrenia patients 398. This further suggests the importance of studying DGCR8-
related gene regulation and its impact on the transcriptome to understand schizophrenia 
aetiology in the 22q11.2 deletion syndrome. 
 
5.1.2.2. 22q11.2 DS patients 
Changes in microRNA levels that have been observed in mouse embryonic stem cell 
Dgcr8 knock out, mouse Dgcr8 knock-out or 22q11.2 mouse models have been similarly 
reported in peripheral leucocytes from 22q11.2 deletion syndrome patients 129. This 
includes miR-185, which was the most significantly downregulated mature miRNA 
reported in the study. These patients were also found to have significantly decreased 
levels of DGCR8 mRNA and protein. Microarray analysis of gene expression of 
peripheral blood mononuclear cells (PBMCs) of 22q11.2 patients compared to 
individuals without this CNV showed a dysregulation of genes implicated in functional 
networks that can be linked to the disorder, such as the nervous system development or 
cardiovascular system development 440. A potential bias of both studies is that 22q11.2 
deletion syndrome patients have been reported to have lower T-cell numbers 43,44. As a 
consequence, it might result in apparent changes in gene expression caused by different 
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cell-type compositions between individuals with or without the CNV (cf. Chapter 2 (p.31) 
for further discussion on this subject in the context of DNA methylation).  
Jalbrzikowski et al. in 2015 have shown that 65% of the differentially expressed genes 
in peripheral blood from 22q11.2 deletion syndrome patients are expressed in the brain 
441. GO analysis showed that the significant genes were enriched in neuron-related 
ontology terms, while gene network IPA analysis showed an association with cellular 
development, growth and proliferation as well as axon guidance signalling. One great 
strength of the study was that they performed a comparison of the transcriptomes of 
22q11.2 deletion syndrome patients with or without neuropsychiatric disorders. First, this 
allowed an analysis of the gene expression differences between patients that develop 
different phenotypes. Moreover, while the issue was not addressed in the study, it should 
reduce the cell-type composition bias. In 22q11.2 deletion syndrome patients, psychosis 
status was associated with differential expression of genes related to mitochondrial 
organisation and transport (GO terms) as well as embryonic development, cellular 
assembly and cellular organisation (canonical pathways). Differentially expressed genes 
depending on autism spectrum disorder status in 22q11.2 deletion syndrome were 
associated with cell morphogenesis in differentiation (GO term) and immune response 
(canonical pathway). 
 
5.1.2.3. Stem cell models 
The development of the Induced Pluripotent Stem Cell (iPSC) technology has been a 
major step forward in the investigation of neurological and neuropsychiatric disorders. 
This technique allows the reprogramming of differentiated cells such as skin fibroblast 
into pluripotent cells that can be differentiated into many other cell types (as reviewed in 
Shi 2017 442). One first advantage of this technique is to be able to study the impact of 
known human mutations in cell types and tissues that might be difficult to access, such 
as the brain. Stem cell differentiation protocols have been developed to obtain different 
types of neurons, for instance cortical neurons, interneurons or dopaminergic neurons (as 
reviewed by Mertens et al. 2016 186). This can facilitate the investigation of disease 
mechanisms in relevant cell types. The second main advantage of the hiPSC technology 
is to study genetic environments that are too complex to be generated with the current 
existing genome editing technologies. Common variants that leads to an increased risk in 
schizophrenia in the general population or in 22q11.2 deletion syndrome patients (cf. 
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Chapter 2 (p.31)) are numerous, and recreating particular combinations of alleles in stem 
cell lines would be extremely strenuous. Despite recent advances in the CRISPR/Cas9 
genome editing system to generate large CNVs 443, the size of the 22q11.2 deletion makes 
it difficult to re-create in human embryonic stem cells. No 22q11.2 deletion has been 
generated yet in embryonic stem cells to my knowledge. 
The first study of gene expression in neurons differentiated from hiPSCs derived from 
22q11.2 deletion syndrome patients with schizophrenia was performed in 2011 by 
Pedrosa et al.444. It revealed that the expression of pluripotency markers Oct4 and Nanog 
are retained for an increased period of time after induction of differentiation; similar 
results have been demonstrated in Dgcr8 knock-out mouse embryonic stem cells 128. 
Microarray transcriptome analysis in hiPSC-derived neurons carrying a 22q11.2 deletion 
revealed that at both neural progenitor stage (day 10) and more mature neurons (day 32) 
there was an enrichment of genes involved in Gene Ontology (GO) terms related to 
neuron morphogenesis as well as cell cycle control and proliferation. There were also 
strong enrichments in biological pathways related to neurological diseases, psychological 
disorders and the cell cycle. A more recent analysis by the same group used RNA-
sequencing and an increased number of hiPSCs-derived cell lines from 22q11.2DS 
patients with psychotic disorders and controls to further investigate gene expression 
changes related to the deletion 445. The top GO terms that were enriched for up-regulated 
genes in 22q11.2DS neurons were related to apoptosis and the immune response, while 
for down-regulated genes it was related to cell cycle as well as the glutamate metabolic 
process, neurotransmission and cytoskeletal organisation terms. One of the canonical 
pathways reported as enriched was ERK/MAPK, which is consistent with what has been 
shown in Van Beveren’s study in PBMCs from 22q11.2 DS patients 440.  
Another independent study of gene expression (microarrays) of neurons derived from 
22q11.2DS hiPSCs showed relatively similar results, with an enrichment of 
downregulated genes for cell-cycle-related pathways and an enrichment of up-regulated 
genes for MAPK-signaling and neurotransmission-related terms 446. MicroRNA-
sequencing of neurons (mainly glutamatergic and GABAergic) derived from 22q11.2DS 
hiPSCs with psychotic disorders revealed 45 differentially expressed microRNAs 
compared to non-22q11.2DS non-schizophrenic controls 419. It is possible that this could 
be due to the significant decrease of DGCR8 expression in these cells due to the 
haploinsufficiency of the gene. However, only 6 of them reached genome-wide 
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significance, of which 4 microRNAs are mapped within the 22q11.2 deletion (including 
miR-185). Interestingly, despite not reaching genome-wide significance, two thirds of the 
differentially expressed microRNAs were upregulated, which is unlikely to be due to a 
direct effect of the DGCR8 deletion. The top disease enrichment (DAVID functional 
annotation) for predicted targets of these upregulated microRNAs was schizophrenia. 
Bundo et al. have also reported that neurons derived from 22q11.2DS hiPSCs have an 
increased retrotransposition of long interspersed nucleotide element-1 (L1) 447. They also 
revealed an increase of L1 content in brain tissue from schizophrenia patients and that 
insertion of these elements was preferential into genes related to this neuropsychiatric 
disorder and to synaptic function. This is of particular interest in the context of 22q11.2 
as the microprocessor complex has been shown to bind to mammalian retrotransposons 
mRNAs such as L1 elements mRNAs (interaction with DGCR8) and control their levels 
via DROSHA-mediated cleavage 448. 
To date there is no transcriptomic data from Dgcr8 knock-out human stem-cell derived 
neuronal progenitor cells (or other neural lineage cells such as neurons). MicroRNA-
sequencing has however been performed in neurons from mouse embryos (E13.5) that 
have a brain-specific conditional knock-out of Dgcr8 449. This study showed the expected 
decrease of microRNA reads, with a stronger effect in the Dgcr8 homozygous knock-out 
mice than in Dgcr8 heterozygous knock-out mice. Dgcr8 KO mouse embryonic stem cell 
also shows a smaller depletion of microRNAs in heterozygous knock-outs than in null 
mutants 450. Similarly, for mRNA expression, only a small number of differentially 
expressed genes were observed in heterozygous cell lines while between around 2000 to 
3000 mRNA levels were significantly altered in homozygous lines. Studies of Dgcr8 null 
mutants mESCs have shown that the resulting miRNA deficiency alters expression of 
genes involved in pluripotency, promoting toward a pluripotent stem cell ground state 298 
that favours stem cell self-renewal 451. In particular, DGCR8-dependent microRNAs from 
the miR-290/302 family have been shown to control this state by repressing genes from 
the AKT pathway and upregulating genes from the MEK/ERK pathway 452.  
 
5.2. Aims of the chapter 
The work described in this chapter set out to conduct a novel investigation of the effect 
of DGCR8 depletion on gene expression during neural differentiation from human 
embryonic stem cells. The goals of the project are the following: 
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- Conduct whole transcriptome gene expression analysis by RNA-sequencing and 
determine which transcripts are differentially expressed in DGCR8 depleted lines. 
- Determine which biological pathways are enriched for differentially expressed 
transcripts. 
- Investigate the presence of transcripts that are similarly differentially expressed in 
DGCR8+/- hESCs- and 22q11.2 IPSCs-derived neurons. 
 
5.3. Methods 
5.3.1. Cell lines 
6 human embryonic stem cell (hESCs) lines were used in this work: WT, WTcrispr1, 
WTcrispr2, Het1, Het2, Het3. They are further described in Chapter 4 Sections 4.4.1 
(p.91) and 4.4.3 (p.98). Briefly, the WT line is a human embryonic stem cell line (H7 
line) from which all the other hESCs lines were derived. Het1, Het2, Het3 are 3 distinct 
DGCR8 +/- heterozygous knock-out lines generated with the CRISPR/Cas9 technology. 
WTcrispr1 and WTcrispr2 are two wildtype control lines that went through the same 
CRISPR/Cas9 protocol but for which the genome editing was not successful at the 
targeted locus. WTcrispr1 results from the same experiment than the Het1/2/3 lines 
(targeting of DGCR8). WTcrispr2 has been provided by Dr. Lucia Cardo (Cardiff 
University) and results from an independent CRISPR/Cas9 targeting study. 
2 human induced pluripotent stem cell (hiPSC) lines were used in this study: 
22q11.2DS hiPSC line and WT hiPSC line. The biopsies used to generate the hIPSC lines 
were provided by the National Centre for Mental Health (NCMH). The 22q11.2DS hiPSC 
was derived from a 27-year old female affected by neuropsychiatric disorders 
(Schizophrenia, Autism spectrum disorders, major depressive disorder (recurrent, sever), 
learning difficulties, panic disorder and agoraphobia). 22q11.2 deletion was maternally 
inherited. The patient was taking antipsychotic medication and the presence of the 
deletion in the 22q11.2DS hiPSC was confirmed by SNP array (mapped to 
Chr22:18892575-21452237 region (LCR A to LCR D), build 37/hg19). The control line 
WT hiPSC was derived from a 27-year-old male individual with no known history of 
psychotic disorder. The presence of the 22q11.2 deletion was not assessed in this 
individual. Consent forms (DEFINE/ECHO consent form, NCMH cell biology consent 
form) were signed by both subjects. Both hiPSC lines were generated by Dr. Craig Joyce 
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(Cardiff University). Dermal fibroblasts derived from skin punch biopsies were 
reprogrammed into hiPSCs using the CytoTune-iPS 2.0 Sendai Reprogramming Kit 
(ThermoFisher Scientific). Cell pluripotency of hiPSCs was confirmed by 
immunocytochemistry using antibodies against pluripotency markers (Nanog, Oct3/4 and 
Tra1-81).  
 
5.3.2. Neural differentiation and RNA extraction 
Samples used for RNA-sequencing were from neural progenitor cells extracted at day 
18 of a dual-SMAD signalling inhibition cortical neuron differentiation protocol as 
described in Chapter 4 Section 4.3.2 (p.87). Total RNA was extracted with mirVana 
miRNA Isolation Kit (ThermoFisher Scientific) according to manufacturer’s protocol. 
For each sample, cells from two wells of a twelve-well plate were lysed and pooled 
together to reduce intra cell-line sample variability. RNA integrity was assessed with 
Bioanalyzer RNA Nano Kits (Agilent) on an Agilent 2100 Bioanalyzer instrument by Dr. 
Amanda Redfern (Central Biotechnology Services, Cardiff University). All samples had 
a RNA Integrity Number RIN > 8.6 (mean = 9.46, s.d. = 0.28). 
Two independent experiments have been performed. For each experiment, all cell 
lines were differentiated simultaneously. 
- Experiment 1: 8 cell lines: WT, WTcrispr1, WTcrispr2, Het1, Het2, Het3. All samples 
were extracted at day 18. 3 biological replicates have been extracted for each cell line. 
- Experiment 2: 4 cell lines: WT, Het1, 22q11.2DS hiPSC, WT hiPSC. This experiment 
was performed in collaboration with Matthieu Trigano (Cardiff University) 
(differentiation and RNA extraction only). 2 other cell lines were used (a hESC 
ZDHHC8+/- knock-out line and its isogenic control). However, results from these two cell 
lines were analysed by Matthieu Trigano and are not discussed in this thesis. WT and 
Het1 cell lines were extracted at day 18, other cell lines were extracted at day 15 to 
account for the faster differentiation rate of these cell lines that have a different 
background than WT/Het1 lines. 6 biological replicates have been extracted for each cell 
line. 
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5.3.3. RNA-seq data acquisition 
Sample preparation and sequencing was performed by Joanne Morgan (NGS Co-
ordinator, Division of Psychological Medicine and Clinical Neurosciences, Cardiff 
University). RNA was quantified with QubitRNA High Sensitivity kits (ThermoFisher). 
Sequencing libraries for mRNA transcriptome analysis were prepared using KAPA 
mRNA HyperPrep kits (Kapa Biosystem) from 1 µg of total RNA per sample. The 
standard protocol was followed, with the following options/modifications: fragmentation 
was performed for 6 min at 94C; 8 cycles of PCR were used for the library amplification 
step; after amplification, samples were cleaned for two rounds using Agencourt AMPure 
XP (Beckman Coulter). Libraries were quantified using QubitRNA High Sensitivity kits 
(ThermoFisher) and sized using High Sensitivity DNA kits (Agilent). Libraries were 
pooled in equimolar amounts (10 nM). The experiment 1 was pooled as a 24-plex; the 
experiment 2 was constituted of two 18-plex pools (with equal distribution of samples 
across the two pools). Clustering and sequencing was carried out as per standard Illumina 
protocols. Library pools were diluted to 3 nM for clustering procedure and spiked with 
1% PhiX control genome. The prepared libraries were sequenced using Illumina’s Hiseq 
4000 with four each lane for each experiment which generated 2 x 75 bp paired-end reads 
(4 lanes for each sample for Experiment 1, 24 samples per lane; 2 lanes for each sample 
for experiment B, 18 samples per lane). This resulted in an average of 57.3 million read 
pairs generated per samples for Experiment 1 (s.d. = 6.5 million reads) and an average of 
38.1 million sequenced read pairs per samples for Experiment 2 (s.d. = 5.2 million reads). 
Alignment of RNA-seq reads was performed by Daniel Cabezas De La Fuente (Cardiff 
University) using a script developed and tested by Daniel Cabezas De La Fuente and Dr. 
Robert Andrews (Cardiff University). Briefly, data was pre-processed with the Trimmotic 
software to trim adaptor sequences and remove poor-quality bases 453. Bases with a Phred 
quality score Q < 30 were eliminated. Data quality control was performed with FastQC 
before and after trimming 454. Data was aligned to the hg38 reference genome using the 
STAR aligner software version 455.  
 
5.3.4. Data analysis 
Data analysis was performed in R (Microsoft R Open 3.4.0 (Microsoft), based on R-
3.4.0 (R Statistics)) using a modified version of a script developed by Daniel Cabezas De 
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La Fuente and Dr. Robert Andrews (Cardiff University). Genes with less than 10 counts 
over all samples were removed from the analysis. Differential gene expression analysis 
was performed with the DESeq2 R package 456,457. Principal component analyses were 
conducted after performing a regularized log transformation (function rlog, DESeq2). 
Functional enrichment analyses (Gene Ontology (GO) and KEGG pathways) were 
performed with the clusterProfiler R package 458 (enrichGO and enrichKEGG functions). 
Samples from the same experiments (experiment 1 or experiment 2) were all normalised 
together and then either analysed together or divided in subsets for differential expression 
analysis. Due to the gender difference between the two hiPSCs lines used, only the 
significant differentially expressed genes obtained when comparing 22q11.2 DS hiPSCs 
vs WT hESCs (both female cell lines) were retained in the list of genes obtained when 
comparing 22q11.2 DS hiPSC (female) versus control hiPSCs (male). 
 
5.4. Results  
5.4.1. Experiment 1: differentially expressed genes in DGCR8+/- neural progenitor 
cells. 
RNA-sequencing was performed with DGCR8 heterozygous knock-out human 
embryonic stem cells and control embryonic stem cells that were differentiated in parallel 
into neural progenitor cells (NPCs). 3 DGCR8+/- KO lines were used, as well as three 
wild-type (WT) control lines (including two lines that were processed in the same way as 
the CRISPR/Cas9 edited cell lines but for which no mutation was been detected at the 
targeted locus). Comparing the three KO lines to the three WT lines identified 1744 
transcripts that were differentially expressed with a FDR-corrected p-value p < 0.01. This 
included 979 transcripts that were upregulated and 765 transcripts that were 
downregulated. 
Principal component analysis (PCA) of the RNA-sequencing data revealed a high 
heterogeneity in the transcriptome of the different cell lines tested, in particular between 
the wild-type control lines. Figure 5-1.A shows the PCA results for the top 500 most 
variable genes between samples (variance of normalised read counts between sample per 
gene). The three KO lines cluster together relatively well, however the three WT cell lines 
appear to cluster independently. One Wild-Type line, WTcrispr1, appears to cluster with 
the KO lines. This line is a wild-type sister clone of the KO lines and has been derived 
from the same CRISPR/Cas9 editing process. This could therefore be due to off-target 
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effects of the CRISPR/Cas9 process, or it could reflect the fact that they are derived from 
the same parental cells (WT line is the same parental line but from a different aliquot of 
cells.). Figure 5-1.B shows the PCA results for the top 500 most significant genes when 
comparing the KO lines to the WT lines. It shows that despite focusing on the genes that 
differentiate the most between KO and WT neural progenitor cells, there still remains 
variability in expression between the wild-type lines. 
 
5.4.1.1. Differential expression analysis 
The heterogeneity in the transcriptome of the different control lines could induce bias 
in the analysis and lead to false gene discovery. In order to determine a list of high-
confidence genes that were differentially expressed, the experiment was divided into 3 
sub-analyses. Each analysis compared independently one of the KO line versus one of the 
WT control line (cf. Figure 5-2.A/B). While this reduces the power of each analysis due 
to the small number of samples used, it was based on the assumption that any genes that 
A B 
Figure 5-1. Principal component analysis (PCA) of RNA-sequencing results and 
variance explained by the first two principal components. (A) PCA based on the top 500 
most variables genes. (B) PCA based on the top 500 most significant genes (Het1/2/3 lines 
versus WT lines). PCAs are based on regularized log count data. Het1/2/3: DGCR8 +/- 
heterozygous knock out lines; WT/WTcrispr1/WTcrispr2: wild-type control lines. 
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are differentially expressed in all 3 separate analyses are more likely to represent a true 
signal and be potentially biologically relevant. This analysis resulted in 288 genes that 
were differentially expressed in all 3 independent analyses. 176 of these genes were 
upregulated in DGCR8 KO NPCs (Figure 5-2.A) and 112 were downregulated (Figure 
5-2.B). Their fold-change values were averaged, and their p-values were combined with 
the Stouffer method 318. Figure 5-2.C represent these value for each of genes. 
 
A B 
C 
Figure 5-2. Analysis of high-confidence genes differentially expressed in DGCR8+/- 
neural progenitor cells. 3 independent differential expression were performed with different 
DGCR8+/- lines and Wild-Type lines (A) Upregulated genes in DGCR8+/- lines. (B) 
Downregulated genes in DGCR8+/- lines. (C) Volcano plots of genes significantly 
differentially expressed in all three independent comparisons. Fold change: mean fold change 
over the three experiments; p-values: combined p-values for the three independent 
experiments (Stouffer’s method). P-value < 1e-300 are set to p = 1e-300. Het1/2/3: DGCR8+/- 
heterozygous knock out lines; WT/WTcrispr1/WTcrispr2: wild-type control lines. 
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5.4.1.2. Biological pathway enrichment analysis 
Functional enrichment analysis was performed on this list of 288 significantly 
differentially expressed genes to determine if they were enriched for specific Gene 
Table 5-1. Gene Ontology gene-set enrichment analysis of high-confidence genes 
differentially expressed in DGCR8+/- neural progenitor cells. (A) All significant genes. (B) 
Upregulated genes only. Note: No significant enrichment for downregulated genes only. 
Differentially expressed genes are defined as genes with an FDR corrected p-value < 0.01. 
Significantly enriched terms have an adjusted p-value < 0.05 (Benjamini-Hochberg 
procedure). BP: biological process; CC: cellular component; MF: molecular function. 
A 
B 
GO term GO type Adjusted p-value
synapse organization BP 1.4E-02
C21-steroid hormone biosynthetic process BP 1.4E-02
muscle tissue development BP 2.9E-02
regulation of binding BP 2.9E-02
synapse assembly BP 2.9E-02
membrane biogenesis BP 4.2E-02
proteinaceous extracellular matrix CC 4.3E-02
GO term GO type Adjusted p-value
proteinaceous extracellular matrix CC 8.3E-05
extracellular matrix CC 1.1E-03
heparin binding MF 1.1E-03
sulfur compound binding MF 3.4E-03
glycosaminoglycan binding MF 3.6E-03
synapse organization BP 6.7E-03
C21-steroid hormone biosynthetic process BP 1.4E-02
connective tissue development BP 1.4E-02
regulation of striated muscle tissue development BP 1.4E-02
regulation of muscle organ development BP 1.4E-02
negative regulation of steroid biosynthetic process BP 1.4E-02
negative regulation of steroid metabolic process BP 1.4E-02
skeletal system development BP 1.4E-02
regulation of muscle tissue development BP 1.4E-02
transmembrane receptor protein serine/threonine kinase signaling 
pathway
BP 2.2E-02
glucocorticoid biosynthetic process BP 2.2E-02
regulation of ketone biosynthetic process BP 2.2E-02
aldehyde biosynthetic process BP 2.2E-02
axon guidance BP 2.9E-02
neuron projection guidance BP 2.9E-02
synapse assembly BP 2.9E-02
endocardial cushion development BP 2.9E-02
collagen metabolic process BP 2.9E-02
ossification BP 2.9E-02
multicellular organism catabolic process BP 2.9E-02
cell morphogenesis involved in neuron differentiation BP 2.9E-02
hindbrain development BP 3.0E-02
regulation of hormone biosynthetic process BP 3.6E-02
osteoblast differentiation BP 3.6E-02
collagen trimer CC 3.9E-02
glucocorticoid metabolic process BP 4.0E-02
negative regulation of DNA binding BP 4.7E-02
transforming growth factor beta receptor signaling pathway BP 4.7E-02
developmental growth involved in morphogenesis BP 4.7E-02
cellular hormone metabolic process BP 5.0E-02
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Ontology (GO) terms or KEGG pathways. This analysis identified multiple biological 
process GO terms that were significantly enriched (p < 0.05) in genes that were 
differentially expressed with p-value < 0.01 (Table 5-1.A). In particular, the most 
significant biological process GO terms was Synapse organisation (p = 0.014). Restricting 
to genes that were upregulated leads to the same most significant Biological Process term 
(Table 5-1.B). No GO terms were significant when the test was restricted to down-
regulated genes. This suggests that the detected enrichment was mainly being driven by 
genes that have greater expression in DGCR8+/- KO lines than in the WT lines. No KEGG 
pathway reached significance when testing for enrichment of all genes or downregulated 
genes. Restricting to upregulated genes shows an enrichment in the Hippo and TGF-beta 
signalling pathways (p= 0.016 and p=0.016 respectively) as well as Axon guidance (p = 
0.029) (Table 5-2). 
 
5.4.2. Experiment 2: DGCR8+/- and 22q11.2 deletion shared transcriptome changes 
A second RNA-sequencing experiment was performed to investigate possible 
similarities between changes in expression due to DGCR8 heterozygous deletions and the 
~3 Mb deletion at 22q11.2 (which also spans DGCR8). For this, 4 cell lines were 
differentiated in parallel into neural progenitor cells: one DGCR8+/- KO human 
embryonic stem cell line (hESCs), one Wild-Type control hESCs, one induced 
pluripotent stem cell (hiPSC) line derived from a patient with the 22q11.2 deletion 
syndrome and one control hiPSC. NPCs differentiated from hiPSCs or hESCs were 
analysed separately to find differentially expressed genes due to DGCR8 KO or 22q11.2 
deletion independently, and the results were compared. 457 genes were significantly 
Table 5-2. KEGG pathway gene-set enrichment analysis of high-confidence genes 
upregulated in DGCR8+/- neural progenitor cells. Only upregulated genes are used in the 
enrichment analysis. Note: No significant enrichment for downregulated genes or all genes 
together. Differentially expressed genes are defined as genes with an FDR corrected p-value 
< 0.01. Significantly enriched pathways have an adjusted p-value < 0.05 (Benjamini-
Hochberg procedure). 
KEGG Pathway Adjusted p-value
Hippo signaling pathway 1.6E-02
TGF-beta signaling pathway 1.6E-02
Axon guidance 2.9E-02
Amoebiasis 4.2E-02
ECM-receptor interaction 4.3E-02
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differentially upregulated in both DGCR8 KO NPCs and 22q11.2DS NPS (FDR-
corrected p-value < 0.01) while 459 genes were significantly differentially downregulated 
(Figure 5-3.A and B respectively). Gene-sets enrichment analysis of genes that were 
upregulated or downregulated in both 22q11.2 DS NPCs or DGCR8+/- NPCs are detailed 
in Supplementary table 5-1. 
 
5.4.3. Investigating high-confidence genes affected by both the DGCR8 deletion in 
DGCR8 KO and 22q11.2DS 
Due to the variability of differentially expressed genes due to DGCR8 heterozygous 
KO depending on which control line is used (Experiment 1, Figure 5-2.A/B), I decided 
to investigate which of the high-confidence genes determined in the first experiment were 
replicated in the second experiment (note: the two lines Het1 and WT used in the second 
experiment were also used in the first experiment, but the results were from different 
experiments of neural differentiation and RNA-sequencing). Of the 288 high-confidence 
genes determined the Experiment 1, 99 were replicated in Experiment 2 (Figure 5-4.A/B). 
Of these, 39 were upregulated and 60 were down-regulated. 63 genes were also 
significantly differentially expressed in NPCs differentiated from 22q11.2 DS hiPSCs; 15 
were upregulated, 48 were downregulated. 
Mapping these genes to their respective chromosomal locations revealed that around 
40% (25 genes) were mapped to the same chromosomal location on chromosome 17 
A B 
Figure 5-3. Overlap between genes differentially expressed in DGCR8+/- KO neural 
progenitor cells and 22q11.2 DS neural progenitor cells (NPCs). (A) Upregulated genes 
(B) Downregulated genes. 22q11.2: cell line with the 22q11.2 deletion; Control: control line 
without the deletion; Het1: DGCR8+/- heterozygous knock out lines; WT: wild-type control 
lines.  
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(Figure 5-4.C). It encompasses around 0.4 Mb and include genes from ZBTB4 to 
AC104581.5. This genomic region corresponds to the cytoband 17p13.1. The average 
fold-change for this set of significant genes located within this region is FC = -1.92 (s.d. 
= 0.25) when comparing DGCR8+/- lines to controls in the Experiment 1, FC = -2.09 (s.d. 
= 0.35) when comparing the DGCR8+/- line to its control in the Experiment 2 and FC = -
2.1 (s.d. = 0.44) when comparing the 22q11.2 DS line to its control in the Experiment 2. 
The normalised read counts for all genes located at the region 17p13.1 (and included 
between ZBTB4 and AC104581.5) for each of these comparisons and their significance 
levels are represented in Supplementary figure 5-1.  
The pairwise comparisons overlaps between the three groups shown in Figure 5-4 are 
statistically significant for both downregulated and upregulated genes, as presented 
Figure 5-5. These overlap remains significant after removing the genes located within the 
17p31.1 region (for the intersect of the three groups, p = 1.17 * 10-13 for upregulated genes 
and p = 7.71 * 10-35 for downregulated genes). 
 
 
 
 
A B 
Figure 5-4. High-confidence genes differentially expressed in DGCR8+/- and 22q11 DS 
neural progenitor cells. (A) Upregulated genes (B) Downregulated genes (C) (Next page) 
Chromosomal locations of genes that are differentially expressed in DGCR8+/- KO NPCs 
(experiment 1 and 2) as well as 22q11.2DS NPCs. Gene ID: ENSEMBL gene ID. 4 Gene ID 
were not recognised by the R package used and are not represented. 
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C 
Gene name Chromosomal location Cytoband Direction
FPGT Chr1:74198212-74234086 1p31.1 Downregulated
LINC01139 Chr1:238480384-238486023 1q43 Upregulated
PLCL1 Chr2:197804702-198572581 2q33.1 Downregulated
PTH1R Chr3:46877746-46903799 3p21.31 Upregulated
OCIAD2 Chr4:48885019-48906937 4p11 Downregulated
NAP1L5 Chr4:88695915-88698235 4q22.1 Downregulated
TICAM2 Chr5:115578650-115602479 5q22.3 Upregulated
PCDHB10 Chr5:141192353-141195642 5q31.3 Upregulated
TFAP2A Chr6:10393186-10419659 6p24.3 Downregulated
ZNF311 Chr6:28994785-29005316 6p22.1 Upregulated
PTCHD4 Chr6:47878028-48068689 6p12.3 Downregulated
ZNF483 Chr9:111525159-111577844 9q31.3 Downregulated
ECHDC3 Chr10:11742366-11764070 10p14 Upregulated
SPAG6 Chr10:22345445-22454224 10p12.2 Upregulated
ZNF22 Chr10:45000475-45005326 10q11.21 Downregulated
CEP164P1 Chr10:45002222-45076066 10q11.21 Downregulated
LINC01515 Chr10:65570338-65768835 10q21.3 Downregulated
TRIM68 Chr11:4598672-4608259 11p15.4 Downregulated
TRIM6 Chr11:5596109-5612958 11p15.4 Upregulated
ALKBH3 Chr11:43880811-43920266 11p11.2 Downregulated
AP000769.1 Chr11:65455258-65466720 11q13.1 Upregulated
AC092490.1 Chr12:8788257-8795789 12p13.31 Upregulated
TSPAN11 Chr12:30926428-30996599 12p11.21 Downregulated
ERBB3 Chr12:56079857-56103505 12q13.2 Upregulated
SERPINA5 Chr14:94561442-94593120 14q32.13 Upregulated
ONECUT1 Chr15:52756989-52791078 15q21.3 Downregulated
AC087632.1 Chr15:64181180-64381510 15q22.31 Downregulated
PCLAF Chr15:64364311-64387687 15q22.31 Downregulated
ZBTB4 Chr17:7459366-7484263 17p13.1 Downregulated
POLR2A Chr17:7484366-7514616 17p13.1 Downregulated
TNFSF12-TNFSF13 Chr17:7549099-7561601 17p13.1 Downregulated
TNFSF13 Chr17:7558292-7561608 17p13.1 Downregulated
SENP3 Chr17:7561875-7571969 17p13.1 Downregulated
SENP3-EIF4A1 Chr17:7563287-7578715 17p13.1 Downregulated
EIF4A1 Chr17:7572706-7579005 17p13.1 Downregulated
AC016876.2 Chr17:7572826-7582024 17p13.1 Downregulated
CD68 Chr17:7579467-7582113 17p13.1 Downregulated
AC016876.1 Chr17:7581964-7584072 17p13.1 Downregulated
MPDU1 Chr17:7583529-7592789 17p13.1 Downregulated
SOX15 Chr17:7588178-7590170 17p13.1 Downregulated
FXR2 Chr17:7591230-7614871 17p13.1 Downregulated
SAT2 Chr17:7626234-7627876 17p13.1 Downregulated
ATP1B2 Chr17:7646627-7657768 17p13.1 Downregulated
TP53 Chr17:7661779-7687550 17p13.1 Downregulated
WRAP53 Chr17:7686071-7703502 17p13.1 Downregulated
EFNB3 Chr17:7705202-7711378 17p13.1 Downregulated
DNAH2 Chr17:7717354-7833744 17p13.1 Downregulated
KDM6B Chr17:7839904-7854796 17p13.1 Downregulated
NAA38 Chr17:7856685-7885238 17p13.1 Downregulated
CYB5D1 Chr17:7857746-7862282 17p13.1 Downregulated
AC104581.5 Chr17:7858943-7866083 17p13.1 Downregulated
PCTP Chr17:55750979-55842830 17q22 Downregulated
TBCD Chr17:82752064-82945922 17q25.3 Downregulated
ZNF100 Chr19:21722766-21767628 19p12 Downregulated
AC005394.2 Chr19:28435388-28727680 19q12 Downregulated
AC005524.1 Chr19:28683071-28727777 19q12 Downregulated
MX2 Chr21:41361943-41409390 21q22.3 Upregulated
SYP ChrX:49187804-49200259 Xp11.23 Downregulated
SLITRK2 ChrX:145817832-145825842 Xq27.3 Downregulated
CLIC2 ChrX:155276211-155334657 Xq28 Downregulated
TMLHE ChrX:155490115-155669944 Xq28 Downregulated
MT-TI ChrMT:4263-4331 NA Upregulated
MT-TQ ChrMT:4329-4400 NA Upregulated
Figure 5-4. High-confidence genes differentially expressed in DGCR8+/- and 22q11 DS 
neural progenitor cells (cont.) 
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5.5. Discussion 
Differential expression analysis of DGCR8+/- heterozygous knock-out neural 
progenitor cells (NPCs) showed that the expression levels of 1744 genes were 
significantly altered compared to wild-type NPCs (adjusted p value p < 0.01). However, 
a principal component analysis revealed an important heterogeneity in the transcription 
profiles of the wild-type control lines used (Figure 5-1). Two of these wild-type lines have 
been derived from a similar CRISPR/Cas9 genome editing process to the DGCR8 KO 
lines. The first line, WTcrispr1, is a sister clone of the DGCR8 line; the second line, 
WTcrispr2, is from a different genome editing experiment targeting another gene. 
Compared to third control line, WT, they have both been submitted to different steps such 
as single-cell dissociation to allow colony selection, as well as antibiotic selection.  
The differences in gene expression revealed by the principal components analysis 
could be due to off-target effects of the CRISPR/Cas9 genome editing process. The 
CRISPR/Cas9 editing can also potentially lead to off-target mutations due to non-specific 
binding of the guideRNAs used to direct the nuclease to a specific locus and induce 
double-strand DNA cleavage. Erroneous non-homologous end-joining repair (cf. Figure 
4-2 Chapter 4 p.85) can potentially lead to insertion/deletion mutations, which can in turn 
affect the gene expression, protein function or introduce a premature stop-codon. This 
off-target effect has been shown to potentially affects many sites for each guideRNA 
Figure 5-5. Statistical significance of overlapping gene sets presented in Figure 5-4, with 
or without genes located within the 17p13.1 locus. P-values are presented for each overlaps, 
as calculated by the R package SuperExactTest 501. Group tested and correspondence to Figure 
5-4: Exp 1 - KOs vs WT: EXp 1 - DGCR8 KOs vs WT (shared genes); Exp 2 - Het1 vs WT; 
Exp 2 - 22q vs Cont.: Exp 2 - 22q11.2 IPSCs vs Control IPSCs. 
Downregulated genes Upregulated genes
Exp 2 - Het1 vs WT Exp 2 - 22q vs Cont. Exp 2 - Het1 vs WT Exp 2 - 22q vs Cont.
Exp 1 - KOs vs WT 1.04E-42 1.33E-35 Exp 1 - KOs vs WT 2.75E-12 5.17E-06
Exp 2 - Het1 vs WT X 9.22E-117 Exp 2 - Het1 vs WT X 2.42E-129
Intersection 3 groups: 8.36E-76 Intersection 3 groups: 1.17E-13
Downregulated genes; without 17p13.1 genes Upregulated genes; without 17p13.1 genes
Exp 2 - Het1 vs WT Exp 2 - 22q vs Cont. Exp 2 - Het1 vs WT Exp 2 - 22q vs Cont.
Exp 1 - KOs vs WT 4.23E-22 7.62E-19 Exp 1 - KOs vs WT 2.75E-12 5.17E-06
Exp 2 - Het1 vs WT X 6.68E-106 Exp 2 - Het1 vs WT X 2.42E-129
Intersection 3 groups: 7.71E-35 Intersection 3 groups: 1.17E-13
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used, with efficiencies that can be similar than at the on-target site 459,460. A common off-
target mutation between the DGCR8 KO lines and the WTcrispr1 line generated in the 
same experiment could explain the clustering of these lines by principal component 
analysis (Figure 5-1.A). The CRISPR/Cas9 experiment conducted to knock-out DGCR8 
has been performed used a modified version of the guideRNAs, by adding two extra 
guanine on the 5’ end of the sequence 461. It has been shown to greatly increase specificity, 
with off-targets insertion/deletion mutations being detected at rates comparable to deep-
sequencing error rates 462. However, due to the clustering of these cell lines, only whole-
genome sequencing of the KO lines will allow to confidently discard the hypothesis that 
they have shared off-target mutations. Finally, all lines contain an antibiotic resistance 
cassette that integrated randomly in the genome rather than in the targeted locus. It is 
therefore possible that the random integration of the antibiotic resistance cassette could 
potentially affect the expression level of a gene within which it integrates, which could in 
turn lead to further transcriptome changes. 
In order to avoid any potential bias caused by the difference in gene expression 
between the control lines, each of these wild-type lines were compared independently to 
one of the DGCR8 KO lines. This allowed to determine a list of 288 genes that are 
differentially expressed regardless of which control line is used. This approach reduces 
the power of the differential expression analysis by dividing the sample size by 3 in each 
analysis, however it allows greater confidence in these results that are reproducible 
between cell lines. Gene Ontology enrichment analysis showed that the biological process 
“Synapse Organisation” and “Synapse assembly” were significantly enriched for 
differentially expressed genes. These two terms have also been shown to be significant 
when testing genes that are differentially expressed in 22q11.2DS hiPSCs-derived 
neurons 444. Other significant GO terms are encompassing a wide-range of biological 
processes, in particular when restricting to upregulated genes (Table 5-1.B). These 
upregulated genes might be directly relevant to DGCR8-mediated gene regulation, as 
deletion of DGCR8 leads to reduced microRNA levels which in turn could lead to 
increased microRNA targets mRNA levels. These significant GO terms include terms 
related to the extracellular matrix, muscle development, ossification, and metabolic 
processes. While the DGCR8 knock-out could affect neural differentiation and result to 
changes in neural-related gene expression levels, its effect on microRNA processing is 
likely to affect many genes in multiple biological pathways. This could explain the 
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diversity of significant GO terms. Enriched KEGG pathways for upregulated genes 
included the Hippo-signalling pathway, the TGF-beta signalling pathway, Axon guidance 
and ECM-receptor interaction. Interestingly, microarray-based transcriptome analysis of 
laser-capture microdissected cortical pyramidal neurons of schizophrenia patients (post-
mortem brain tissue) found an enrichment of genes involved in TGF-beta signalling, 
cytoskeleton/dendritic integrity and extra-cellular matrix (ECM) regulation (as well as 
apoptosis and DNA damage repair) 463. 
A second independent experiment was conducted to assess if the differentially 
expressed genes observed in neural progenitor cells differentiated from DGCR8 KO lines 
shared any similarity to the NPCs obtained from a 22q11.2DS hiPSC line. This revealed 
that about 30% of genes that were differentially expressed in the tested DGCR8 KO NPCs 
(916 for 3097 total) were also significantly dysregulated in the 22q11.2DS NPCs. These 
genes were compared to the 288 high-confidence genes differentially expressed in 
DGCR8 KO NPCs from the first experiment using multiple cell lines. The primary goal 
of this comparison was to gain more confidence in genes that might be dysregulated in 
22q11.2DS NPCs, potentially due to the heterozygous deletion of DGCR8. It also allowed 
genes to be restricted to a smaller list of candidates that could be studied further to 
understand the effect of the DGCR8 deletion. This process identified a list of 63 genes. 
Some of these genes could be of particular interest in the context of 22q11.2 deletion 
syndrome. For instance, the Trimethyllysine hydroxylase epsilon (TMLHE) gene has been 
proposed as risk factor for autism, which is a symptom present in 22q11.2DS patients. 
However, while conducting this analysis I observed that around 40% of these genes 
mapped to the same chromosomal region 17p13.1. Moreover, their expression level was 
on average halved in DGCR8 KO NPCs or 22q11.2DS NPCs compared to their respective 
controls. This unexpected result could be explained by the following hypotheses: 
- The presence of a copy-number variant (CNV) could have appeared “by chance”. 
Specifically, a hemizygous deletion at locus 17p13.1, that was then positively selected 
for in DGCR8 KO and 22q11DS lines. It has been shown that human embryonic in culture 
can accumulate genomic alterations with increased passage number, such as 
mitochondrial DNA mutations, promoter methylation or copy number variation 464. In 
2010, SNP arrays analysis of multiple human embryonic stem cell lines from different 
laboratories after different numbers of passages identified 843 CNVs with sizes ranging 
from 50 kb to 3 Mb 465. The number of CNV found per sample (29 in hESCs) was similar 
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than found in HapMap samples (26 per samples), but there is a different distribution of 
the CNV with most differences occurring on chromosomes 10, 14, 20 as well as allosomes 
(X/Y). The most frequent regions of variants shared by the different cells lines were at 
the regions 1p36.13, 1p36.33, 2p11.2, 7q35, 14q32.32, 15q11.2, 21p11.2, 22q11.22, 
22q11.21. Further studies in other cell lines including hiPSCs confirmed the presence of 
many genomic aberrations in pluripotent cell lines and that they tend to accumulate during 
cell culture 466. However, in hiPSC lines it appears that there are more CNVs in early-
passage cells than in intermediate passage due to a selection against cells that gain such 
genomic aberrations 467. Some of the common CNVs in hESCs can be positively selected; 
for instance, it has been shown that the recurrent CNV at 20q11.21, first identified in 2008 
468, is present in around 25% of karyotypically normal cell lines 469. This CNV increase 
cell survival due to the duplication of the BCL2L1 gene 470. 
In the present project, the deletion is at the locus 17p13.1. Deletion of this region in 
human stem cells has been reported in 2015 471. It includes the gene TP53, a known 
tumour suppressor gene 472. The observed deletions at this locus were of different size but 
all included this gene, suggesting that its deletion probably confers a growth or survival 
advantage leading to positive selection. This was later confirmed that cells without a copy 
of the 17p13.1 or with a shRNA-mediated TP53 knock-down have a growth advantage 
due to increased proliferation and survival 473. This positive selection could explain the 
observed presence of this deletion in NPCs derived from DGCR8 KO lines and the 
22q11.2 hiPSC line. The heterozygous loss of DGCR8 could lead to a negative pressure 
on the cells, and cells randomly gaining this deletion on chromosome 17p13.1 would 
compensate this effect by conferring a growth advantage. This would explain why it does 
not seem to be present in the WTcrispr1 line that has been generated in the same 
experiment than the DGCR8 KO lines. 
- The presence of a CNV on 17p13.1 could be due positive selection of CNVs in this 
region directly due to DGCR8 hemizygous deletion. While TP53 deletion could confer a 
growth advantage, it has been shown that other CNVs, such as the duplication at 20q11.21 
470, could also be positively selected due to increased cell survival or growth. In this 
project, all DGCR8 KO lines tested, as well as the 22q11.2DS line, seem to potentially 
present the same CNV. This could suggest that the deletion at 17p13.1 occurred 
preferentially when one copy of DGCR8 was deleted, compared to other CNVs. It has 
been shown that DROSHA, part of the microprocessor complex with DGCR8, as well as 
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DICER, involved in microRNA biogenesis, are both important for the DNA-damage 
response (DDR) of cells 474,475. It has been proposed that a particular class of DICER- and 
DROSHA- dependent small non-coding RNA, called DDRNAS, help to recruits DDR 
factors to damaged DNA regions. Moreover, multiple microRNA have been shown to 
target the mRNA of genes involved in the DDR, as reviewed by Wan et al. 476, including 
TP53. Finally, TP53 is known to interact with the microprocessor complex, modulate its 
activity and in results affects the levels of multiple microRNAs 477. The multiple links 
between the microprocessor complex, microRNAs and TP53 could suggest that in 
DGCR8 KO lines (and the 22q11.2DS line), cells with the deletion of TP53 (locus 
17p13.1) are positively selected as a compensatory mechanism for the loss of one copy 
of DGCR8. 
- DGCR8 deletion could lead to the epigenetic repression of a large cluster of genes 
located on region 17p13.1. It has been shown that large chromosomal regions including 
multiple genes can be repressed, notably in cancer, in a process called long-range 
epigenetic silencing (LRES). For instance in Wilm’s tumours at the chromosomal locus 
5q31 a large cluster of paralogous genes present promoter hypermetylation 478. A study 
in LRES regions in prostate cancer have shown that they are also associated with histone 
modifications 479. Moreover, analysis in hESCs showed that many genes within these 
prostate cancer LRES regions are also repressed in the embryonic stem cells. It is possible 
that the decrease of expression at the locus 17p13.1 is not due to a CNV but rather to an 
epigenetic silencing. This repression could, as mentioned above, act as a compensatory 
mechanism for the loss of DGCR8. 
The presence of this possible artefact at chromosome 17p13.1 in all DGCR8 KO lines 
and 22q11.2DS lines impose caution regarding the interpretation of the enrichment 
analysis of genes dysregulated due to DGCR8 heterozygous knock-out. While some of 
the affected genes (including those within the significant overlap of differentially 
expressed genes between experiments after removing genes within this region (Figure 
5-5)) are likely to results from the loss of one copy of DGCR8, it is not possible to 
determine which genes could results from this mutation and which would be due to the 
possible CNV at 17p13.1. Multiple hypotheses have been proposed to possibly explain 
the reduced expression at this locus, however further work will be needed to investigate 
this issue. The priority will be to assess the presence of CNVs in the tested lines, by the 
use of SNP arrays and/or whole-genome sequencing. To my knowledge, this CNV has 
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not been reported in any mouse embryonic stem cell DGCR8 KO line or in 22q11.2 DS 
hiPSCs lines.  
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6. General discussion 
6.1. Summary and implication for the understanding of 22q11.2DS 
This PhD thesis aimed to investigate genetic mechanisms that could explain the 
heterogeneity of symptoms observed in 22q11.2 deletion syndrome patients, and in 
particular why not all of these patients develop schizophrenia. For this I used a wide range 
of methods and techniques such as microarray-based genetic and epigenetic profiling, 
CRISPR/Cas9 genome editing and next-generation sequencing-based transcriptome 
analysis. The main hypothesis behind this research was the existence of genetic modifiers 
that have a cumulative effect with the deletion at chromosome 22q11.2DS, additively or 
through epistatic interactions, following a multiple-hit hypothesis. The goal of the first 
part of this thesis was to assess the presence of such modifiers, by looking at the burden 
of common polymorphisms associated with schizophrenia in 22q11.2DS patients with 
this neuropsychiatric disorder. It has already been suggested that copy-number variants 
outside of the 22q11.2 region can potentially act as a second hit in 22q11.2DS patients 
with schizophrenia 157,158, but the role of single-nucleotide polymorphisms had yet to be 
determined. The other parts of the thesis investigated possible mechanisms of interactions 
between the 22q11.2 deletion and genetic modifiers. The second results chapter aimed at 
looking at the effect of the deletion on DNA methylation and to see if epigenetic changes 
were affecting genes and pathways relevant to schizophrenia. The goal of the final parts 
of the thesis was to study the effect of DGCR8 haploinsufficiency during cortical neuron 
differentiation. For this, human embryonic stem cells were altered with the CRISPR/Cas9 
genome editing technology to knock-out DGCR8 and then the generated cell lines were 
differentiated into neural progenitor cells. This facilitated the investigation of 
transcriptional changes due to the DGCR8 mutation. DGCR8 is a gene located within the 
22q11.2 deletion and its role in genetic regulation, via the microprocessor complex that 
regulate microRNA biogenesis 173, makes it an interesting candidate to investigate 
epistatic interactions between the 22q11.2 deletion and the rest of the genome 480. 
Disruption of the microRNA-buffering system can potentially lead to an uncovering of 
cryptic mutations, such as the common variants studied in the first result chapter. 
In the first chapter, I used a polygenic risk score (PRS) analysis approach to 
characterise a potential role of common variants in the aetiology of schizophrenia in 
22q11.2DS. I established a PRS profile of patients with or without 22q11.2DS and with 
or without schizophrenia to be able to compare them. It has been previously shown that 
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the PRS allows the discrimination of groups of individuals with or without schizophrenia 
in the general population 92,202, with SNPs accounting for 23% of the variation in liability 
in schizophrenia 201. Results of this PhD project revealed that PRS was also allowing the 
discrimination of 22q11.2DS patients depending on their schizophrenia status. This 
indicates that common variants associated with schizophrenia do indeed play a role in the 
aetiology of this psychiatric disorder in patients with the 22q11.2 deletion. 22q11.2DS 
patients with schizophrenia have a lower PRS than schizophrenia patients without the 
deletion, supporting a multifactorial threshold model in which both the deletion and 
common polymorphisms participate to the total liability for schizophrenia. 
In the second results chapter, I used DNA methylation microarrays to compare the 
methylome of individuals with or with the 22q11.2 deletion. It revealed that the 
haploinsufficiency of genes within this region leads to DNA methylation changes in other 
part of the genome in 22q11.2DS patients. These changes were affecting genes included 
in biological pathways potentially relevant to schizophrenia, such as intracellular 
membrane trafficking, metabolism, cell signalling and adhesion. Examples of significant 
pathways include the MAPK and AKT signalling pathways, known to be affected in 
schizophrenia 349,350. Moreover, differentially methylated regions (regions that included 
multiple differentially methylated sites) have been characterised in the promoter regions 
of genes potentially associated with schizophrenia and/or neurodevelopment. As the 
DNA methylation levels of promoter regions is known to affect gene expression 248, the 
22q11.2 deletion could potentially lead to an increased risk for schizophrenia through a 
genetic dysregulation of the expression of these genes. Furthermore, this dysregulation 
could interact epistatically with mutations within these genes. 
In the third result chapter, I generated DGCR8 knock-out human embryonic stem cell 
(hESC) lines with the CRISPR/Cas9 genome editing technology 406,407. These cell lines 
exhibited molecular and cellular phenotypes, some of which have been previously 
demonstrated in other DGCR8+/- models. DGCR8+/- hESCs had altered levels of different 
levels of RNA known to be processed by DGCR8, such as microRNAs from the miR 
17~92 cluster 420 but also DGCR8’s own mRNA, that contain microRNA-like hairpin 
structures 415,481. Differentiation of DGCR8+/- hESCs into neural progenitor cells (NPCs) 
suggest that their ability to process mRNA with such structures is also altered in this cell 
type, as shown by increased levels of DGCR8 mRNA as well as NEUROG2 mRNA (a 
pro-neuronal transcription factor whose mRNA contain hairpin structures and is regulated 
by the microprocessor complex).  
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In the final result chapter, I investigated the transcriptome of these DGCR8+/- NPCs. 
The haploinsufficiency of DGCR8 lead to difference of many mRNA levels, some of 
which are affecting pathways relevant to schizophrenia. There is also an overlap between 
dysregulated DGCR8+/- NPCs and NPCs differentiated from induced pluripotent stem 
cells derived from 22q11.2DS patients. It indicates that the dysregulation of gene 
expression that is observed in these patients 441 is likely due -at least in part- to the deletion 
of DGCR8. However, a potential genomic abnormality has been detected in the DGCR8+/- 
and 22q11.2DS cell lines used and prevents further interpretation of the results at this 
stage (as discussed below). 
 
6.2. Main limitations and possible solutions 
The study of 22q11.2DS-specific DNA methylation changes informs us about 
epigenetic changes due to the haploinsufficiency of genes within this region. They can 
affect genes that are associated with schizophrenia, however comparing the DNA 
methylation profile of patients with or without the 22q11.2 deletion does not inform about 
possible changes specific to patients with schizophrenia. A second analysis would be 
required, comparing the methylome of 22q11.2DS patients with or without this 
neuropsychiatric disorder. Performing such symptom-specific epigenome-wide 
association study of 22q11.2DS patients would help to understand the molecular 
mechanisms underlying the heterogeneity of clinical features observed between these 
patients. 
The use of DNA from blood samples revealed an important bias due to the different 
leucocytes composition in 22q11.2DS patients (T-cell deficits). This lead to an 
enrichment of abnormal methylation for genes involved in immune-related biological 
pathways. While this can be partially accounted for by estimating the cell type 
composition from the methylation data and adjusting for it in the statistical analysis, it is 
likely that it leads to a decrease in statistical power (thus rejecting true positive differences 
in methylation) while keeping part of the bias (thus not rejecting all false positive 
differences). Although using DNA extracted from brain tissue would be more biologically 
relevant to study DNA methylation in the context of schizophrenia, cell composition 
differences between 22q11.2DS patients and controls might also occur. FACS-sorting or 
laser capture microdissection of a specific cell type of interest would allow the detection 
of differences in DNA methylation directly due to the 22q11.2 deletion without being 
confounded by cell type-specific effects. 
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Finally, a potential artefact has been detected at the locus 22q11.2. The analysis 
revealed a strong window of association at the 22q11.2 locus, and current data does not 
allow the determination of whether it is due to a technical artefact or to a true biological 
signal. However, re-analysis of published data from patients with or without a deletion at 
chromosome 7q11.23 330 revealed a similar window of association. This indicates that 
such changes might be due to hemizygosity of the region, but it is not possible at this 
stage to determine their origin (technical or biological). The analysis of DNA methylation 
profiles from patients with CNVs located at other loci would help to confirm these results. 
Then, a more in-depth analysis of these regions should be performed using other methods 
that measure DNA methylation, such as targeted pyrosequencing or whole-genome 
reduced representation bisulfite sequencing (RRBS) 482. It would help to understand if 
this artefact is of technical origin. 
Note: at the time of writing this thesis, Starnawska et al. published a study 
investigating neonatal DNA methylation differences between 22q11.2DS patients that 
developed psychiatric disorders later on in life 483 (published online 29 August 2017). The 
analysis included 164 22q11.2DS patients, 48 of which have been diagnosis with a 
neuropsychiatric disorder. They detected significant DNA methylation changes 
associated with neuropsychiatric disorders in 22q11.2DS patients, including changes 
specific to subphenotypes such as schizophrenia or intellectual disability. They compared 
DNA methylation profiles between 22q11.2DS patients with the small (LCR A to LCR 
B) and large (LCR A to LCR D) deletions, revealing 107 differentially methylated probes, 
of which 100 (93%) where mapped to genes located between LCR C and LCR D (region 
non-overlapping between the two types of deletion). This result is particularly interesting 
as it replicates the effect reported in this thesis of an association of differential 
methylation at haploinsufficient regions, implicating that differential methylation at such 
loci is likely to be a technical artefact. 
 
The transcriptome analysis of neural progenitor cells differentiated from DGCR8+/- 
human embryonic stem cells and 22q11.2DS human induced pluripotent stem cells 
revealed a region of reduced expression on chromosome 17p13.1. The decrease in 
expression of the 25 differentially expressed genes within this region is -2-fold, which 
could suggest the presence of a copy-number variation (deletion). Such a deletion at 
17p13.1 has been previously reported in human embryonic stem cells 471. However, if 
such a deletion occurred, it must have occurred independently in DGCR8+/- and 
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22q11.2DS NPCs but not in any of the control lines. Further work would be required to 
establish if this is coincidental or potentially indicates a genomic instability common to 
the DGCR8+/- and 22q11.2DS NPCs. A likely hypothesis is that the reduced expression 
observed at genes spanning 17p13.1 is be due to a positive selection of cells containing a 
deletion at this region. This could be due to pro-proliferation or pro-survival effects of 
the haplosuficiency of genes within it, or due to a compensation of negative effects due 
to the deletion of DGCR8. The use of genotyping microarray (or whole-genome 
sequencing) in the tested lines will allow the presence of a CNV to be confirmed. The 
next step will be to try and understand how this event occurred, and this could be achieved 
by characterising additional DGCR8+/- lines. Multiple heterozygous knock-out lines have 
been generated but not analysed (including lines not referenced in Figure 4-5.B Chapter 
4 p.92 because they have not yet been sequenced for the presence of mutations on the 
second allele of DGCR8). If a CNV is confirmed, the rate of occurrence of this event 
should be compared between DGCR8+/- hESCs lines and sister lines generated in the same 
CRISPR/Cas9 editing process but without DGCR8 mutations. Similar comparisons 
should be done for other 22q11.2DS hiPSCs lines. This would help to understand if the 
CNV occurred randomly or whether it was stimulated by the presence of a DGCR8 
deletion. 
 
6.3. Future work 
The work presented in this thesis only uncovers a small part of the complex 
mechanisms leading to the heterogeneity of symptoms in 22q11.2DS patients. It presents 
the importance of the genetic background in the development of schizophrenia in these 
patients (common polymorphisms) as well as potential mechanisms of interactions 
between the deletion and the genetic background (DNA methylation changes and 
transcriptome changes through DGCR8-dependent microRNA dysregulation). However, 
an effort should be made to integrate genetic, epigenetic and transcriptomic data to try 
and understand the interplay between these different levels of complexity. 
It has been shown that SNP alleles can be associated with different methylation levels 
of CpG sites 484. These specific common polymorphisms are called methylation 
quantitative trait loci (mQTL). Hannon et al. (2016) have shown that mQTLs in human 
foetal brain samples are enriched for SNPs that are associated in schizophrenia in 
genome-wide association studies 485. This supports the neurodevelopmental hypothesis of 
schizophrenia aetiology and proposes a possible epigenetic effect of genetic variation on 
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the development of this disorder. Moreover, this group also showed that the levels of 
particular CpG methylation sites were correlated with the schizophrenia polygenic risk 
score 486. The schizophrenia PRS can also be associated with differential methylation in 
different brain regions specifically 264. It would thus be interesting to determine if there 
are such associations between schizophrenia PRS and differences in methylation between 
22q11.2DS patients with or without schizophrenia. Ideally, samples would be run on three 
types of arrays: genotyping microarrays, DNA methylation microarrays and expression 
microarrays (or alternatively RNA-sequencing). This would allow the investigation of the 
relationship between PRS and DNA methylation in 22q11.2DS, as well as the presence 
of mQTL in 22q11.2DS patients and determine their effect on gene expression.  
In order to test the hypothesis of DGCR8-mediated epistatic interactions (through 
microRNA dysregulation), it would be interesting to investigate genetic and epigenetic 
variation in genes affected by DGCR8-dependent microRNAs specifically. Merico et al. 
have demonstrated that the genes that are predicted to be regulated by DGCR8-dependent 
microRNAs are significantly represented in a network of genes relevant to schizophrenia 
487. They also have identified in 22q11.2DS patients an increased burden of rare damaging 
variants that affect genes involved in neuronal functions; while being underpowered, the 
study showed that restricting the analysis to genes predicted to be impacted by a DGCR8 
deletion led to increased differences between patients with or without the deletion 160. 
Restricting a polygenic risk score analysis to such genes affected by DGCR8 
haploinsufficiency might reveal an enrichment of schizophrenia-associated variation in 
genes targeted by microRNA in 22q11.2DS patients with schizophrenia compared to 
schizophrenia patients without the deletion. Similarly, analysing DNA methylation 
profiles for genes that are regulated by microRNAs might reveal synergistic mechanisms 
between DNA methylation and microRNA regulation in genes associated with 
schizophrenia risk.  
The effect of DGCR8 deletions on microRNA levels in human brain tissue is still 
unknown. Performing microRNA-sequencing on neural progenitor cells and neurons 
differentiated from the DGCR8+/- hESCs generated in this PhD project will help to 
understand how gene regulation is affected by DGCR8 haploinsufficiency. Moreover, it 
will help to interpret the results of mRNA-sequencing; establishing which mRNA levels 
might be directly affected by abnormal microRNA levels and which mRNA levels might 
be changed due to more indirect effect, such as an altered neurodifferentiation. 
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DNA methylation sites that are the most significantly altered in 22q11.2DS patients 
could be specifically tested in NPC and neurons derived from 22q11.2DS hiPSCs by 
performing a targeted analysis (for instance with pyrosequencing). It could also be 
performed in DGCR8+/- NPC and neurons which would allow the investigation of a 
possible role of DGCR8 deletions on the epigenetic changes observed in 22q11.2DS 
patients. 
 
6.4. Conclusions 
The findings presented in this PhD thesis provide insights into the molecular 
mechanisms leading to schizophrenia and heterogeneous phenotypes in 22q11.2 deletion 
syndrome patients. They show the importance of genetic variation outside the deletion 
for the development of psychosis, and present evidence of the involvement of epigenetic 
changes. A DGCR8 knock-out model have also been generated to study the changes in 
the regulation of gene expression in 22q11.2DS. While this model needs further 
characterisation, it could be used to study the role of one of the most promising 
22q11.2DS candidate genes in the development of tissues affected in this syndrome (such 
as the brain or the heart). It could also help to understand the regulation of gene expression 
in a further extent by allowing the study of the canonical pathways of microRNA 
biogenesis in human cells. Hopefully, integration of genetic, epigenetic and 
transcriptomic studies will lead to a better understanding of 22q11.2DS and to the 
discovery of potential treatments. 
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2. Supplementary information: Schizophrenia polygenic risk 
score analysis in 22q11.2 deletion syndrome patients 
  
Supplementary table 2-1. Case/Control sample sizes (after quality control) and their origin 
(international sites participating in the 22q11.2 IBBC).  
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Supplementary table 2-2. Data processing and quality control steps. The different steps that 
have been performed to process the data before analysis are detailed, as well as the number of 
samples and variants (single nucleotide polymorphisms, SNPs) removed and remaining after each 
step.  
Step
22q11 
samples 
removed
CLOZUK 
samples 
removed
SNP 
removed
# 22q11.2 
samples 
after step
# CLOZUK 
samples 
after step
# SNPs 
after step 
Sex check 25 x x 1135 x 908440
Exclude non-autosomal SNPs x x 37162 1103 x 871278
Exclude SNPs with no name ("00") or with a null allele (0) and for 
duplicate SNP, removed the one with highest missingness 
x x 4552 1103 x 866726
Exclude SNP with missingness > 5% x x 73976 1103 x 792750
Exclude samples with missingness > 3% 32 x x 1071 x 783213
Perform IBD analysis; for each IBD pair, remove one sample based 
on phenotype status and sample missingness (PI_HAT > 0.125)
145 x x 926 x 783213
Merge samples with 1000 genome data, perform PCA and exclude 
outliers more than 3 standard deviation away from any principal 
component mean
56 x x 926 x 783213
Exclude sample with heterozygosity threshold |F| > 0.2 0 x x 870 x 783213
Exclude SNP with Hardy-Weinberg equilibrium HWE < 10e-5 x x 9537 870 x 783213
Perform imputation on the Michigan Imputation server x x x 870 x
Perform pre-QC on 22Q imputed data (INFO SCORE 0.9, SNP 
missingness < 1%, HWE midp < 10e-5)
x x x 870 x 6346287
Perform pre-QC on CLOZUK imputed data (INFO SCORE 0.9, SNP 
missingness 0%, HWE midp < 10e-5)
x x x 870 35802 199619
Merge 22Q data with CLOZUK data (keep only common SNPs) x x x 870 35802 181030
Exclude SNP with missingness > 1% x x 2 870 35802 181028
Exclude samples with missingness > 1% (safety check) 0 0 x 870 35802 181028
Perform IBD analysis; for each IBD pair, remove one sample based 
on phenotype status and sample missingness (PI_HAT > 0.125)
0 136 x 870 35666 181028
Merge samples with 1000 genome data, perform PCA and exclude 
outliers more than 6 standard deviation away from any principal 
component mean
201 290 x 669 35376 181028
Remove samples from CLOZUK that have a known CNV x 324 x 669 35052 181028
Remove variants within 22q11.2 deletion x x 112 669 35052 180916
Remove variants with MAF < 0.1 x x 27021 669 35052 153895
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Supplementary figure 2-1. Principal component analysis (PCA) and ethnicity-based outlier 
removal before (A) and after (B) imputation and merging 22q11.2 data with 
CLOZUK/WTCCC data. In each case outliers were defined as samples further away than N 
standard deviation from the mean of any principal component (N = 2 for (A) and N = 5 for (B)). 
Red dotted lines delimit this zone of exclusion. PCA was performed after merging data with 1000 
Genomes data that contains samples from ethnically different populations and sub-populations. 
Details of these populations are available in supplementary figure 3). 
A 
B 
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Supplementary table 2-3. Population and subpopulation details of the 1000 Genomes 
Project data used in the principal component analysis. Data from the International Genome 
Sample Resource (IGSR, REF). ID: 1000 Genomes Project Phase 3 population ID; Size: number 
of samples included (total: 2504 samples). 
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Supplementary figure 2-2. Principal component analysis (PCA) of the data used for analysis 
for all principal components used as covariates in the regression analysis model. PCA is 
showing that the data is relatively homogenous.  
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   A 
B 
Supplementary figure 2-3. Effect of adjusting the gender ratios. (A) Proportion of 
variance in schizophrenia explained by polygenic risk score (PRS) between groups with 
similar gender ratios. Samples were randomly excluded to adjust the gender ratio between 
groups (N = 10,000 permutations). Gender ratios are adjusted to the ratio of the smallest group 
(22q11 SCZ) to maximize sample size. Separate analysis for genders was not performed due 
to small sample sizes. The displayed R2 values are the mean values of R2 values for 10,000 
permutations. The p-value thresholds pT for selecting risk alleles are shown by colours (cf. 
legend on top). The displayed p-values on top of bars are the geometric mean values of p-
values of association of phenotype with PRS for the 10,000 permutations. (B) Groups sample 
sizes after gender ratio adjustment.  
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Supplementary figure 2-4. Association of polygenic risk score with phenotype 
determined by permutation analysis (N = 10,000 permutations). The p-value thresholds 
pT for selecting risk alleles are shown by colours (cf. legend on top). For each pairwise 
comparison, the phenotypes were randomised while keeping the same case/control ratio. The 
p-values represent the probability of obtaining a smaller p-value by chance (after random 
sampling). Sample sizes and R2 values obtained are the same than used in Figure 2-4. p < 1e-4 
is the minimal displayed p-value due to the number of permutation performed (10,000). 
Supplementary figure 2-5. Proportion of variance in schizophrenia explained by 
polygenic risk score (PRS) between groups of equal sample sizes (N = 107 samples, 
random sample selection, 10,000 permutations). The displayed R2 values are the mean 
values of R2 values for 10,000 permutations. The p-value thresholds pT for selecting risk 
alleles are shown by colours (cf. legend on top). The displayed p-values on top of bars are the 
geometric mean values of p-values of association of phenotype with PRS for the 10,000 
permutations.  
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A B 
Supplementary figure 2-6. Effect of processing 22q11.2 dataset without CLOZUK data 
and effect of sample origin. The p-value represented on top of bars represent the association 
of PRS with the phenotype in the model for each p-value threshold (shown by colours, cf. 
legend on top). (A) Proportion of variance in schizophrenia explained by polygenic risk 
score (PRS) for 22q11.2 samples processed without CLOZUK data. The same 22q11.2 
samples analysed with CLOZUK data previously were processed independently (N=105 
22q11.2 samples with schizophrenia and N= 171 22q11.2 samples without schizophrenia) and 
SNPs (N = 4003865 SNPs, around 20 times more than in the co-analysis with CLOZUK data 
due to the relatively modest overlap of quality SNPs between both datasets). The data 
processing, quality control steps and analysis were similar to what is detailed in the methods, 
without merging the data with the CLOZUK sample. (B) Proportion of variance in 
schizophrenia explained by polygenic risk score (PRS) for 22q11.2 samples processed 
without CLOZUK data, after including the sample origin as a covariate in the regression 
model. (C) Number of independent SNPs included in the analysis for each p-value 
threshold pT.  
C 
pT 0.0001 0.001 0.005 0.01 0.05 0.1 0.2 0.3 0.4 0.5 1
# SNPs 805 2380 5375 7868 18981 27644 40232 49621 56826 62566 77651
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3. Supplementary information: Effect of the 22q11.2 deletion 
on DNA methylation 
  
Supplementary figure 2-1. Density plots of methylation levels for each sample before (A) or 
after (B) ssNoob normalisation. Control samples are represented in green, 22q11.2DS cases in 
orange. Plots generated with the ChAMP R package. 
A 
B 
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A
 
Supplementary figure 3-2. eFORGE analysis of enrichment of tissue-specific signal of the 
top 1000 most significant probes (A) Before correction for cell-type composition (B, next page) 
After Correction for cell-type composition. Red dots represent probes cluster for which FRD q-
value < 0.01. Plots generated online on the eForge website. 
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Supplementary figure 3-3. Population stratification in DNA-methylation samples (A) 
Principal component analysis discrimination of samples from different ethnicity. (B) Scree plot 
(variance explained by principal components (PC)). (C) Correction of the genomic inflation due 
to population stratification (C.1/C.2: before/after correction). Lambda = genomic inflation factor. 
A lambda close to 1 indicate that results are not inflated by unaccounted variance. The red line 
represents the uniform distribution; red dotted lines represent the 95% confidence interval. 
A 
B 
C.1 C.2 
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Supplementary figure 3-4. Overlap between enriched KEGG pathways (for DMPs FDR < 
0.05, |Beta| > 0), including all genes within the pathways (A) or only genes within the 
pathways that contain at least one DMP (B). The size and color of dots represent the overlap 
between pathways. Values of 0 and 1 represent a 0% or 100% overlap respectively between the 
two pathways. DMP: differentially methylated probe. Plots generated with the corrplot R 
package. 
A 
B 
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Supplementary figure 3-5. Overlap between enriched KEGG pathways (for DMPs FDR < 
0.05, |Beta| > 0.05), including all genes within the pathways (A) or only genes within the 
pathways that contain at least one DMP (B). The size and color of dots represent the overlap 
between pathways. Values of 0 and 1 represent a 0% or 100% overlap respectively between the 
two pathways. DMP: differentially methylated probe. Plots generated with the corrplot R 
package. 
A 
B 
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Supplementary figure 3-6. KEGG pathway enrichment analysis for probes 
hypermethylated (A) and hypomethylated (B) in 22q11.2DS samples. (A.1) DMPs with FDR 
< 0.05 and Beta > 0 (NDMP = 380). (A.2) DMPs with FDR < 0.05 and Beta > 0.05 (NDMP = 
246). (B.1) DMPs with FDR < 0.05 and Beta < 0 (NDMP =281). (B.2) DMPs with FDR < 0.05 
and Beta < 0.05 (NDMP = 155). N: number of gene in the pathway; NDMP: number of DMP tested; 
DE: number of genes associated with at least one DMP; FDR: false discovery rate (the number 
of probes per gene is taken into account to adjust the probability of significant differential 
expression). Only significant KEGG pathway enrichment (FDR < 0.05) are shown. 
A.1 A.2 
B.1 B.2 
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Supplementary figure 3-7. Differentially methylated regions (DMRs) not associated with a 
gene promoter region. DeltaBeta: average beta value differences for the probes (deltaBeta > 0: 
hypermethylation in 22q11.2DS samples); OverlappingGenes: genes overlapping the DMR; 
NearestGenes: Gene closest to the DMR Location: genomic location. Stouffer: combined false 
discovery rates for the probes, with the Stouffer method; Width: DMR size. 
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editing of DGCR8 in human embryonic stem cells 
 
  
Supplementary figure 4-1. DGCR8 orthologues gene tree. Source: ensemble.org. 
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Figure Primer set Forward primer Reverse primer Ref. 
Figure 
1-4 
A GAGTGGATTGCTGTGCTCTG AGACTGCCTTGGGAAAAGC   
B GCCTTCTGTGTGTTCCAGAAA CTAAAGCGCATGCTCCAGAC   
C TGGGCTCTATGGCTTCTGAG GCAAAACACGCTGTTCAGAC   
D GGGCTCGAGATCCACTAGTTC CTTCTTCCAGCAGAGCATCC   
E TGCAGAGGTAATGGACGTTG AGCTCTCGGTAAAGCTCACG   
Figure 
4-6, 
Figure 
4-8, 
Figure 
4-9 
DGCR8 Exon 1/2 CTTTCCCGGCTGTGGTTTGG CTGGCGACTAAGCGAGTCTG   
Figure 
4-6, 
Figure 
4-9 
DGCR8 miRNA 
sites 
GGCAGTGGTTCTAAAAGCTGTC AGGTGGTGGAGACTGCTCAC   
DGCR8 Target site CGGAGCTTCTCTTCTCTCCA ACTCCTGCAGCTCTCGGTAA   
DGCR8 Exon 12/14 CAAGCAGGAGACATCGGACAAG CACAATGGACATCTTGGGCTTC 481 
 
Figure 
4-7, 
Figure 
4-9 
pri-miR-185 AGACCTGCTGGCTAGAGCTG CAAGGGAAGGCCATAAACAG   
pri-let-7a-1 GATTCCTTTTCACCATTCACCCTGGATGTT TTTCTATCAGACCGCCTGGATGCAGACTTT 415  
  pri-miR-16-1 GAAAAGGTGCAGGCCATATTGT CGCCAATATTTACGTGCTGCTA 
pri-miR-17-92a GGGAAACTCAAACCCCTTTCTAC CAACAGGCCGGGACAAGT 
488 
  
pri-miR-17-19a TGCCCTAAGTGCTCCTTCTG AAATAGCAGGCCACCATCAG 
pri-miR-20-19a GCCCAATCAAACTGTCCTGT ACAATCCCCACCAAACTCAA 
 
Figure 
4-8, 
Figure 
4-9 
 
Nestin GTGCAGAGGTGGGAAGATACG CCTGCTCTACCACCTCCTCCT   
Tuj1 CATGGACAGTGTCCGCTCAG CAGGCAGTCGCAGTTTTCAC   
Pax6 AATAACCTGCCTATGCAACCC AACTTGAACTGGAACTGACACAC   
Neurog2 TCAGACATGGACTATTGGCAG GGGACAGGAAAGGGAACC 
425 
NeuroD1 ACGACCTCGAAACCATGAAC CTTCCAGGTCCTCATCTTCG 
  GAPDH ACGACCCCTTCATTGACCTCAACT ATATTTCTCGTGGTTCACACCCAT   
Supplementary table 4-1. Table of primer sequences. 
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5. Supplementary information: Transcriptome analysis of 
DGCR8 knock-out lines 
GO term GO type Adjusted p-value
cell morphogenesis involved in neuron differentiation BP 5.6E-05
axon development BP 5.6E-05
locomotion BP 4.9E-04
cell adhesion BP 5.2E-04
biological adhesion BP 5.2E-04
movement of cell or subcellular component BP 5.2E-04
regulation of anatomical structure morphogenesis BP 5.2E-04
developmental growth involved in morphogenesis BP 5.2E-04
extracellular matrix CC 6.3E-04
proteinaceous extracellular matrix CC 6.3E-04
tissue development BP 6.8E-04
morphogenesis of a branching structure BP 6.8E-04
regulation of cell projection organization BP 1.6E-03
regulation of cell morphogenesis involved in differentiation BP 1.7E-03
response to external stimulus BP 1.8E-03
regulation of developmental growth BP 1.9E-03
glycosaminoglycan binding MF 1.9E-03
calcium ion binding MF 1.9E-03
sulfur compound binding MF 1.9E-03
heparin binding MF 1.9E-03
tissue morphogenesis BP 3.7E-03
enzyme linked receptor protein signaling pathway BP 4.2E-03
chemotaxis BP 5.4E-03
taxis BP 5.4E-03
regulation of neuron projection development BP 5.4E-03
system process BP 9.5E-03
head development BP 9.5E-03
regulation of cell proliferation BP 1.1E-02
negative regulation of response to stimulus BP 1.3E-02
regulation of growth BP 1.4E-02
cell motility BP 1.4E-02
localization of cell BP 1.4E-02
growth BP 1.5E-02
receptor binding MF 1.6E-02
signaling receptor activity MF 1.7E-02
sodium ion homeostasis BP 1.7E-02
response to axon injury BP 1.8E-02
regulation of response to wounding BP 2.0E-02
positive regulation of peptidyl-serine phosphorylation BP 2.3E-02
positive regulation of developmental process BP 2.3E-02
response to lipid BP 2.7E-02
cell proliferation BP 2.8E-02
negative regulation of multicellular organismal process BP 2.8E-02
response to nicotine BP 2.8E-02
hindlimb morphogenesis BP 2.8E-02
single-organism behavior BP 3.2E-02
regulation of extent of cell growth BP 3.4E-02
positive regulation of kinase activity BP 3.5E-02
regulation of body fluid levels BP 3.5E-02
regulation of vascular permeability BP 3.5E-02
regulation of cardiac muscle tissue development BP 3.5E-02
negative regulation of developmental process BP 4.1E-02
cardiac muscle tissue development BP 4.1E-02
negative regulation of cell adhesion BP 4.4E-02
peptidase inhibitor activity MF 4.6E-02
protein tyrosine kinase activity MF 4.6E-02
signal transducer activity MF 4.6E-02
long-term synaptic potentiation BP 4.7E-02
A 
Supplementary table 5-1. Gene Ontology gene-set enrichment analysis of high-
confidence genes differentially expressed in DGCR8+/- and 22q11.2DS neural progenitor 
cells. Legend on next page. 
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GO term GO type Adjusted p-value
calcium ion binding MF 2.6E-06
cell-cell adhesion via plasma-membrane adhesion molecules BP 7.2E-06
cell adhesion BP 7.2E-06
biological adhesion BP 7.2E-06
proteinaceous extracellular matrix CC 2.8E-02
extracellular space CC 2.8E-02
GO term GO type Adjusted p-value
neuron differentiation BP 1.4E-05
head development BP 4.6E-05
locomotion BP 4.4E-04
cell projection organization BP 5.8E-04
movement of cell or subcellular component BP 3.1E-03
heparin binding MF 3.5E-03
regulation of nervous system development BP 3.8E-03
regulation of neuron projection development BP 3.8E-03
glycosaminoglycan binding MF 4.2E-03
sulfur compound binding MF 5.3E-03
response to nicotine BP 7.7E-03
regulation of developmental growth BP 7.8E-03
regulation of cell morphogenesis involved in differentiation BP 8.7E-03
regulation of anatomical structure morphogenesis BP 9.7E-03
animal organ morphogenesis BP 1.1E-02
mitotic spindle organization BP 1.5E-02
transcriptional activator activity, RNA polymerase II core promoter 
proximal region sequence-specific binding
MF 1.9E-02
cell motility BP 1.9E-02
localization of cell BP 1.9E-02
developmental growth involved in morphogenesis BP 1.9E-02
growth BP 2.3E-02
sodium ion homeostasis BP 2.3E-02
regulation of growth BP 2.4E-02
positive regulation of developmental process BP 2.4E-02
epithelium development BP 2.6E-02
Supplementary table 5-1. Gene Ontology gene-set enrichment analysis of high-
confidence genes differentially expressed in DGCR8+/- and 22q11.2DS neural progenitor 
cells. (A) All significant genes. (B) Upregulated genes only. (C) Downregulated genes only. 
Differentially expressed genes are defined as genes with an FDR corrected p-value < 0.01. 
Significantly enriched terms have an adjusted p-value < 0.05 (Benjamini-Hochberg 
procedure). BP: biological process; CC: cellular component; MF: molecular function. 
B 
C 
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